U.S. patent number 8,119,359 [Application Number 13/016,887] was granted by the patent office on 2012-02-21 for methods of indentifying sweet taste modulators.
This patent grant is currently assigned to Senomyx, Inc.. Invention is credited to Jon E. Adler, Fernando Echeverri, Xiaodong Li, Lena Staszewski, Hong Xu.
United States Patent |
8,119,359 |
Adler , et al. |
February 21, 2012 |
Methods of indentifying sweet taste modulators
Abstract
Newly identified mammalian taste-cell-specific G protein-coupled
receptors which function as hetero-oligomeric complexes in the
sweet taste transduction pathway, and the genes and cDNA encoding
said receptors are described. Specifically, T1R G protein-coupled
receptors active in sweet taste signaling as hetero-oligomeric
complexes, and the genes and cDNA encoding the same, are described,
along with methods for isolating such genes and for isolating and
expressing such receptors. Methods for identifying putative taste
modulating compounds using such hetero-oligomeric complexes also
described, as is a novel surface expression facilitating peptide
useful for targeting integral plasma membrane proteins to the
surface of a cell.
Inventors: |
Adler; Jon E. (San Diego,
CA), Li; Xiaodong (San Diego, CA), Staszewski; Lena
(San Diego, CA), Xu; Hong (San Diego, CA), Echeverri;
Fernando (Chula Vista, CA) |
Assignee: |
Senomyx, Inc. (San Diego,
CA)
|
Family
ID: |
46303862 |
Appl.
No.: |
13/016,887 |
Filed: |
January 28, 2011 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20110201046 A1 |
Aug 18, 2011 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
12185392 |
Aug 4, 2008 |
7892765 |
|
|
|
11050804 |
Feb 7, 2005 |
7419791 |
|
|
|
09897427 |
Jul 3, 2001 |
6955887 |
|
|
|
60300434 |
Jun 26, 2001 |
|
|
|
|
60284547 |
Apr 19, 2001 |
|
|
|
|
Current U.S.
Class: |
435/7.21;
435/7.2; 530/350 |
Current CPC
Class: |
G01N
33/5008 (20130101); G01N 33/5041 (20130101); G01N
33/74 (20130101); G01N 33/5023 (20130101); C07K
14/723 (20130101); G01N 2333/705 (20130101); G01N
2333/726 (20130101); G01N 2500/00 (20130101) |
Current International
Class: |
G01N
33/567 (20060101); G01N 33/53 (20060101); C07K
1/00 (20060101); C07K 14/00 (20060101); C07K
17/00 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO 95/08627 |
|
Mar 1995 |
|
WO |
|
WO 00/006592 |
|
Feb 2000 |
|
WO |
|
WO 00/006593 |
|
Feb 2000 |
|
WO |
|
WO 01/64882 |
|
Sep 2001 |
|
WO |
|
WO 01/66563 |
|
Sep 2001 |
|
WO |
|
WO 01/83749 |
|
Nov 2001 |
|
WO |
|
WO 02/064631 |
|
Aug 2002 |
|
WO |
|
WO 03/001876 |
|
Jan 2003 |
|
WO |
|
WO 03/004992 |
|
Jan 2003 |
|
WO |
|
WO 03/025137 |
|
Mar 2003 |
|
WO |
|
WO 2005/015158 |
|
Feb 2005 |
|
WO |
|
WO 2005/033125 |
|
Apr 2005 |
|
WO |
|
WO 2005/041684 |
|
May 2005 |
|
WO |
|
WO 2006/084246 |
|
Aug 2006 |
|
WO |
|
Other References
Adler, E. et al., "A Novel Family of Mammalian Taste Receptors",
Cell, vol. 100, No. 6, p. 693-702, Mar. 17, 2000. cited by other
.
Alexander, et al., "Altering the Antigenicity of proteins", Proc.
Natl. Acad. Sci. USA, vol. 89, p. 3352-3356, Apr. 1992. cited by
other .
Bonigk, W., et al., "The Native Rat Olfactory Cyclic
Nucleotide-Gated Channel is Composed of Three Distinct Subunits",
The Journal of Neuroscience, vol. 19, No. 136, p. 5332-5347, Jul.
1, 1999. cited by other .
Bowie, et al., "Deciphering the Message in Protein Sequences:
Tolerance to Amino Acid Substitutions", Science, vol. 247, p.
13061310, Mar. 16, 1990. cited by other .
Damak, S., "Detection of Sweet and Umani Taste in the Absence of
Taste Receptor T1r3," vol. 301, pp. 850-853, 2003. cited by other
.
Guo, et al., "Protein Tolerance to Random Amino Acid change", PNAS,
vol. 101, No. 25, p. 9205-9210, Jun. 22, 2004. cited by other .
Hoon, et al., "Putative Mammalian Taste Receptors: A Class of
Taste-Specific GPCRs with Distinct Topographic Selectivity", Cell,
vol. 96, p. 541-551, Feb. 19, 1999. cited by other .
Johnson, C., et al., "The Effect of the Sweetness Inhibitor
2(-4-methoxyphenoxy) propanoic acid (sodium salt) (Na-PMP) on the
taste of bitter-sweet stimuli", Chemical Senses, vol. 19, No. 4, p.
349-358, 1994. cited by other .
Kinnamon, S. And Cummings, T., "Chemosensory Transduction
Mechanisms in Taste", Annu. Rev. Physoil., vol. 54, p. 715-731,
1992. cited by other .
Kitagawa, M., et al., "Molecular Genetic Identification of a
Candidate Receptor Gene for Sweet Taste", Biochemical and
Biophysical Research Communications, vol. 283, p. 236-242, 2001.
cited by other .
Krautwurst, et al., "Identification of Ligands for Olfactory
Receptors by Functional Expression of a Receptor Library", Cell,
vol. 95, p. 917-926, Dec. 23, 1998. cited by other .
Li, X., et al., "Human Receptors for Sweet and umami taste",
Proceeding of the National Academy of Science, vol. 99, No. 7, p.
4692-4696, Apr. 2, 2002. cited by other .
Lindemann, "A Taste for Umami", Nature Neuroscience, ol. 3, No. 2,
p. 99-100, Feb. 2000. cited by other .
Max, M., et al., "Tas1r3, encoding a new candidate taste receptor,
is allelic to the sweet responsiveness locus Sac", Nature Genetics,
vol. 28, p. 58-63, May 2001. cited by other .
Montmayeur, J.P., et al., "A Candidate Taste Receptor Gene Near a
Sweet Taste Locus", Nature Neuroscience, vol. 4, No. 5, May 2001.
cited by other .
Nelson, et al., "An Amino-acid Taste Receptor", Nature, vol. 416,
p. 199-202, Mar. 14, 2002. cited by other .
Nelson, et al., "Mammalian Sweet Taste Receptors", Cell, vol. 106,
p. 381-390, Aug. 10, 2001. cited by other .
Perruccio, et al., "Possible Role for gustducin in Taste
Transduction in Hirudo Medicinalis", Society for Neuroscience
Abstracts, vol. 26, No. 1-2, Abstract No. 66.15, 2000. cited by
other .
Sainz, E., et al., "Identification of a Novel Member of the T1R
family of putative taste receptors", Journal of Neurochemistry,
vol. 77, p. 896-903, 2001. cited by other .
Temussi, P., et al., "The history of sweet taste: not exactly a
piece of cake", Journal of Molecular Recognition, 2006, 19:
188-199. cited by other .
Waterston, R.H. "Direct Submission", Genome Sequencing Center, Apr.
21, 2000--XP002262036. cited by other .
Database EMBL 'Online!, embl heidelberg; Acc#: Ac062024, Jun. 21,
2000. cited by other .
GenBank Accession No. AA907022, May 19, 1998. cited by other .
GenBank Accession No. AL139287, clone RP5-89003, Feb. 13, 2000.
cited by other .
Extended European Search Report and Opinion for European
Application No. 08075748.7, dated Nov. 21, 2008. cited by other
.
European Search Report for European Application No. 08153652.6,
dated Jan. 21, 2009. cited by other .
U.S. Appl. No. 12/721,463, unpublished, Zuker et al. cited by other
.
U.S. Appl. No. 12/852,941, unpublished, Li et al. cited by other
.
U.S. Appl. No. 13/020,068, unpublished, Li et al. cited by other
.
U.S. Appl. No. 13/023,836, unpublished, Adler et al. cited by other
.
U.S. Appl. No. 13/087,556, unpublished, Adler et al. cited by other
.
U.S. Appl. No. 13/092,598, unpublished, Adler et al. cited by other
.
U.S. Appl. No. 13/016,887, unpublished, Adler et al. cited by other
.
U.S. Appl. No. 11/932,721, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 11/932,900, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 11/939,415, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 11/939,433, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 11/939,438, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 12/759,172, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 13/023,462, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 13/023,502, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 13/036,723, unpublished, Zoller et al. cited by
other .
U.S. Appl. No. 13/099,327, unpublished, Zoller et al. cited by
other .
Akabas MH, Dodd J, Al-Awqati Q (1988) A bitter substance induces a
rise in intracellular calcium in a subpopulation of rat taste
cells. Science 242:1047-1050. cited by other .
Akabas MH, Dodd J, Al-Awqati Q (1990) Identification of
electrophysiologically distinct subpopulations of rat taste cells.
J Membr Biol 114:71-78. cited by other .
Avenet P, Lindemann B (1987) Patch-clamp study of isolated taste
receptor cells of the frog. J Membr Biol 97:223-240. cited by other
.
Avenet P, Lindemann B (1989) Perspectives of taste reception. J
Membrane Biol 112:1-8. cited by other .
Behe P, DeSimone JA, Avenet P, Lindemann B (1990) Membrane currents
in taste cells of the rat fungiform papillae: evidence for two
types of Ca currents and inhibition of K currents by saccharin. J
Gen Physiol 96:1061-1084. cited by other .
Bernhardt SJ, Naim M, Zehavi U, Lindemann B (1996) Changes in
IP.sub.3 and cytosolic Ca.sup.2+ in response to sugars and
non-sugar sweeteners in transduction of sweet taste in the rat. J
Physiol 490 ( Pt 2):325-36. cited by other .
Boughter Jr JD, Gilbertson TA (1999) From channels to behavior: an
integrative model of NaCl taste. Neuron 22:213-215. cited by other
.
Chen Y, Herness MS (1997) Electrophysiological actions of quinine
on voltage-dependent currents in dissociated rat taste cells.
Pflugers Arch 434:215-226. cited by other .
Chen Y, Sun X-D, Herness MS (1996) Characteristics of action
potentials and their underlying outward currents in rat taste
receptor cells. J Neurophysiol 75:820-831. cited by other .
Cummings TA, Daniels C, Kinnamon SC (1996) Sweet taste transduction
in hamster: sweeteners and cyclic nucleotides depolarize taste
cells by reducing a K+current. J Neurophysiol 75:1256-1263. cited
by other .
Erickson RP (1968) Stimulus coding in topographic and
nontopographic afferent modalities: on the significance of the
activity of individual sensory neurons. Psychol Rev 75:447-465.
cited by other .
Frank M, Pfaffmann C (1969) Taste nerve fibers: a random
distribution of sensitivities to four tastes. Science
164:1183-1185. cited by other .
Frank ME, Contreras RJ, Hettinger TP (1983) Nerve fibers sensitive
to ionic taste stimuli in chorda tympani of the rat. J Neurophysiol
50:941-960. cited by other .
Frank ME, Bieber SL, Smith DV (1988) The organization of taste
sensibilities in hamster chorda tympani nerve fibers. J Gen Physiol
91:861-896. cited by other .
Furue H, Yoshii K (1997) In situ tight-seal recordings of taste
substance elicited action currents and voltage-gated Ba currents
from single taste bud cells in the peeled epithelium of mouse
tongue. Brain Res 776:133-139. cited by other .
Furue H, Yoshii K (1998) A method for in-situ tight-seal recordings
from single taste bud cells of mice. J Neurosci Methods 84:109-114.
cited by other .
Gilbertson TA (1995) Patch-clamping of taste cells in hamster and
rat. In: Experimental cell biology of taste and olfaction: current
techniques and protocols (Spielman AI, Brand JG, eds), pp. 317-328.
Boca Raton, FL: CRC. cited by other .
Gilbertson TA, Zhang H (1998) Characterization of sodium transport
in gustatory epithelia from the hamster and rat. Chem Senses
23:283-293. cited by other .
Gilbertson TA, Avenet P, Kinnamon SC, Roper SD (1992) Proton
currents through amiloride-sensitive Na channels in hamster taste
cells: role in acid transduction. J Gen Physiol 100:803-824. cited
by other .
Gilbertson TA, Roper SD, Kinnamon SC (1993) Proton currents through
amiloride-sensitive Na+ channels in isolated hamster taste cells:
enhancement by vasopressin and cAMP. Neuron 10:931-942. cited by
other .
Gilbertson TA, Fontenot DT, Zhang H, Liu L, Monroe WT (1997) Fatty
acid modulation of K+ channels in taste receptor cells: gustatory
cues for dietary fat. Am J Physiol 272(4 Pt 1):C1203-C1210. cited
by other .
Gilbertson TA, Zhang H, Boughter Jr JD, Smith DV (1999) Multiple
sensitivity of rat fungiform taste cells: whole cell responses to
apical chemical stimulation. Chem Senses 24:569. cited by other
.
Gilbertson TA, Boughter JD Jr, Zhang H, Smith DV (2001)
Distribution of gustatory sensitivities in rat taste cells:
whole-cell responses to apical chemical stimulation. J Neurosci.
21:4931-4941. cited by other .
Herness MS, Gilbertson TA (1999) Cellular mechanisms of taste
transduction. Annu Rev Physiol 61:873-900. cited by other .
Herness MS, Sun X-D (1995) Voltage-dependent sodium currents
recorded from dissociated rat taste cells. J Membr Biol 146:73-84.
cited by other .
Kimura K, Beidler LM (1961) Microelectrode study of taste receptor
of rat and hamster. J Cell Comp Physiol 58:131-140. cited by other
.
Kinnamon S (1988) Taste transduction: a diversity of mechanisms.
Trends Neurosci 11:491-496. cited by other .
Kinnamon SC, Dionne VE, Beam KG (1988) Apical localization of
K.sup.+ channels in taste cells provides the basis for sour taste
transduction. Proc Natl Acad Sci U S A. 85:7023-7027. cited by
other .
Lindemann B (1996) Taste reception. Physiol Rev 76:719-766. cited
by other .
Mackay-Sim A, Delay RJ, Roper SD, Kinnamon SC (1996) Development of
voltage-dependent currents in taste receptor cells. J Comp Neurol
365:278-288. cited by other .
Monroe WT, Smith DV, Gilbertson TA (1996) The MU chamber: a new
method to record electrophysiological responses of taste receptor
cells to gustatory stimuli. Chem Senses 21:644-645. cited by other
.
Ogawa H, Sato M, Yamashita S (1968) Multiple sensitivity of chorda
tympani fibres of the rat and hamster to gustatory and thermal
stimuli. J Physiol (Lond) 199:223-240. cited by other .
Ohtubo Y, Suemitsu T, Shobara S, Matsumoto T, Kumazawa T, Yoshii K
(2001) Optical recordings of taste responses from fungiform
papillae of mouse in situ. J Physiol (Lond) 530:287-293. cited by
other .
Ozeki M, SatoM (1972) Responses of gustatory cells in the tongue of
rat to stimuli representing four taste qualities. Comp Biochem
Physiol [A] 41:391-407. cited by other .
Pfaffmann C (1955) Gustatory nerve impulses in rat, cat and rabbit.
J Neurophysiol 18:429-440. cited by other .
Pfaffmann C (1959) The afferent code for sensory quality. Am
Psychol 14:226-232. cited by other .
Roper SD (1993) Synaptic interactions in taste buds. In: Mechanisms
of taste transduction (Simon SA, Roper SD, eds), pp. 275-293. Boca
Raton, FL: CRC. cited by other .
Roper SD, McBride Jr DW (1989) Distribution of ion channels on
taste cells and its relationship to chemosensory transduction. J
Membr Biol 109:29-39. cited by other .
Sato T, Beidler LM (1982) The response characteristics of rat taste
cells to four basic taste stimuli. Comp Biochem Physiol A 73:1-10.
cited by other .
Sato T, Beidler LM (1997) Broad tuning of rat taste cells to four
basic taste stimuli. Chem Senses 22:287-293. cited by other .
Seto E, Hayashi Y, Mori T (1999) Patch clamp recording of the
responses to three bitter stimuli in mouse taste cells. Cell Mol
Biol 45:317-325. cited by other .
Smith DV, Frank ME (1993) Sensory coding by peripheral taste
fibers. In: Mechanisms of Taste Transduction (Simon SA, Roper SD,
eds), pp. 295-338. Boca Raton, FL: CRC. cited by other .
Smith DV, St John SJ (1999) Neural coding of gustatory information.
Curr Opin Neurobiol 9:427-435. cited by other .
Smith DV, Travers JB (1979) A metric for the breadth of tuning of
gustatory neurons. Chem Senses Flav 4:215-229. cited by other .
Smith DV, Van Buskirk RL, Travers JB, Bieber SL (1983) Coding of
taste stimuli by hamster brain stem neurons. J Neurophysiol
50:541-558. cited by other .
Smith DV, Zhang H, Boughter Jr JD, St. John SJ, Gilbertson TA
(2000) Random distribution of gustatory sensitivities across rat
taste receptor cells and brainstem neurons. Chem Senses 25:661.
cited by other .
Spector AC, Markison S, St. John SJ, Garcea M (1997) Sucrose vs.
maltose taste discrimination by rats depends on the input of the
seventh cranial nerve. Am J Physiol 272 (4 Pt 2):R1210-R1218. cited
by other .
Sweazey RD, Smith DV (1987) Convergence onto hamster medullary
taste neurons. Brain Res 408:173-184. cited by other .
Tonosaki K, Funakoshi M (1984) Intracellular taste cell responses
of mouse. Comp Biochem Physiol [A] 78:651-656. cited by other .
Travers JB, Smith DV (1979) Gustatory sensitivities in neurons of
the hamster nucleus tractus solitarius. Sens Processes 3:1-26.
cited by other .
Travers SP (1993) Orosensory processing in neural systems of the
nucleus of the solitary tract. In: Mechanisms of taste transduction
(Simon SA, Roper SD, eds), pp. 339-394. Boca Raton, FL: CRC. cited
by other .
Van Buskirk RL, Smith DV (1981) Taste sensitivity of hamster
parabrachial pontine neurons. J Neurophysiol 45:144-171. cited by
other .
Wong GT, Gannon KS, Margolskee RF (1996) Transduction of bitter and
sweet taste by gustducin. Nature 381:796-800. cited by other .
Yamamoto T, Yuyama N, Kato T, Kawamura Y (1984) Gustatory responses
of cortical neurons in rats. I. Response characteristics. J
Neurophysiol 51:616-635. cited by other .
Han G, Hampson DR (1999) Ligand binding to the amino-terminal
domain of the mGluR4 subtype of metabotropic glutamate receptor. J
Biol Chem. 274(15):10008-13. cited by other.
|
Primary Examiner: Landsman; Robert
Attorney, Agent or Firm: Hunton & Williams LLP
Parent Case Text
RELATED APPLICATIONS
This application is a divisional of U.S. application Ser. No.
12/185,392, filed on Aug. 4, 2008, now U.S. Pat. No. 7,892,765,
which is a continuation of U.S. application Ser. No. 11/050,804,
filed on Feb. 7, 2005, now U.S. Pat. No. 7,419,791, which is a
continuation of U.S. application Ser. No. 09/897,427, filed on Jul.
3, 2001, now U.S. Pat. No. 6,955,887, which claims priority to U.S.
Provisional Application No. 60/300,434, filed on Jun. 26, 2001, and
U.S. Provisional Application No. 60/284,547, filed on Apr. 19,
2001, all which are incorporated by reference in their entirety
herein.
Claims
What is claimed:
1. A method of screening for a compound that putatively blocks or
activates sweet taste signaling, the method comprising the steps
of: (a) contacting cells comprising isolated mammalian cells or
cultured mammalian cells with one or more compounds, wherein said
cells express a receptor that binds to sweet taste compounds; and
(b) detecting whether said one or more compounds specifically bind
to said receptor and/or specifically activate said receptor and,
based thereon, identifying said one or more compounds as compounds
that putatively block or activate sweet taste signaling, wherein
(1) said receptor that binds to sweet compounds comprises a T1R2
polypeptide and a T1R3 polypeptide, (2) said T1R2 polypeptide is
selected from the group consisting of: (i) a polypeptide that is
identical to the polypeptide of SEQ ID NO: 4; and (ii) a
polypeptide that is at least 90% identical to the polypeptide of
SEQ ID NO: 4; and (3) said T1R3 polypeptide is selected from the
group consisting of: (i) a polypeptide that is identical to the
polypeptide of SEQ ID NO: 6; and (ii) a polypeptide that is at
least 90% identical to the T1R3 polypeptide of SEQ ID NO: 6.
2. A method of screening for a compound that putatively modulates
sweet taste signaling, the method comprising the steps of: (a)
contacting cells comprising isolated mammalian cells or cultured
mammalian cells with one or more compounds, wherein said cells
express a receptor that binds to sweet taste compounds; and (b)
detecting whether said one or more compounds affect the binding of
another compound to said receptor and/or modulate the activation of
said receptor by another compound and, based thereon, identifying
said one or more compounds as compounds that putatively modulate
sweet taste signaling, wherein (1) said receptor that binds to
sweet compounds comprises a T1R2 polypeptide and a T1R3
polypeptide, (2) said T1R2 polypeptide is selected from the group
consisting of: (i) a polypeptide that is identical to the
polypeptide of SEQ ID NO: 4; and (ii) a polypeptide that is at
least 90% identical to the polypeptide of SEQ ID NO: 4; and (3)
said T1R3 polypeptide is selected from the group consisting of: (i)
a polypeptide that is identical to the polypeptide of SEQ ID NO: 6;
and (ii) a polypeptide that is at least 90% identical to the T1R3
polypeptide of SEQ ID NO: 6.
3. The method of claim 1 that further includes a taste test to
determine the effect of said identified compound on sweet taste
and, based on the result of the taste test, identifying the
compound as a compound that blocks or activates sweet taste
signaling.
4. The method of claim 2 that further includes a taste test to
determine the effect of said identified compound on sweet taste
and, based on the result of the taste test, identifying the
compound as a compound that modulates sweet taste signaling.
5. The method of claim 1, wherein said T1R2 polypeptide is
expressed from a gene that is endogenous to said cells, and wherein
said T1R2 polypeptide is at least 95% identical to the polypeptide
of SEQ ID NO: 4.
6. The method of claim 1, wherein said T1R3 polypeptide is
expressed from a gene that is endogenous to said cells, and wherein
said T1R3 polypeptide is at least 95% identical to the T1R3
polypeptide of SEQ ID NO: 6.
7. The method of claim 1, wherein said T1R2 polypeptide is
expressed from a gene that is endogenous to said cells and T1R3
polypeptide is expressed from a gene that is endogenous to said
cells, and wherein said T1R2 polypeptide is at least 95% identical
to the polypeptide of SEQ ID NO: 4 and/or said T1R3 polypeptide is
at least 95% identical to the T1R3 polypeptide of SEQ ID NO: 6.
8. The method of claim 2, wherein said T1R2 polypeptide is
expressed from a gene that is endogenous to said cells, and wherein
said T1R2 polypeptide is at least 95% identical to the polypeptide
of SEQ ID NO: 4.
9. The method of claim 2, wherein said T1R3 polypeptide is
expressed from a gene that is endogenous to said cells, and wherein
said T1R3 polypeptide is at least 95% identical to the T1R3
polypeptide of SEQ ID NO: 6.
10. The method of claim 2, wherein said T1R2 polypeptide is
expressed from a gene that is endogenous to said cells and T1R3
polypeptide is expressed from a gene that is endogenous to said
cells, and wherein said T1R2 polypeptide is at least 95% identical
to the polypeptide of SEQ ID NO: 4 and/or said T1R3 polypeptide is
at least 95% identical to the T1R3 polypeptide of SEQ ID NO: 6.
11. The method of claim 1, wherein said cells include human
cells.
12. The method of claim 2, wherein said cells include human
cells.
13. The method of claim 5, wherein said cells include human
cells.
14. The method of claim 6, wherein said cells include human
cells.
15. The method of claim 7, wherein said cells include human
cells.
16. The method of claim 8, wherein said cells include human
cells.
17. The method of claim 9, wherein said cells include human
cells.
18. The method of claim 10, wherein said cells include human
cells.
19. The method of claim 1, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
20. The method of claim 2, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
21. The method of claim 5, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
22. The method of claim 6, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
23. The method of claim 7, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
24. The method of claim 8, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
25. The method of claim 9, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
26. The method of claim 10, wherein said cells are identified by a
method comprising detecting the expression of a T1R2 and/or T1R3
polypeptide or T1R2- and/or T1R3-encoding nucleic acid by said
cells.
27. The method of claim 1, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
28. The method of claim 2, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
29. The method of claim 5, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
30. The method of claim 6, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
31. The method of claim 7, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
32. The method of claim 8, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
33. The method of claim 9, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
34. The method of claim 10, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
35. The method of claim 19, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
36. The method of claim 20, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
37. The method of claim 21, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
38. The method of claim 22, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
39. The method of claim 23, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
40. The method of claim 24, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
41. The method of claim 25, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
42. The method of claim 26, wherein said cells comprise a
heterologous nucleic acid encoding a detectable label that provides
for the identification of compounds that specifically bind or
modulate the activity of said receptor.
43. The method of claim 1, wherein said cells endogenously
expresses a G protein or comprise a heterologous nucleic acid
encoding a G protein.
44. The method of claim 2, wherein said cells endogenously
expresses a G protein or comprise a heterologous nucleic acid
encoding a G protein.
45. The method of claim 19, wherein said cells endogenously
expresses a G protein or comprise a heterologous nucleic acid
encoding a G protein.
46. The method of claim 20, wherein said cells endogenously
expresses a G protein or comprise a heterologous nucleic acid
encoding a G protein.
47. The method of claim 43, wherein said G protein comprises
G.alpha.15 or G.alpha.16 or another promiscuous G protein.
48. The method of claim 44, wherein said G protein comprises
G.alpha.15 or G.alpha.16 or another promiscuous G protein.
49. The method of claim 45, wherein said G protein comprises
G.alpha.15 or G.alpha.16 or another promiscuous G protein.
50. The method of claim 46, wherein said G protein comprises
G.alpha.15 or G.alpha.16 or another promiscuous G protein.
51. The method of claim 1, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
52. The method of claim 2, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
53. The method of claim 5, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
54. The method of claim 6, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
55. The method of claim 7, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
56. The method of claim 8, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
57. The method of claim 9, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
58. The method of claim 10, wherein said cells are identified using
at least one probe that specifically detects the expression of T1R2
and/or T1R3 genes by said cells.
59. The method of claim 51, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
60. The method of claim 52, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
61. The method of claim 53, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
62. The method of claim 54, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
63. The method of claim 55, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
64. The method of claim 56, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
65. The method of claim 57, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
66. The method of claim 58, wherein said at least one probe
comprises a nucleic acid that specifically detects T1R2 or T1R3
nucleic acids expressed by said cells or comprises an antibody that
specifically detects T1R2 or T1R3 polypeptides expressed by said
cells.
67. The method of claim 59, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
68. The method of claim 60, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
69. The method of claim 61, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
70. The method of claim 62, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
71. The method of claim 63, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
72. The method of claim 64, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
73. The method of claim 65, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
74. The method of claim 66, wherein said T1R2 or T1R3 nucleic acid
is an RNA and is detected by a method selected from the group
consisting of Northern analysis, dot blot, RNase protection, S1
analysis, a nucleic acid amplification technique, and in situ
hybridization.
75. The method of claim 67, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
76. The method of claim 68, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
77. The method of claim 67, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
78. The method of claim 70, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
79. The method of claim 71, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
80. The method of claim 72, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
81. The method of claim 73, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
82. The method of claim 74, wherein said at least one probe
comprises a T1R2- and/or T1R3-specific primer.
83. The method of claim 1, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
84. The method of claim 2, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
85. The method of claim 5, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
86. The method of claim 6, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
87. The method of claim 7, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
88. The method of claim 8, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
89. The method of claim 9, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
90. The method of claim 10, wherein step (b) comprises detecting an
alteration in said cells in one or more of intracellular Ca.sup.2+,
intracellular IP3, an intracellular cyclic nucleotide,
intracellular cAMP, intracellular cGMP, membrane voltage, and G
protein binding to GTP.gamma.S.
91. The method of claim 1, wherein said cells are obtained from a
mammalian tissue.
92. The method of claim 2, wherein said cells are obtained from a
mammalian tissue.
93. The method of claim 5, wherein said cells are obtained from a
mammalian tissue.
94. The method of claim 6, wherein said cells are obtained from a
mammalian tissue.
95. The method of claim 7, wherein said cells are obtained from a
mammalian tissue.
96. The method of claim 8, wherein said cells are obtained from a
mammalian tissue.
97. The method of claim 9, wherein said cells are obtained from a
mammalian tissue.
98. The method of claim 10, wherein said cells are obtained from a
mammalian tissue.
99. The method of claim 1, wherein said cells are obtained from a
human tissue.
100. The method of claim 2, wherein said cells are obtained from a
human tissue.
101. The method of claim 5, wherein said cells are obtained from a
human tissue.
102. The method of claim 6, wherein said cells are obtained from a
human tissue.
103. The method of claim 7, wherein said cells are obtained from a
human tissue.
104. The method of claim 8, wherein said cells are obtained from a
human tissue.
105. The method of claim 9, wherein said cells are obtained from a
human tissue.
106. The method of claim 10, wherein said cells are obtained from a
human tissue.
107. The method of claim 1, wherein said cells are obtained from a
human cell culture.
108. The method of claim 2, wherein said cells are obtained from a
human cell culture.
109. The method of claim 5, wherein said cells are obtained from a
human cell culture.
110. The method of claim 6, wherein said cells are obtained from a
human cell culture.
111. The method of claim 7, wherein said cells are obtained from a
human cell culture.
112. The method of claim 8, wherein said cells are obtained from a
human cell culture.
113. The method of claim 9, wherein said cells are obtained from a
human cell culture.
114. The method of claim 10 wherein said cells are obtained from a
human cell culture.
115. The method of claim 91, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
116. The method of claim 92, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
117. The method of claim 93, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
118. The method of claim 94, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
119. The method of claim 95, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
120. The method of claim 96, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
121. The method of claim 97, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
122. The method of claim 98, wherein said mammalian tissue
comprises tongue, oral cavity tissue, gastrointestinal epithelium,
or epiglottis.
123. The method of claim 99, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
124. The method of claim 100, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
125. The method of claim 101, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
126. The method of claim 102, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
127. The method of claim 103, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
128. The method of claim 104, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
129. The method of claim 105, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
130. The method of claim 106, wherein said human tissue comprises
tongue, oral cavity tissue, gastrointestinal epithelium, or
epiglottis.
131. The method of claim 1, wherein at least one of said T1R2 or
T1R3 polypeptides is expressed from a nucleic acid heterologous to
said cells.
132. The method of claim 2, wherein at least one of said T1R2 or
T1R3 polypeptides is expressed from a nucleic acid heterologous to
said cells.
133. The method of claim 5, wherein at least one of said T1R2 or
T1R3 polypeptides is expressed from a nucleic acid heterologous to
said cells.
134. The method of claim 6, wherein at least one of said T1R2 or
T1R3 polypeptides is expressed from a nucleic acid heterologous to
said cells.
135. The method of claim 8, wherein at least one of said T1R2 or
T1R3 polypeptides is expressed from a nucleic acid heterologous to
said cells.
136. The method of claim 9, wherein at least one of said T1R2 or
T1R3 polypeptides is expressed from a nucleic acid heterologous to
said cells.
137. The method of claim 1, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste
signaling.
138. The method of claim 2, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blacker, or antagonist of sweet taste
signaling.
139. The method of claim 5, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste
signaling.
140. The method of claim 6, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste
signaling.
141. The method of claim 7, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste
signaling.
142. The method of claim 8, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste
signaling.
143. The method of claim 9, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste
signaling.
144. The method of claim 10, wherein said compound that modulates
sweet taste signaling is an activator, inhibitor, stimulator,
enhancer, agonist, blocker, or antagonist of sweet taste signaling.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to newly identified mammalian chemosensory G
protein-coupled receptors, to family of such receptors, and to the
genes and cDNA encoding said receptors. More particularly, the
invention relates to newly identified mammalian chemosensory G
protein-coupled receptors active in taste signaling which function
as hetero-oligomers.
2. Description of the Related Art
The taste system provides sensory information about the chemical
composition of the external world. Taste transduction is one of the
most sophisticated forms of chemical-triggered sensation in
animals. At present, the means by which taste sensations are
elicited remains poorly understood. See, e.g., Margolskee,
BioEssays, 15:645-50 (1993); Avenet et al., J. Membrane Biol.,
112:1-8 (1989). Taste signaling is found throughout the animal
kingdom, from simple metazoans to the most complex of vertebrates.
Taste sensation is thought to involve distinct signaling pathways.
These pathways are believed to be mediated by receptors, i.e.,
metabotropic or inotropic receptors. Cells which express taste
receptors, when exposed to certain chemical stimuli, elicit taste
sensation by depolarizing to generate an action potential, which is
believed to trigger the sensation. This event is believed to
trigger the release of neurotransmitters at gustatory afferent
neuron synapses, thereby initiating signaling along neuronal
pathways that mediate taste perception. See, e.g., Roper, Ann. Rev.
Neurosci., 12:329-53 (1989).
As such, taste receptors specifically recognize molecules that
elicit specific taste sensation. These molecules are also referred
to herein as "tastants." Many taste receptors belong to the
7-transmembrane receptor superfamily (Hoon et al., Cell 96:451
(1999); Adler et al., Cell 100:693 (2000)), which are also known as
G protein-coupled receptors (GPCRs). Other tastes are believed to
be mediated by channel proteins. G protein-coupled receptors
control many physiological functions, such as endocrine function,
exocrine function, heart rate, lipolysis, carbohydrate metabolism,
and transmembrane signaling. The biochemical analysis and molecular
cloning of a number of such receptors has revealed many basic
principles regarding the function of these receptors.
For example, U.S. Pat. No. 5,691,188 describes how upon a ligand
binding to a GPCR, the receptor presumably undergoes a
conformational change leading to activation of the G protein. G
proteins are comprised of three subunits: a guanyl nucleotide
binding .alpha. subunit, a .beta. subunit, and a .gamma. subunit. G
proteins cycle between two forms, depending on whether GDP or GTP
is bound to the .alpha. subunit. When GDP is bound, the G protein
exists as a heterotrimer: the G.alpha.P.gamma. complex. When GTP is
bound, the .alpha. subunit dissociates from the heterotrimer,
leaving a G.beta..gamma. complex. When a G.alpha..beta..gamma.
complex operatively associates with an activated G protein-coupled
receptor in a cell membrane, the rate of exchange of GTP for bound
GDP is increased and the rate of dissociation of the bound G.alpha.
subunit from the G.alpha..beta..gamma. complex increases. The free
G.alpha. subunit and G.beta..gamma. complex are thus capable of
transmitting a signal to downstream elements of a variety of signal
transduction pathways. These events form the basis for a
multiplicity of different cell signaling phenomena, including for
example the signaling phenomena that are identified as neurological
sensory perceptions such as taste and/or smell.
Mammals are believed to have five basic taste modalities: sweet,
bitter, sour, salty, and umami (the taste of monosodium glutamate).
See, e.g., Kawamura et al., Introduction to Umami: A Basic Taste
(1987); Kinnamon et al., Ann. Rev. Physiol., 54:715-31 (1992);
Lindemann, Physiol. Rev., 76:718-66 (1.996); Stewart et al., Am. J.
Physiol., 272:1-26(1997). Numerous physiological studies in animals
have shown that taste receptor cells may selectively respond to
different chemical stimuli. See, e.g., Akabas et al., Science,
242:1047-50 (1988); Gilbertson et al., J. Gen. Physiol., 100:803-24
(1992); Bernhardt et al., J. Physiol., 490:325-36 (1996); Cummings
et al., J. Neurophysiol., 75:1256-63 (1996).
In mammals, taste receptor cells are assembled into taste buds that
are distributed into different papillae in the tongue epithelium.
Circumvallate papillae, found at the very back of the tongue,
contain hundreds to thousands of taste buds. By contrast, foliate
papillae, localized to the posterior lateral edge of the tongue,
contain dozens to hundreds of taste buds. Further, fungiform
papillae, located at the front of the tongue, contain only a single
or a few taste buds.
Each taste bud, depending on the species, contains 50-150 cells,
including precursor cells, support cells, and taste receptor cells.
See, e.g., Lindemann, Physiol. Rev., 76:718-66 (1996). Receptor
cells are innervated at their base by afferent nerve endings that
transmit information to the taste centers of the cortex through
synapses in the brain stem and thalamus. Elucidating the mechanisms
of taste cell signaling and information processing is important to
understanding the function, regulation, and perception of the sense
of taste.
Although much is known about the psychophysics and physiology of
taste cell function, very little is known about the molecules and
pathways that mediate its sensory signaling response. The
identification and isolation of novel taste receptors and taste
signaling molecules could allow for new methods of chemical and
genetic modulation of taste transduction pathways. For example, the
availability of receptor and channel molecules could permit the
screening for high affinity agonists, antagonists, inverse
agonists, and modulators of taste activity. Such taste modulating
compounds could be useful in the pharmaceutical and food industries
to improve the taste of a variety of consumer products, or to block
undesirable tastes, e.g., in certain pharmaceuticals.
Complete or partial sequences of numerous human and other
eukaryotic chemosensory receptors are currently known. See, e.g.,
Pilpel, Y. and Lancet, D., Protein Science, 8:969-977 (1999);
Mombaerts, P., Annu. Rev. Neurosci., 22:487-50 (1999). See also,
EP0867508A2, U.S. Pat. No. 5,874,243, WO 92/17585, WO 95/18140, WO
97/17444, WO 99/67282. Because of the complexity of ligand-receptor
interactions, and more particularly tastant-receptor interactions,
information about ligand-receptor recognition is lacking. In part,
the present invention addresses the need for better understanding
of the interactions between chemosensory receptors and chemical
stimuli. The present invention also provides, among other things,
novel chemosensory receptors, and methods for utilizing such
receptors, and the genes a cDNAs encoding such receptors, to
identify molecules that can be used to modulate chemosensory
transduction, such as taste sensation.
SUMMARY OF THE INVENTION
The invention relates to a new family of G protein-coupled
receptors, and to the genes and cDNAs encoding said receptors. The
receptors are thought to be primarily involved in sweet taste
transduction as hetero-oligomeric complexes, but can be involved in
transducing signals from other taste modalities as well.
The invention provides methods for identifying putative taste
modulating compounds. Preferably, such methods may be performed by
using the receptor polypeptides and genes encoding said receptor
polypeptides disclosed herein.
Toward that end, it is an object of the invention to provide a new
family of mammalian G protein-coupled receptors, herein referred to
as T1Rs, active in taste perception as hetero-oligomeric complexes.
It is another object of the invention to provide fragments and
variants of such T1Rs that retain tastant-binding activity. It is
yet another object of the invention to provide nucleic acid
sequences or molecules that encode such T1Rs, fragments, or
variants thereof.
It is still another object of the invention to provide expression
vectors which include nucleic acid sequences that encode such T1Rs,
or fragments or variants thereof, which are operably linked to at
least one regulatory sequence such as a promoter, enhancer, or
other sequence involved in positive or negative gene transcription
and/or translation.
It is still another object of the invention to provide human or
non-human cells that functionally express at least one of such
T1Rs, or fragments or variants thereof.
It is still another object of the invention to provide T1R fusion
proteins or polypeptides which include at least a fragment of at
least one of such T1Rs.
It is another object of the invention to provide an isolated
nucleic acid molecule encoding a T1R polypeptide comprising a
nucleic acid sequence that is at least 50%, preferably 75%, 85%,
90%, 95%, 96%, 97%, 98%; or 99% identical to a nucleic acid
sequence selected from the group consisting of: SEQ ID NOS: 1, 3,
5, 7, and conservatively modified variants thereof.
It is a further object of the invention to provide an isolated
nucleic acid molecule comprising a nucleic acid sequence that
encodes a polypeptide having an amino acid sequence at least 35 to
50%, and preferably 60%, 75%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%
identical to an amino acid sequence selected from the group
consisting of SEQ ID NOS: 2, 4, 6, and conservatively modified
variants thereof, wherein the fragment is at least 20, preferably
40, 60, 80, 100, 150, 200, or 250 amino acids in length.
Optionally, the fragment can be an antigenic fragment which binds
to an anti-T1R antibody.
It is still a further object of the invention to provide an
isolated polypeptide comprising a variant of said fragment, wherein
there is a variation in at most 10, preferably 5, 4, 3, 2, or 1
amino acid residues.
It is still another object of the invention to provide agonists or
antagonists of such T1Rs, or fragments or variants thereof.
It is still another object of the invention to provide a
PDZ-interacting peptide (herein referred to as PDZIP) which can
facilitate surface expression of integral plasma membrane proteins,
specifically GPCRs. It is also an object of the invention to
provide vectors including PDZIP, host cells expressing such
vectors, and methods of using PDZIP to facilitate surface
expression.
It is yet another object of the invention to provide methods for
identifying taste modulating compounds, particularly sweet taste
modulating compounds. Preferably, such methods may be performed by
using a combination of T1Rs, or fragments or variants thereof, and
genes encoding such T1Rs, or fragments or variants thereof,
disclosed herein.
It is still a further object of the invention to provide a method
of screening one or more compounds for the presence of a taste
detectable by a mammal, comprising: a step of contacting said one
or more compounds with at least one hetero-oligomeric complex of
the disclosed T1Rs, fragments or variants thereof, preferably
wherein the mammal is a human.
It is another object of the invention to provided a method for
simulating a taste, comprising the steps of: for each of a
plurality of T1R hetero-oligomers, or fragments of variants thereof
disclosed herein, preferably human T1Rs, ascertaining the extent to
which the T1R hetero-oligomer interacts with the tastant; and
combining a plurality of compounds, each having a previously
ascertained interaction with one or more of the T1R
hetero-oligomer, in amounts that together provide a
receptor-stimulation profile that mimics the profile for the taste.
Interaction of a tastant with a T1R hetero-oligomer can be
determined using any of the binding or reporter assays described
herein. The plurality of compounds may then be combined to form a
mixture. If desired, one or more of the plurality of the compounds
can be combined covalently. The combined compounds substantially
stimulate at least 50%, 60%, 70%, 75%, 80% or 90% or all of the
receptors that are substantially stimulated by the tastant.
In yet another aspect of the invention, a method is provided
wherein a plurality of standard compounds are tested against a
plurality of T1R hetero-oligomers, or fragments or variants
thereof, to ascertain the extent to which the T1Rs hetero-oligomers
each interact with each standard compound, thereby generating a
receptor stimulation profile for each standard compound. These
receptor stimulation profiles may then be stored in a relational
database on a data storage medium. The method may further comprise
providing a desired receptor-stimulation profile for a taste;
comparing the desired receptor stimulation profile to the
relational database; and ascertaining one or more combinations of
standard compounds that most closely match the desired
receptor-stimulation profile. The method may further comprise
combining standard compounds in one or more of the ascertained
combinations to simulate the taste.
BRIEF DESCRIPTION OF THE FIGURES
FIG. 1A contains the results of an immunofluorescence staining of
Myc-tagged hT1R2 which indicates that PDZIP increases expression of
hT1R2 on the plasma membrane.
FIG. 1B contains FACS analysis data demonstrating that PDZIP
increases expression of hT1R2 on the plasma membrane.
FIGS. 2A through 2L contain calcium imaging data demonstrating
hT1R2/hT1R3 responses to sweet stimuli.
FIG. 3 contains cDNA expression data showing that hT1R2 and hT1R3
are expressed in human tongue epithelium.
FIG. 4 A-E contains fluorescence microscopy data which indicates
that hT1R2 and hT1R3 act in combination and bind sweet taste
stimuli ligands.
FIG. 5 contains normalized dose-response curves the results of
which indicate that T1R2 and T1R3 function together as the human
sweet taste receptor based on their dose-specific interaction with
values sweet stimuli.
FIG. 6 presents cyclamate responses for cells expressing
hT1R2/hT1R3 and for cells expressing hT1R3.
FIG. 7 depicts the glutamate binding site in the x-ray crystal
structure of mGluR1.
DETAILED DESCRIPTION OF THE INVENTION
The invention thus provides isolated nucleic acid molecules
encoding taste-cell-specific G protein-coupled receptors ("GPCR"),
and the polypeptides they encode. These nucleic acid molecules and
the polypeptides that they encode are members of the T1R family of
taste-cell-specific GPCRs. Members of the T1R family of
taste-cell-specific GPCRs are identified in Hoon et al., Cell,
96:541-551 (1999), WO 00/06592, WO 00/06593, and U.S. Ser. No.
09/799,629, all of which are incorporated herein by reference in
their entireties.
More particularly, the invention provides nucleic acids encoding a
novel family of taste-cell-specific GPCRs. These nucleic acids and
the receptors that they encode are referred to as members of the
"T1R" family of taste-cell-specific GPCRs. In particular
embodiments of the invention, the T1R family members include rT1R3,
mT1R3, hT1R3, and hT1R1. While not wishing to be bound by theory,
it is believed that these taste-cell-specific GPCRs are components
of the taste transduction pathway, and may be involved in the taste
detection of sweet substances and/or other taste modalities.
Further, it is believed that T1R family members act in combination
as hetero-oligomeric complexes with other T1R family members, other
taste-cell-specific GPCRs, or a combination thereof, to thereby
effect chemosensory taste transduction. For instance, it is
believed that T1R2 and T1R3 may be co-expressed within the same
taste receptor cell type, and the two receptors may physically
interact to form a heterodimeric taste receptor. Additional
receptors may also be co-expressed forming hetero-oligomeric taste
receptor with the T1Rs disclosed herein. Alternatively, T1R2 and
T1R3 may both independently bind to the same type of ligand, and
their combined binding may result in a specific perceived taste
sensation.
These nucleic acids provide valuable probes for the identification
of taste cells, as the nucleic acids are specifically expressed in
taste cells. For example, probes for T1R polypeptides and proteins
can be used to identify taste cells present in foliate,
circumvallate, and fungiform papillae, as well as taste cells
present in the geschmackstreifen, oral cavity, gastrointestinal
epithelium, and epiglottis. They may also serve as tools for the
generation of taste topographic maps that elucidate the
relationship between the taste cells of the tongue and taste
sensory neurons leading to taste centers in the brain. In
particular, methods of detecting T1Rs can be used to identify taste
cells sensitive to sweet tastants or other specific modalities of
tastants. Furthermore, the nucleic acids and the proteins they
encode can be used as probes to dissect taste-induced behaviors.
Also, chromosome localization of the genes encoding human T1Rs can
be used to identify diseases, mutations, and traits caused by and
associated with T1R family members.
The nucleic acids encoding the T1R proteins and polypeptides of the
invention can be isolated from a variety of sources, genetically
engineered, amplified, synthesized, and/or expressed recombinantly
according to the methods disclosed in WO 00/035374, which is herein
incorporated by reference in its entirety.
The invention also provides methods of screening for modulators,
e.g., activators, inhibitors, stimulators, enhancers, agonists, and
antagonists, of these novel taste-cell-specific GPCRs. Such
modulators of taste transduction are useful for pharmacological,
chemical, and genetic modulation of taste signaling pathways. These
methods of screening can be used to identify high affinity agonists
and antagonists of taste cell activity. These modulatory compounds
can then be used in the food and pharmaceutical industries to
customize taste, e.g., to modulate the sweet tastes of foods or
drugs.
Thus, the invention provides assays for detecting and
characterizing taste modulation, wherein T1R family members act as
direct or indirect reporter molecules of the effect of modulators
on taste transduction. GPCRs can be used in assays to, e.g.,
measure changes in ligand binding, ion concentration, membrane
potential, current flow, ion flux, transcription, signal
transduction, receptor-ligand interactions, second messenger
concentrations, in vitro, in vivo, and ex vivo. In one embodiment,
members of the T1R family can be used as indirect reporters via
attachment to a second reporter molecule such as green fluorescent
protein (see, e.g., Mistili & Spector, Nature Biotechnology,
15:961-964 (1997)). In another embodiment, T1R family members may
be recombinantly expressed in cells, and modulation of taste
transduction via GPCR activity may be assayed by measuring changes
in Ca.sup.2+ levels and other intracellular messages such as cAMP,
cGMP, or IP3.
In certain embodiments, a domain of a T1R polypeptide, e.g., an
extracellular, transmembrane, or intracellular domain, is fused to
a heterologous polypeptide, thereby forming a chimeric polypeptide,
e.g., a chimeric polypeptide with GPCR activity. Such chimeric
polypeptides are useful, e.g., in assays to identify ligands,
agonists, antagonists, or other modulators of a T1R polypeptide. In
addition, such chimeric polypeptides are useful to create novel
taste receptors with novel ligand binding specificity, modes of
regulation, signal transduction pathways, or other such properties,
or to create novel taste receptors with novel combinations of
ligand binding specificity, modes of regulation, signal
transduction pathways, etc.
In one embodiment, a T1R polypeptide is expressed in a eukaryotic
cell as a chimeric receptor with a heterologous, chaperone sequence
that facilitates plasma membrane trafficking, or maturation and
targeting through the secretory pathway. The optional heterologous
sequence may be a rhodopsin, sequence, such as an N-terminal
fragment of a rhodopsin. Alternatively, the optional heterologous
sequence may be a PDZ-interacting peptide, such as a C-terminal
PDZIP fragment (SEQ ID NO 10). PDZIP is an ER export signal which,
according to the present invention, has been shown to facilitate
surface expression of heterologous proteins such as the T1R
receptors described herein. More particularly, in one aspect of the
invention, PDZIP can be used to promote proper targeting of
problematic membrane proteins such as olfactory receptors, T2R
taste receptors, and the T1R taste receptors described herein.
Such chimeric T1R receptors can be expressed in any eukaryotic
cell, such as HEK-293 cells. Preferably, the cells comprise a G
protein, e.g., G.alpha.15 or G.alpha.16 or another type of
promiscuous G protein capable of pairing a wide range of
chemosensory GPCRs to an intracellular signaling pathway or to a
signaling protein such as phospholipase C. Activation of such
chimeric receptors in such cells can be detected using any standard
method, such as by detecting changes in intracellular calcium by
detecting FURA-2 dependent fluorescence in the cell. If preferred
host cells do not express an appropriate G protein, they may be
transfected with a gene encoding a promiscuous G protein such as
those described in U.S. application Ser. No. 60/243,770, which is
herein incorporated by reference in its entirety.
Methods of assaying for modulators of taste transduction include in
vitro ligand-binding assays using: T1R polypeptides, portions
thereof, i.e., the extracellular domain, transmembrane region, or
combinations thereof, or chimeric proteins comprising one or more
domains of a T1R family member; oocyte or tissue culture cells
expressing T1R polypeptides, fragments, or fusion proteins;
phosphorylation and dephosphorylation of T1R family members; G
protein binding to GPCRs; ligand-binding assays; voltage, membrane
potential and conductance changes; ion flux assays; changes in
intracellular second messengers such as cGMP, CAMP and inositol
triphosphate (IP3); changes in intracellular calcium levels; and
neurotransmitter release.
Further, the invention provides methods of detecting T1R nucleic
acid and protein expression, allowing investigation of taste
transduction regulation and specific identification of taste
receptor cells. T1R family members also provide useful nucleic acid
probes for paternity and forensic investigations. T1R genes are
also useful as a nucleic acid probes for identifying taste receptor
cells, such as foliate, fungiform, circumvallate,
geschmackstreifen, and epiglottis taste receptor cells. T1R
receptors can also be used to generate monoclonal and polyclonal
antibodies useful for identifying taste receptor cells. Taste
receptor cells can be identified using techniques such as reverse
transcription and amplification of mRNA, isolation of total RNA or
poly A+ RNA, northern blotting, dot blotting, in situ
hybridization, RNase protection, S1 digestion, probing DNA
microchip arrays, western blots, and the like.
Functionally, the T1R polypeptides comprise a family of related
seven transmembrane G protein-coupled receptors, which are believed
to be involved in taste transduction and may interact with a G
protein to mediate taste signal transduction as hetero-oligomeric
complexes (see, e.g., Fong, Cell Signal, 8:217 (1996); Baldwin,
Curr. Opin. Cell Biol., 6:180 (1994)). Structurally, the nucleotide
sequences of T1R family members may encode related polypeptides
comprising an extracellular domain, seven transmembrane domains,
and a cytoplasmic domain. Related T1R family genes from other
species share at least about 50%, and optionally 60%, 70%, 80%, or
90%, nucleotide sequence identity over a region of at least about
50 nucleotides in length, optionally 100, 200, 500, or more
nucleotides in length to SEQ ID NOS 1, 3, 5, 7, or conservatively
modified variants thereof, or encode polypeptides sharing at least
about 35 to 50%, and optionally 60%, 70%, 80%, or 90%, amino acid
sequence identity over an amino acid region at least about 25 amino
acids in length, optionally 50 to 100 amino acids in length to SEQ
ID NOS: 2, 4, 6, or conservatively modified variants thereof.
Several consensus amino acid sequences or domains have also been
identified that are characteristic of T1R family members. For
example, T1R family members typically comprise a sequence having at
least about 50%, optionally 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95-99%, or higher, identity to T1R consensus sequences 1 and 2 (SEQ
ID NOs 8 and 9, respectively). These conserved domains thus can be
used to identify members of the T1R family, by identity, specific
hybridization or amplification, or specific binding by antibodies
raised against a domain. Such T1R consensus sequences have the
following amino acid sequences:
TABLE-US-00001 T1R Family Consensus Sequence 1: (SEQ ID NO: 8)
(TR)C(FL)(RQP)R(RT)(SPV)(VERKT)FL(AE)(WL)(RHG)E T1R Family
Consensus Sequence 2: (SEQ ID NO: 9)
(LQ)P(EGT)(NRC)YN(RE)A(RK)(CGF)(VLI)T(FL)(AS)(ML)
These consensus sequences are inclusive of those found in the T1R
polypeptides described herein, but T1R family members from other
organisms may be expected to comprise consensus sequences having
about 75% identity or more to the inclusive consensus sequences
described specifically herein.
Specific regions of the T1R nucleotide and amino acid sequences may
be used to identify polymorphic variants, interspecies homologs,
and alleles of T1R family members. This identification can be made
in vitro, e.g., under stringent hybridization conditions or PCR
(e.g., using primers encoding the T1R consensus sequences
identified above), or by using the sequence information in a
computer system for comparison with other nucleotide sequences.
Different alleles of T1R genes within a single species population
will also be useful in determining whether differences in allelic
sequences correlate to differences in taste perception between
members of the population. Classical PCR-type amplification and
cloning techniques are useful for isolating orthologs, for example,
where degenerate primers are sufficient for detecting related genes
across species, which typically have a higher level of relative
identity than paralogous members of the T1R family within a single
species.
Typically, identification of polymorphic variants and alleles of
T1R family members can be made by comparing an amino acid sequence
of about 25 amino acids or more, e.g., 50-100 amino acids. Amino
acid identity of approximately at least 35 to 50%, and optionally
60%, 70%, 75%, 80%, 85%, 90%, 95-99%, or above typically
demonstrates that a protein is a polymorphic variant, interspecies
homolog, or allele of a T1R family member. Sequence comparison can
be performed using any of the sequence comparison algorithms
discussed below. Antibodies that bind specifically to T1R
polypeptides or a conserved region thereof can also be used to
identify alleles, interspecies homologs, and polymorphic
variants.
Polymorphic variants, interspecies homologs, and alleles of T1R
genes can be confirmed by examining taste-cell-specific expression
of the putative T1R polypeptide. Typically, T1R polypeptides having
an amino acid sequence disclosed herein can be used as a positive
control in comparison to the putative T1R polypeptide to
demonstrate the identification of a polymorphic variant or allele
of the T1R family member. The polymorphic variants, alleles, and
interspecies homologs are expected to retain the seven
transmembrane structure of a G protein-coupled receptor. For
further detail, see WO 00/06592, which discloses related T1R family
members, GPCR-B3s, the contents of which are herein incorporated by
reference in a manner consistent with this disclosure. GPCR-B3
receptors are referred to herein as rT1R1 and mT1R1. Additionally,
see WO 00/06593, which also discloses related T1R family members,
GPCR-B4s, the contents of which are herein incorporated by
reference in a manner consistent with this disclosure. GPCR-B4
receptors are referred to herein as rT1R2 and mT1R2.
Nucleotide and amino acid sequence information for T1R family
members may also be used to construct models of taste-cell-specific
polypeptides in a computer system. These models can be subsequently
used to identify compounds that can activate or inhibit T1R
receptor proteins. Such compounds that modulate the activity of T1R
family members can then be used to investigate the role of T1R
genes and receptors in taste transduction.
The present invention also provides assays, preferably high
throughput assays, to identify molecules that interact with and/or
modulate T1R polypeptide hetero-oligomeric complexes. In numerous
assays, a particular domain of a T1R family member is used in
combination with a particular domain of another T1R family member,
e.g., an extracellular, transmembrane, or intracellular domain or
region. In numerous embodiments, an extracellular domain,
transmembrane region or combination thereof may be bound to a solid
substrate, and used, e.g., to isolate ligands, agonists,
antagonists, or any other molecules that can bind to and/or
modulate the activity of a T1R polypeptide.
While not wishing to be bound to any particular theory, the T1R
family of receptors is predicted to be involved in sweet taste
transduction by virtue of the linkage of mT1R3 to the Sac locus, a
locus on the distal end of chromosome four that influences sweet
taste. Human T1R3 has also been reported to localize to
1p36.2-1p36.33, a region that displays conserved synteny with the
mouse interval containing Sac and T1R1. Further hetero-oligomeric
complexes of T1R family members have been shown to respond to sweet
taste stimuli. However, T1R type receptors may mediate other taste
modalities, such as bitter, umami, sour and salty.
Various conservative mutations and substitutions are envisioned to
be within the scope of the invention. For instance, it would be
within the level of skill in the art to perform amino acid
substitutions using known protocols of recombinant gene technology
including PCR, gene cloning, site-directed mutagenesis of cDNA,
transfection of host cells, and in-vitro transcription. The
variants could then be screened for taste-cell-specific GPCR
functional activity.
A. DEFINITIONS
As used herein, the following terms have the meanings ascribed to
them unless specified otherwise.
"Taste cells" include neuroepithelial cells that are organized into
groups to form taste buds of the tongue, e.g., foliate, fungiform,
and circumvallate cells (see, e.g., Roper et al., Ann. Rev.
Neurosci. 12:329-353 (1989)). Taste cells are also found in the
palate and other tissues, such as the esophagus and the
stomach.
"T1R" refers to one or more members of a family of G
protein-coupled receptors that are expressed in taste cells such as
foliate, fungiform, and circumvallate cells, as well as cells of
the palate, and esophagus (see, e.g., Hoon et al., Cell, 96:541-551
(1999), herein incorporated by reference in its entirety). Members
of this family are also referred to as GPCR-B3 and TR1 in WO
00/06592 as well as GPCR-B4 and TR2 in WO 00/06593. GPCR-B3 is also
herein referred to as rT1R1, and GPCR-B4 is referred to as rT1R2.
Taste receptor cells can also be identified on the basis of
morphology (see, e.g., Roper, supra), or by the expression of
proteins specifically expressed in taste cells. T1R family members
may have the ability to act as receptors for sweet taste
transduction, or to distinguish between various other taste
modalities.
"T1R" nucleic acids encode a family of GPCRs with seven
transmembrane regions that have "G protein-coupled receptor
activity," e.g., they may bind to G proteins in response to
extracellular stimuli and promote production of second messengers
such as IP3, cAMP, cGMP, and Ca.sup.2+ via stimulation of enzymes
such as phospholipase C and adenylate cyclase (for a description of
the structure and function of GPCRs, see, e.g., Fong, supra, and
Baldwin, supra). A single taste cell may contain many distinct T1R
polypeptides.
The term "T1R" family therefore refers to polymorphic variants,
alleles, mutants, and interspecies homologs that: (1) have at least
about 35 to 50% amino acid sequence identity, optionally about 60,
75, 80, 85, 90, 95, 96, 97, 98, or 99% amino acid sequence identity
to SEQ ID NOS: 2, 4, or 6 over a window of about 25 amino acids,
optionally 50-100 amino acids; (2) specifically bind to antibodies
raised against an immunogen comprising an amino acid sequence
selected from the group consisting of SEQ ID NOS: 2, 4, 6, and
conservatively modified variants thereof; (3) are encoded by a
nucleic acid molecule which specifically hybridize (with a size of
at least about 100, optionally at least about 500-1000 nucleotides)
under stringent hybridization conditions to a sequence selected
from the group consisting of SEQ ID NOS: 1, 3, 5, 7, and
conservatively modified variants thereof; or (4) comprise a
sequence at least about 35 to 50% identical to an amino acid
sequence selected from the group consisting of SEQ ID NOS: 2, 4,
and 6.
Topologically, certain chemosensory GPCRs have an "N-terminal
domain;" "extracellular domains;" "transmembrane domains"
comprising seven transmembrane regions, and corresponding
cytoplasmic, and extracellular loops; "cytoplasmic domains," and a
"C-terminal domain" (see, e.g., Hoon et al., Cell, 96:541-551
(1999); Buck & Axel, Cell, 65:175-187 (1991)). These domains
can be structurally identified using methods known to those of
skill in the art, such as sequence analysis programs that identify
hydrophobic and hydrophilic domains (see, e.g., Shyer,
Biochemistry, (3rd ed. 1988); see also any of a number of Internet
based sequence analysis programs, such as those found at
dot.imgen.bcm.tmc.edu). Such domains are useful for making chimeric
proteins and for in vitro assays of the invention, e.g.,
ligand-binding assays.
"Extracellular domains" therefore refers to the domains of T1R
polypeptides that protrude from the cellular membrane and are
exposed to the extracellular face of the cell. Such domains
generally include the "N terminal domain" that is exposed to the
extracellular face of the cell, and optionally can include portions
of the extracellular loops of the transmembrane domain that are
exposed to the extracellular face of the cell, i.e., the loops
between transmembrane regions 2 and 3, between transmembrane
regions 4 and 5, and between transmembrane regions 6 and 7.
The "N-terminal domain" region starts at the N-terminus and extends
to a region close to the start of the transmembrane domain. More
particularly, in one embodiment of the invention, this domain
starts at the N-terminus and ends approximately at the conserved
glutamic acid at amino acid position 563 plus or minus
approximately 20 amino acid. These extracellular domains are useful
for in vitro ligand-binding assays, both soluble and solid phase.
In addition, transmembrane regions, described below, can also bind
ligand either in combination with the extracellular domain, and are
therefore also useful for in vitro ligand-binding assays.
"Transmembrane domain," which comprises the seven "transmembrane
regions," refers to the domain of T1R polypeptides that lies within
the plasma membrane, and may also include the corresponding
cytoplasmic (intracellular) and extracellular loops. In one
embodiment, this region corresponds to the domain of T1R family
members which starts approximately at the conserved glutamic acid
residue at amino acid position 563 plus or minus 20 amino acids and
ends approximately at the conserved tyrosine amino acid residue at
position 812 plus or minus approximately 10 amino acids. The seven
transmembrane regions and extracellular and cytoplasmic loops can
be identified using standard methods, as described in Kyte &
Doolittle, J. Mol. Biol., 157:105-32 (1982)), or in Stryer,
supra.
"Cytoplasmic domains" refers to the domains of T1R polypeptides
that face the inside of the cell, e.g., the "C-terminal domain" and
the intracellular loops of the transmembrane domain, e.g., the
intracellular loop between transmembrane regions 1 and 2, the
intracellular loop between transmembrane regions 3 and 4, and the
intracellular loop between transmembrane regions 5 and 6.
"C-terminal domain" refers to the region that spans the end of the
last transmembrane domain and the C-terminus of the protein, and
which is normally located within the cytoplasm. In one embodiment,
this region starts at the conserved tyrosine amino acid residue at
position 812 plus or minus approximately 10 amino acids and
continues to the C-terminus of the polypeptide.
The term "ligand-binding region" or "ligand-binding domain" refers
to sequences derived from a chemosensory receptor, particularly a
taste receptor, that substantially incorporates at least the
extracellular domain of the receptor. In one embodiment, the
extracellular domain of the ligand-binding region may include the
N-terminal domain and, optionally, portions of the transmembrane
domain, such as the extracellular loops of the transmembrane
domain. The ligand-binding region may be capable of binding a
ligand, and more particularly, a tastant.
The phrase "hetero-oligomer" or "hetero-oligomeric complex" in the
context of the T1R receptors or polypeptides of the invention
refers to a functional combination of at least two T1R receptors or
polypeptides, at least one T1R receptor or polypeptide and another
taste-cell-specific GPCRs, or a combination thereof, to thereby
effect chemosensory taste transduction. For instance, the receptors
or polypeptides may be co-expressed within the same taste receptor
cell type, and the two receptors may physically interact to form a
hetero-oligomeric taste receptor. Alternatively, the receptors or
polypeptides may both independently bind to the same type of
ligand, and their combined binding may result in a specific
perceived taste sensation.
The phrase "functional effects" in the context of assays for
testing compounds that modulate T1R family member mediated taste
transduction includes the determination of any parameter that is
indirectly or directly under the influence of the receptor, e.g.,
functional, physical and chemical effects. It includes ligand
binding, changes in ion flux, membrane potential, current flow,
transcription, G protein binding, GPCR phosphorylation or
dephosphorylation, signal transduction, receptor-ligand
interactions, second messenger concentrations (e.g., cAMP, cGMP,
IP3, or intracellular Ca.sup.2+), in vitro, in vivo, and ex vivo
and also includes other physiologic effects such increases or
decreases of neurotransmitter or hormone release.
By "determining the functional effect" in the context of assays is
meant assays for a compound that increases or decreases a parameter
that is indirectly or directly under the influence of a T1R family
member, e.g., functional, physical and chemical effects. Such
functional effects can be measured by any means known to those
skilled in the art, e.g., changes in spectroscopic characteristics
(e.g., fluorescence, absorbance, refractive index), hydrodynamic
(e.g., shape), chromatographic, or solubility properties, patch
clamping, voltage-sensitive dyes, whole cell currents, radioisotope
efflux, inducible markers, oocyte T1R gene expression; tissue
culture cell T1R expression; transcriptional activation of T1R
genes; ligand-binding assays; voltage, membrane potential and
conductance changes; ion flux assays; changes in intracellular
second messengers such as cAMP, cGMP, and inositol triphosphate
(IP3); changes in intracellular calcium levels; neurotransmitter
release, and the like.
"Inhibitors," "activators," and "modulators" of T1R genes or
proteins are used interchangeably to refer to inhibitory,
activating, or modulating molecules identified using in vitro and
in vivo assays for taste transduction, e.g., ligands, agonists,
antagonists, and their homologs and mimetics. Inhibitors are
compounds that, e.g., bind to, partially or totally block
stimulation, decrease, prevent, delay activation, inactivate,
desensitize, or down regulate taste transduction, e.g.,
antagonists. Activators are compounds that, e.g., bind to,
stimulate, increase, open, activate, facilitate, enhance
activation, sensitize, or up regulate taste transduction, e.g.,
agonists. Modulators include compounds that, e.g., alter the
interaction of a receptor with: extracellular proteins that bind
activators or inhibitor (e.g., ebnerin and other members of the
hydrophobic carrier family); G proteins; kinases (e.g., homologs of
rhodopsin kinase and beta adrenergic receptor kinases that are
involved in deactivation and desensitization of a receptor); and
arrestins, which also deactivate and desensitize receptors.
Modulators can include genetically modified versions of T1R family
members, e.g., with altered activity, as well as naturally
occurring and synthetic ligands, antagonists, agonists, small
chemical molecules and the like. Such assays for inhibitors and
activators include, e.g., expressing T1R family members in cells or
cell membranes, applying putative modulator compounds, in the
presence or absence of tastants, e.g., sweet tastants, and then
determining the functional effects on taste transduction, as
described above. Samples or assays comprising T1R family members
that are treated with a potential activator, inhibitor, or
modulator are compared to control samples without the inhibitor,
activator, or modulator to examine the extent of modulation.
Control samples (untreated with modulators) are assigned a relative
T1R activity value of 100%. Inhibition of a T1R is achieved when
the T1R activity value relative to the control is about 80%,
optionally 50% or 25-0%. Activation of a T1R is achieved when the
T1R activity value relative to the control is 110%, optionally
150%, optionally 200-500%, or 1000-3000% higher.
The terms "purified," "substantially purified," and "isolated" as
used herein refer to the state of being free of other, dissimilar
compounds with which the compound of the invention is normally
associated in its natural state, so that the "purified,"
"substantially purified," and "isolated" subject comprises at least
0.5%, 1%, 5%, 10%, or 20%, and most preferably at least 50% or 75%
of the mass, by weight, of a given sample. In one preferred
embodiment, these terms refer to the compound of the invention
comprising at least 95% of the mass, by weight, of a given sample.
As used herein, the terms "purified," "substantially purified," and
"isolated" "isolated," when referring to a nucleic acid or protein,
of nucleic acids or proteins, also refers to a state of
purification or concentration different than that which occurs
naturally in the mammalian, especially human, body. Any degree of
purification or concentration greater than that which occurs
naturally in the mammalian, especially human, body, including (1)
the purification from other associated structures or compounds or
(2) the association with structures or compounds to which it is not
normally associated in the mammalian, especially human, body, are
within the meaning of "isolated." The nucleic acid or protein or
classes of nucleic acids or proteins, described herein, may be
isolated, or otherwise associated with structures or compounds to
which they are not normally associated in nature, according to a
variety of methods and processes known to those of skill in the
art.
The term "nucleic acid" or "nucleic acid sequence" refers to a
deoxy-ribonucleotide or ribonucleotide oligonucleotide in either
single- or double-stranded form. The term encompasses nucleic
acids, i.e., oligonucleotides, containing known analogs of natural
nucleotides. The term also encompasses nucleic-acid-like structures
with synthetic backbones (see e.g., Oligonucleotides and Analogues,
a Practical Approach, ed. F. Eckstein, Oxford Univ. Press (1991);
Antisense Strategies, Annals of the N.Y. Academy of Sciences, Vol.
600, Eds. Baserga et al. (NYAS 1992); Milligan J. Med. Chem.
36:1923-1937 (1993); Antisense Research and Applications (1993, CRC
Press), WO 97/03211; WO 96/39154; Mata, Toxicol. Appl. Pharmacol.
144:189-197 (1997); Strauss-Soukup, Biochemistry 36:8692-8698
(1997); Samstag, Antisense Nucleic Acid Drug Dev, 6:153-156
(1996)).
Unless otherwise indicated, a particular nucleic acid sequence also
implicitly encompasses conservatively modified variants thereof
(e.g., degenerate codon substitutions) and complementary sequences,
as well as the sequence explicitly indicated. Specifically,
degenerate codon substitutions may be achieved by generating, e.g.,
sequences in which the third position of one or more selected
codons is substituted with mixed-base and/or deoxyinosine residues
(Batzer et al., Nucleic Acid Res., 19:5081 (1991); Ohtsuka et al.,
J. Biol. Chem., 260:2605-2608 (1985); Rossolini et al., Mol. Cell.
Probes, 8:91-98 (1994)). The term nucleic acid is used
interchangeably with gene, cDNA, mRNA, oligonucleotide, and
polynucleotide.
The terms "polypeptide," "peptide" and "protein" are used
interchangeably herein to refer to a polymer of amino acid
residues. The terms apply to amino acid polymers in which one or
more amino acid residue is an artificial chemical mimetic of a
corresponding naturally occurring amino acid, as well as to
naturally occurring amino acid polymers and non-naturally occurring
amino acid polymer.
The term "plasma membrane translocation domain" or simply
"translocation domain" means a polypeptide domain that, when
incorporated into a polypeptide coding sequence, can with great
efficiency "chaperone" or "translocate" the hybrid ("fusion")
protein to the cell plasma membrane. For instance, a "translocation
domain" may be derived from the amino terminus of the bovine
rhodopsin receptor polypeptide, a 7-transmembrane receptor.
However, rhodopsin from any mammal may be used, as can other
translocation facilitating sequences. Thus, the translocation
domain is particularly efficient in translocating 7-transmembrane
fusion proteins to the plasma membrane, and a protein (e.g., a
taste receptor polypeptide) comprising an amino terminal
translocating domain will be transported to the plasma membrane
more efficiently than without the domain. However, if the
N-terminal domain of the polypeptide is active in binding, as with
the T1R receptors of the present invention, the use of other
translocation domains may be preferred. For instance, a
PDZ-interacting peptide, as described herein, may be used.
The "translocation domain," "ligand-binding domain", and chimeric
receptors compositions described herein also include "analogs," or
"conservative variants" and "mimetics" ("peptidomimetics") with
structures and activity that substantially correspond to the
exemplary sequences. Thus, the terms "conservative variant" or
"analog" or "mimetic" refer to a polypeptide which has a modified
amino acid sequence, such that the change(s) do not substantially
alter the polypeptide's (the conservative variant's) structure
and/or activity, as defined herein. These include conservatively
modified variations of an amino acid sequence, i.e., amino acid
substitutions, additions or deletions of those residues that are
not critical for protein activity, or substitution of amino acids
with residues having similar properties (e.g., acidic, basic,
positively or negatively charged, polar or non-polar, etc.) such
that the substitutions of even critical amino acids does not
substantially alter structure and/or activity.
More particularly, "conservatively modified variants" applies to
both amino acid and nucleic acid sequences. With respect to
particular nucleic acid sequences, conservatively modified variants
refers to those nucleic acids which encode identical or essentially
identical amino acid sequences, or where the nucleic acid does not
encode an amino acid sequence, to essentially identical sequences.
Because of the degeneracy of the genetic code, a large number of
functionally identical nucleic acids encode any given protein.
For instance, the codons GCA, GCC, GCG and GCU all encode the amino
acid alanine. Thus, at every position where an alanine is specified
by a codon, the codon can be altered to any of the corresponding
codons described without altering the encoded polypeptide.
Such nucleic acid variations are "silent variations," which are one
species of conservatively modified variations. Every nucleic acid
sequence herein which encodes a polypeptide also describes every
possible silent variation of the nucleic acid. One of skill will
recognize that each codon in a nucleic acid (except AUG, which is
ordinarily the only codon for methionine, and TGG, which is
ordinarily the only codon for tryptophan) can be modified to yield
a functionally identical molecule. Accordingly, each silent
variation of a nucleic acid which encodes a polypeptide is implicit
in each described sequence.
Conservative substitution tables providing functionally similar
amino acids are well known in the art. For example, one exemplary
guideline to select conservative substitutions includes (original
residue followed by exemplary substitution): ala/gly or ser;
arg/lys; asn/gln or his; asp/glu; cys/ser; gln/asn; gly/asp;
gly/ala or pro; his/asn or gin; ile/leu or val; leu/ile or val;
lys/arg or gln or glu; met/leu or tyr or ile; phe/met or leu or
tyr; ser/thr; thr/ser; trp/tyr; tyr/trp or phe; val/ile or leu. An
alternative exemplary guideline uses the following six groups, each
containing amino acids that are conservative substitutions for one
another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic
acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4)
Arginine (R), Lysine (I); 5) Isoleucine (I), Leucine (L),
Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y),
Tryptophan (W); (see also, e.g., Creighton, Proteins, W.H. Freeman
and Company (1984); Schultz and Schimer, Principles of Protein
Structure, Springer-Vrlag (1979)). One of skill in the art will
appreciate that the above-identified substitutions are not the only
possible conservative substitutions. For example, for some
purposes, one may regard all charged amino acids as conservative
substitutions for each other whether they are positive or negative.
In addition, individual substitutions, deletions or additions that
alter, add or delete a single amino acid or a small percentage of
amino acids in an encoded sequence can also be considered
"conservatively modified variations."
The terms "mimetic" and "peptidomimetic" refer to a synthetic
chemical compound that has substantially the same structural and/or
functional characteristics of the polypeptides, e.g., translocation
domains, ligand-binding domains, or chimeric receptors of the
invention. The mimetic can be either entirely composed of
synthetic, non-natural analogs of amino acids, or may be a chimeric
molecule of partly natural peptide amino acids and partly
non-natural analogs of amino acids. The mimetic can also
incorporate any amount of natural amino acid conservative
substitutions as long as such substitutions also do not
substantially alter the mimetic's structure and/or activity.
As with polypeptides of the invention which are conservative
variants, routine experimentation will determine whether a mimetic
is within the scope of the invention, i.e., that its structure
and/or function is not substantially altered. Polypeptide mimetic
compositions can contain any combination of non-natural structural
components, which are typically from three structural groups: a)
residue linkage groups other than the natural amide bond ("peptide
bond") linkages; b) non-natural residues in place of naturally
occurring amino acid residues; or c) residues which induce
secondary structural mimicry, i.e., to induce or stabilize a
secondary structure, e.g., a beta turn, gamma turn, beta sheet,
alpha helix conformation, and the like. A polypeptide can be
characterized as a mimetic when all or some of its residues are
joined by chemical means other than natural peptide bonds.
Individual peptidomimetic residues can be joined by peptide bonds,
other chemical bonds or coupling means, such as, e.g.,
glutaraldehyde, N-hydroxysuccinimide esters, bifunctional
maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or
N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an
alternative to the traditional amide bond ("peptide bond") linkages
include, e.g., ketomethylene (e.g., --C(.dbd.O)--CH.sub.2-- for
--C(.dbd.O)--NH--), aminomethylene (CH.sub.2--NH), ethylene, olefin
(CH.dbd.CH), ether (CH.sub.2--O), thioether (CH.sub.2--S),
tetrazole (CN.sub.4), thiazole, retroamide, thioamide, or ester
(see, e.g., Spatola, Chemistry and Biochemistry of Amino Acids,
Peptides and Proteins, Vol. 7, pp 267-357, "Peptide Backbone
Modifications," Marcel Dekker, NY (1983)). A polypeptide can also
be characterized as a mimetic by containing all or some non-natural
residues in place of naturally occurring amino acid residues;
non-natural residues are well described in the scientific and
patent literature.
A "label" or a "detectable moiety" is a composition detectable by
spectroscopic, photochemical, biochemical, immunochemical, or
chemical means. For example, useful labels include .sup.32P,
fluorescent dyes, electron-dense reagents, enzymes (e.g., as
commonly used in an ELISA), biotin, digoxigenin, or haptens and
proteins which can be made detectable, e.g., by incorporating a
radiolabel into the peptide or used to detect antibodies
specifically reactive with the peptide.
A "labeled nucleic acid probe or oligonucleotide" is one that is
bound, either covalently, through a linker or a chemical bond, or
noncovalently, through ionic, van der Waals, electrostatic, or
hydrogen bonds to a label such that the presence of the probe may
be detected by detecting the presence of the label bound to the
probe.
As used herein a "nucleic acid probe or oligonucleotide" is defined
as a nucleic acid capable of binding to a target nucleic acid of
complementary sequence through one or more types of chemical bonds,
usually through complementary base pairing, usually through
hydrogen bond formation. As used herein, a probe may include
natural (i.e., A, G, C, or T) or modified bases (7-deazaguanosine,
inosine, etc.). In addition, the bases in a probe may be joined by
a linkage other than a phosphodiester bond, so long as it does not
interfere with hybridization. Thus, for example, probes may be
peptide nucleic acids in which the constituent bases are joined by
peptide bonds rather than phosphodiester linkages. It will be
understood by one of skill in the art that probes may bind target
sequences lacking complete complementarity with the probe sequence
depending upon the stringency of the hybridization conditions. The
probes are optionally directly labeled as with isotopes,
chromophores, lumiphores, chromogens, or indirectly labeled such as
with biotin to which a streptavidin complex may later bind. By
assaying for the presence or absence of the probe, one can detect
the presence or absence of the select sequence or subsequence.
The term "heterologous" when used with reference to portions of a
nucleic acid indicates that the nucleic acid comprises two or more
subsequences that are not found in the same relationship to each
other in nature. For instance, the nucleic acid is typically
recombinantly produced, having two or more sequences from unrelated
genes arranged to make a new functional nucleic acid, e.g., a
promoter from one source and a coding region from another source.
Similarly, a heterologous protein indicates that the protein
comprises two or more subsequences that are not found in the same
relationship to each other in nature (e.g., a fusion protein).
A "promoter" is defined as an array of nucleic acid sequences that
direct transcription of a nucleic acid. As used herein, a promoter
includes necessary nucleic acid sequences near the start site of
transcription, such as, in the case of a polymerase II type
promoter, a TATA element. A promoter also optionally includes
distal enhancer or repressor elements, which can be located as much
as several thousand base pairs from the start site of
transcription. A "constitutive" promoter is a promoter that is
active under most environmental and developmental conditions. An
"inducible" promoter is a promoter that is active under
environmental or developmental regulation. The term "operably
linked" refers to a functional linkage between a nucleic acid
expression control sequence (such as a promoter, or array of
transcription factor binding sites) and a second nucleic acid
sequence, wherein the expression control sequence directs
transcription of the nucleic acid corresponding to the second
sequence.
As used herein, "recombinant" refers to a polynucleotide
synthesized or otherwise manipulated in vitro (e.g., "recombinant
polynucleotide"), to methods of using recombinant polynucleotides
to produce gene products in cells or other biological systems, or
to a polypeptide ("recombinant protein") encoded by a recombinant
polynucleotide. "Recombinant means" also encompass the ligation of
nucleic acids having various coding regions or domains or promoter
sequences from different sources into an expression cassette or
vector for expression of, e.g., inducible or constitutive
expression of a fusion protein comprising a translocation domain of
the invention and a nucleic acid sequence amplified using a primer
of the invention.
The phrase "selectively (or specifically) hybridizes to" refers to
the binding, duplexing, or hybridizing of a molecule only to a
particular nucleotide sequence under stringent hybridization
conditions when that sequence is present in a complex mixture
(e.g., total cellular or library DNA or RNA).
The phrase "stringent hybridization conditions" refers to
conditions under which a probe will hybridize to its target
subsequence, typically in a complex mixture of nucleic acid, but to
no other sequences. Stringent conditions are sequence dependent and
will be different in different circumstances. Longer sequences
hybridize specifically at higher temperatures. An extensive guide
to the hybridization of nucleic acids is found in Tijssen,
Techniques in Biochemistry and Molecular Biology--Hybridisation
with Nucleic Probes, "Overview of principles of hybridization and
the strategy of nucleic acid assays" (1993). Generally, stringent
conditions are selected to be about 5-10.degree. C. lower than the
thermal melting point (Tm) for the specific sequence at a defined
ionic strength pH. The Tm is the temperature (under defined ionic
strength, pH, and nucleic concentration) at which 50% of the probes
complementary to the target hybridize to the target sequence at
equilibrium (as the target sequences are present in excess, at Tm,
50% of the probes are occupied at equilibrium). Stringent
conditions will be those in which the salt concentration is less
than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium
ion concentration (or other salts) at pH 7.0 to 8.3 and the
temperature is at least about 30.degree. C. for short probes (e.g.,
10 to 50 nucleotides) and at least about 60.degree. C. for long
probes (e.g., greater than 50 nucleotides). Stringent conditions
may also be achieved with the addition of destabilizing agents such
as formamide. For selective or specific hybridization, a positive
signal is at least two times background, optionally 10 times
background hybridization. Exemplary stringent hybridization
conditions can be as following: 50% formamide, S.times.SSC, and 1%
SDS, incubating at 42.degree. C., or, S.times.SSC, 1% SDS,
incubating at 65.degree. C., with wash in 0.2.times.SSC, and 0.1%
SDS at 65.degree. C. Such hybridizations and wash steps can be
carried out for, e.g., 1, 2, 5, 10, 15, 30, 60; or more
minutes.
Nucleic acids that do not hybridize to each other under stringent
conditions are still substantially related if the polypeptides
which they encode are substantially related. This occurs, for
example, when a copy of a nucleic acid is created using the maximum
codon degeneracy permitted by the genetic code. In such cases, the
nucleic acids typically hybridize under moderately stringent
hybridization conditions. Exemplary "moderately stringent
hybridization conditions" include a hybridization in a buffer of
40% formamide, 1 M NaCI, 1% SDS at 37.degree. C., and a wash in
1.times.SSC at 45.degree. C. Such hybridizations and wash steps can
be carried out for, e.g., 1, 2, 5, 10, 15, 30, 60, or more minutes.
A positive hybridization is at least twice background. Those of
ordinary skill will readily recognize that alternative
hybridization and wash conditions can be utilized to provide
conditions of similar stringency.
"Antibody" refers to a polypeptide comprising a framework region
from an immunoglobulin gene or fragments thereof that specifically
binds and recognizes an antigen. The recognized immunoglobulin
genes include the kappa, lambda, alpha, gamma, delta, epsilon, and
mu constant region genes, as well as the myriad immunoglobulin
variable region genes. Light chains are classified as either kappa
or lambda. Heavy chains are classified as gamma, mu, alpha, delta,
or epsilon, which in turn define the immunoglobulin classes, IgG,
IgM, IgA, IgD and IgE, respectively.
An exemplary immunoglobulin (antibody) structural unit comprises a
tetramer. Each tetramer is composed of two identical pairs of
polypeptide chains, each pair having one "light" (about 25 kDa) and
one "heavy" chain (about 50-70 kDa). The N-terminus of each chain
defines a variable region of about 100 to 110 or more amino acids
primarily responsible for antigen recognition. The terms variable
light chain (VL) and variable heavy chain (VH) refer to these light
and heavy chains respectively.
A "chimeric antibody" is an antibody molecule in which (a) the
constant region, or a portion thereof, is altered, replaced or
exchanged so that the antigen binding site (variable region) is
linked to a constant region of a different or altered class,
effector function and/or species, or an entirely different molecule
which confers new properties to the chimeric antibody, e.g., an
enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the
variable region, or a portion thereof, is altered, replaced or
exchanged with a variable region having a different or altered
antigen specificity.
An "anti-T1R" antibody is an antibody or antibody fragment that
specifically binds a polypeptide encoded by a T1R gene, cDNA, or a
subsequence thereof.
The term "immunoassay" is an assay that uses an antibody to
specifically bind an antigen. The immunoassay is characterized by
the use of specific binding properties of a particular antibody to
isolate, target, and/or quantify the antigen.
The phrase "specifically (or selectively) binds" to an antibody or,
"specifically (or selectively) immunoreactive with," when referring
to a protein or peptide, refers to a binding reaction that is
determinative of the presence of the protein in a heterogeneous
population of proteins and other biologics. Thus, under designated
immunoassay conditions, the specified antibodies bind to a
particular protein at least two times the background and do not
substantially bind in a significant amount to other proteins
present in the sample. Specific binding to an antibody under such
conditions may require an antibody that is selected for its
specificity for a particular protein. For example, polyclonal
antibodies raised to a T1R family member from specific species such
as rat, mouse, or human can be selected to obtain only those
polyclonal antibodies that are specifically immunoreactive with the
T1R polypeptide or an immunogenic portion thereof and not with
other proteins, except for orthologs or polymorphic variants and
alleles of the T1R polypeptide. This selection may be achieved by
subtracting out antibodies that cross-react with T1R molecules from
other species or other T1R molecules. Antibodies can also be
selected that recognize only T1R GPCR family members but not GPCRs
from other families. A variety of immunoassay formats may be used
to select antibodies specifically immunoreactive with a particular
protein. For example, solid-phase ELISA immunoassays are routinely
used to select antibodies specifically immunoreactive with a
protein (see, e.g., Harlow & Lane, Antibodies, A Laboratory
Manual, (1988), for a description of immunoassay formats and
conditions that can be used to determine specific
immunoreactivity). Typically a specific or selective reaction will
be at least twice background signal or noise and more typically
more than 10 to 100 times background.
The phrase "selectively associates with" refers to the ability of a
nucleic acid to "selectively hybridize" with another as defined
above, or the ability of an antibody to "selectively (or
specifically) bind to a protein, as defined above.
The term "expression vector" refers to any recombinant expression
system for the purpose of expressing a nucleic acid sequence of the
invention in vitro or in vivo, constitutively or inducibly, in any
cell, including prokaryotic, yeast, fungal, plant, insect or
mammalian cell. The term includes linear or circular expression
systems. The term includes expression systems that remain episomal
or integrate into the host cell genome. The expression systems can
have the ability to self-replicate or not, i.e., drive only
transient expression in a cell. The term includes recombinant
expression "cassettes which contain only the minimum elements
needed for transcription of the recombinant nucleic acid.
By "host cell" is meant a cell that contains an expression vector
and supports the replication or expression of the expression
vector. Host cells may be prokaryotic cells such as E. coli or
eukaryotic cells such as yeast, insect, amphibian, or mammalian
cells such as CHO, HeLa, HEK-293, and the like, e.g., cultured
cells, explants, and cells in vivo.
B. ISOLATION AND EXPRESSION OF T1R POLYPEPTIDES
Isolation and expression of the T1Rs, or fragments or variants
thereof, of the invention can be performed as described below. PCR
primers can be used for the amplification of nucleic acids encoding
taste receptor ligand-binding regions, and libraries of these
nucleic acids can optionally be generated. Individual expression
vectors or libraries of expression vectors can then be used to
infect or transfect host cells for the functional expression of
these nucleic acids or libraries. These genes and vectors can be
made and expressed in vitro or in vivo. One of skill will recognize
that desired phenotypes for altering and controlling nucleic acid
expression can be obtained by modulating the expression or activity
of the genes and nucleic acids (e.g., promoters, enhancers and the
like) within the vectors of the invention. Any of the known methods
described for increasing or decreasing expression or activity can
be used. The invention can be practiced in conjunction with any
method or protocol known in the art, which are well described in
the scientific and patent literature.
The nucleic acid sequences of the invention and other nucleic acids
used to practice this invention, whether RNA, cDNA, genomic DNA,
vectors, viruses or hybrids thereof, may be isolated from a variety
of sources, genetically engineered, amplified, and/or expressed
recombinantly. Any recombinant expression system can be used,
including, in addition to mammalian cells, e.g., bacterial, yeast,
insect, or plant systems.
Alternatively, these nucleic acids can be synthesized in vitro by
well-known chemical synthesis techniques, as described in, e.g.,
Carruthers, Cold Spring Harbor Symp. Quant. Biol. 47:411-418
(1982); Adams, Am. Chem. Soc. 105:661 (1983); Belousov, Nucleic
Acids Res. 25:3440-3444 (1997); Frenkel, Free Radic. Biol. Med.
19:373-380 (1995); Blommers, Biochemistry 33:7886-7896 (1994);
Narang, Meth. Enzymol. 68:90 (1979); Brown, Meth. Enzymol. 68:109
(1979); Beaucage, Tetra. Lett. 22:1859 (1981); U.S. Pat. No.
4,458,066. Double-stranded DNA fragments may then be obtained
either by synthesizing the complementary strand and annealing the
strands together under appropriate conditions, or by adding the
complementary strand using DNA polymerase with an appropriate
primer sequence.
Techniques for the manipulation of nucleic acids, such as, for
example, for generating mutations in sequences, subcloning,
labeling probes, sequencing, hybridization and the like are well
described in the scientific and patent literature. See, e.g.,
Sambrook, ed., Molecular Cloning: a Laboratory manual (2nd ed.),
Vols. 1-3, Cold Spring Harbor Laboratory (1989); Current Protocols
in Molecular Biology, Ausubel, ed. John Wiley & Sons, Inc., New
York (1997); Laboratory Techniques in Biochemistry and Molecular
Biology: Hybridization With Nucleic Acid Probes, Part I, Theory and
Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).
Nucleic acids, vectors, capsids, polypeptides, and the like can be
analyzed and quantified by any of a number of general means well
known to those of skill in the art. These include, e.g., analytical
biochemical methods such as NMR, spectrophotometry, radiography,
electrophoresis, capillary electrophoresis, high performance liquid
chromatography (HPLC), thin layer chromatography (TLC), and
hyperdiffusion chromatography, various immunological methods, e.g.,
fluid or gel precipitin reactions, immunodiffusion,
immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked
immunosorbent assays (ELISAs), immuno-fluorescent assays, Southern
analysis, Northern analysis, dot-blot analysis, gel electrophoresis
(e.g., SDS-PAGE), RT-PCR, quantitative PCR, other nucleic acid or
target or signal amplification methods, radiolabeling,
scintillation counting, and affinity chromatography.
Oligonucleotide primers may be used to amplify nucleic acid
fragments encoding taste receptor ligand-binding regions. The
nucleic acids described herein can also be cloned or measured
quantitatively using amplification techniques. Amplification
methods are also well known in the art, and include, e.g.,
polymerase chain reaction, PCR (PCR Protocols, a Guide to Methods
and Applications, ed. Innis. Academic Press, N.Y. (1990) and PCR
Strategies, ed. Innis, Academic Press, Inc., N.Y. (1995), ligase
chain reaction (LCR) (see, e.g., Wu, Genomics 4:560 (1989);
Landegren, Science 241:1077, (1988); Baninger, Gene 89:117 (1990));
transcription amplification (see, e.g., Kwoh, Proc. Natl. Acad.
Sci. USA 86:1173 (1989)); and, self-sustained sequence replication
(see, e.g., Guatelli, Proc. Natl. Acad. Sci. USA 87:1874 (1990)); Q
Beta replicase amplification (see, e.g., Smith, J. Clin. Microbiol.
35:1477-1491 (1997)); automated Q-beta replicase amplification
assay (see, e.g., Burg, Mol. Cell. Probes 10:257-271 (1996)) and
other RNA polymerase mediated techniques (e.g., NASBA, Cangene,
Mississauga, Ontario); see also Berger, Methods Enzymol.
152:307-316 (1987); Sambrook; Ausubel; U.S. Pat. Nos. 4,683,195 and
4,683,202; Sooknanan, Biotechnology 13:563-564 (1995). The primers
can be designed to retain the original sequence of the "donor"
7-membrane receptor. Alternatively, the primers can encode amino
acid residues that are conservative substitutions (e.g.,
hydrophobic for hydrophobic residue, see above discussion) or
functionally benign substitutions (e.g., do not prevent plasma
membrane insertion, cause cleavage by peptidase, cause abnormal
folding of receptor, and the like). Once amplified, the nucleic
acids, either individually or as libraries, may be cloned according
to methods known in the art, if desired, into any of a variety of
vectors using routine molecular biological methods; methods for
cloning in vitro amplified nucleic acids are described, e.g., U.S.
Pat. No. 5,426,039.
The primer pairs may be designed to selectively amplify
ligand-binding regions of the T1R family members. These regions may
vary for different ligands or tastants. Thus, what may be a minimal
binding region for one tastant, may be too limiting for a second
tastant. Accordingly, ligand-binding regions of different sizes
comprising different extracellular domain structures may be
amplified.
Paradigms to design degenerate primer pairs are well known in the
art. For example, a COnsensus-DEgenerate Hybrid Oligonucleotide
Primer (CODEHOP) strategy computer program is accessible and is
directly linked from the BlockMaker multiple sequence alignment
site for hybrid primer prediction beginning with a set of related
protein sequences, as known taste receptor ligand-binding regions
(see, e.g., Rose, Nucleic Acids Res. 26:1628-1635 (1998); Singh,
Biotechniques 24:318-319 (1998)).
Means to synthesize oligonucleotide primer pairs are well known in
the art. "Natural" base pairs or synthetic base pairs can be used.
For example, use of artificial nucleobases offers a versatile
approach to manipulate primer sequence and generate a more complex
mixture of amplification products. Various families of artificial
nucleobases are capable of assuming multiple hydrogen bonding
orientations through internal bond rotations to provide a means for
degenerate molecular recognition. Incorporation of these analogs
into a single position of a PCR primer allows for generation of a
complex library of amplification products. See, e.g., Hoops,
Nucleic Acids Res. 25:4866-4871 (1997). Nonpolar molecules can also
be used to mimic the shape of natural DNA bases. A
non-hydrogen-bonding shape mimic for adenine can replicate
efficiently and selectively against a nonpolar shape mimic for
thymine (see, e.g., Morales, Nat. Struct. Biol. 5:950-954 (1998)).
For example, two degenerate bases can be the pyrimidine base 6H,
8H-3,4-dihydropyrimido[4,5-c][1,2]oxazin-7-one or the purine base
N6-methoxy-2,6-diaminopurine (see, e.g., Hill, Proc. Natl. Acad.
Sci. USA 95:4258-4263 (1998)). Exemplary degenerate primers of the
invention incorporate the nucleobase analog
5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine,
3-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (the term "P"
in the sequences, see above). This pyrimidine analog hydrogen bonds
with purines, including A and G residues.
Polymorphic variants, alleles, and interspecies homologs that are
substantially identical to a taste receptor disclosed herein can be
isolated using the nucleic acid probes described above.
Alternatively, expression libraries can be used to clone T1R
polypeptides and polymorphic variants, alleles, and interspecies
homologs thereof, by detecting expressed homologs immunologically
with antisera or purified antibodies made against a T1R
polypeptide, which also recognize and selectively bind to the T1R
homolog.
Nucleic acids that encode ligand-binding regions of taste receptors
may be generated by amplification (e.g., PCR) of appropriate
nucleic acid sequences using degenerate primer pairs. The amplified
nucleic acid can be genomic DNA from any cell or tissue or mRNA or
cDNA derived from taste receptor-expressing cells.
In one embodiment, hybrid protein-coding sequences comprising
nucleic acids encoding T1Rs fused to translocation sequences may be
constructed. Also provided are hybrid T1Rs comprising the
translocation motifs and tastant-binding domains of other families
of chemosensory receptors, particularly taste receptors. These
nucleic acid sequences can be operably linked to transcriptional or
translational control elements, e.g., transcription and translation
initiation sequences, promoters and enhancers, transcription and
translation terminators, polyadenylation sequences, and other
sequences useful for transcribing DNA into RNA. In construction of
recombinant expression cassettes, vectors, and transgenics, a
promoter fragment can be employed to direct expression of the
desired nucleic acid in all desired cells or tissues.
In another embodiment, fusion proteins may include C-terminal or
N-terminal translocation sequences. Further, fusion proteins can
comprise additional elements, e.g., for protein detection,
purification, or other applications. Detection and purification
facilitating domains include, e.g., metal chelating peptides such
as polyhistidine tracts, histidine-tryptophan modules, or other
domains that allow purification on immobilized metals; maltose
binding protein; protein A domains that allow purification on
immobilized inununoglobulin; or the domain utilized in the FLAGS
extension/affinity purification system (Immunex Corp, Seattle
Wash.).
The inclusion of a cleavable linker sequences such as Factor Xa
(see, e.g., Ottavi, Biochimie 80:289-293 (1998)), subtilisin
protease recognition motif (see, e.g., Polyak, Protein Eng.
10:615-619 (1997)); enterokinase (Invitrogen, San Diego, Calif.),
and the like, between the translocation domain (for efficient
plasma membrane expression) and the rest of the newly translated
polypeptide may be useful to facilitate purification. For example,
one construct can include a polypeptide encoding a nucleic acid
sequence linked to six histidine residues followed by a
thioredoxin, an enterokinase cleavage site (see, e.g., Williams,
Biochemistry 34:1787-1797 (1995)), and an C-terminal translocation
domain. The histidine residues facilitate detection and
purification while the enterokinase cleavage site provides a means
for purifying the desired protein(s) from the remainder of the
fusion protein. Technology pertaining to vectors encoding fusion
proteins and application of fusion proteins are well described in
the scientific and patent literature, see, e.g., Kroll, DNA Cell.
Biol. 12:441-53 (1993).
Expression vectors, either as individual expression vectors or as
libraries of expression vectors, comprising the ligand-binding
domain encoding sequences may be introduced into a genome or into
the cytoplasm or a nucleus of a cell and expressed by a variety of
conventional techniques, well described in the scientific and
patent literature. See, e.g., Roberts, Nature 328:731 (1987);
Berger supra; Schneider, Protein Expr. Purif. 6435:10 (1995);
Sambrook; Tijssen; Ausubel. Product information from manufacturers
of biological reagents and experimental equipment also provide
information regarding known biological methods. The vectors can be
isolated from natural sources, obtained from such sources as ATCC
or GenBank libraries, or prepared by synthetic or recombinant
methods.
The nucleic acids can be expressed in expression cassettes, vectors
or viruses which are stably or transiently expressed in cells
(e.g., episomal expression systems). Selection markers can be
incorporated into expression cassettes and vectors to confer a
selectable phenotype on transformed cells and sequences. For
example, selection markers can code for episomal maintenance and
replication such that integration into the host genome is not
required. For example, the marker may encode antibiotic resistance
(e.g., chloramphenicol, kanamycin, G418, bleomycin, hygromycin) or
herbicide resistance (e.g., chlorosulfuron or Basta) to permit
selection of those cells transformed with the desired DNA sequences
(see, e.g., Blondelet-Rouault, Gene 190:315-317 (1997); Aubrecht,
J. Pharmacol. Exp. Ther. 281:992-997 (1997)). Because selectable
marker genes conferring resistance to substrates like neomycin or
hygromycin can only be utilized in tissue culture, chemoresistance
genes are also used as selectable markers in vitro and in vivo.
A chimeric nucleic acid sequence may encode a T1R ligand-binding
domain within any 7-transmembrane polypeptide. Because
7-transmembrane receptor polypeptides have similar primary
sequences and secondary and tertiary structures, structural domains
(e.g., extracellular domain, TM domains, cytoplasmic domain, etc.)
can be readily identified by sequence analysis. For example,
homology modeling, Fourier analysis and helical periodicity
detection can identify and characterize the seven domains with a
7-transmembrane receptor sequence. Fast Fourier Transform (FFT)
algorithms can be used to assess the dominant periods that
characterize profiles of the hydrophobicity and variability of
analyzed sequences. Periodicity detection enhancement and alpha
helical periodicity index can be done as by, e.g., Donnelly,
Protein Sci. 2:55-70 (1993). Other alignment and modeling
algorithms are well known in the art, see, e.g., Peitsch, Receptors
Channels 4:161-164 (1996); Kyte & Doolittle, J. Md. Bio.,
157:105-132 (1982); Cronet, Protein Eng. 6:59-64 (1993) (homology
and "discover modeling"); the website of the Bioinformatics and
Biological Computing Unit at the Weizmann Institute of Science.
The present invention also includes not only the DNA and proteins
having the specified nucleic and amino acid sequences, but also DNA
fragments, particularly fragments of, e.g., 40, 60, 80, 100, 150,
200, or 250 nucleotides, or more, as well as protein fragments of,
e.g., 10, 20, 30, 50, 70, 100, or 150 amino acids, or more.
Optionally, the nucleic acid fragments can encode an antigenic
polypeptide which is capable of binding to an antibody raised
against a T1R family member. Further, a protein fragment of the
invention can optionally be an antigenic fragment which is capable
of binding to an antibody raised against a T1R family member.
Also contemplated are chimeric proteins, comprising at least 10,
20, 30, 50, 70, 100, or 150 amino acids, or more, of one of at
least one of the T1R polypeptides described herein, coupled to
additional amino acids representing all or part of another GPCR,
preferably a member of the 7 transmembrane superfamily. These
chimeras can be made from the instant receptors and another GPCR,
or they can be made by combining two or more of the present
receptors. In one embodiment, one portion of the chimera
corresponds tom or is derived from the extracellular domain of a
T1R polypeptide of the invention. In another embodiment, one
portion of the chimera corresponds to, or is derived from the
extracellular domain and one or more of the transmembrane domains
of a T1R polypeptide described herein, and the remaining portion or
portions can come from another GPCR. Chimeric receptors are well
known in the art, and the techniques for creating them and the
selection and boundaries of domains or fragments of G
protein-coupled receptors for incorporation therein are also well
known. Thus, this knowledge of those skilled in the art can readily
be used to create such chimeric receptors. The use of such chimeric
receptors can provide, for example, a taste selectivity
characteristic of one of the receptors specifically disclosed
herein, coupled with the signal transduction characteristics of
another receptor, such as a well known receptor used in prior art
assay systems.
For example, a domain such as a ligand-binding domain, an
extracellular domain, a transmembrane domain, a transmembrane
domain, a cytoplasmic domain, an N-terminal domain, a C-terminal
domain, or any combination thereof, can be covalently linked to a
heterologous protein. For instance, an T1R extracellular domain can
be linked to a heterologous GPCR transmembrane domain, or a
heterologous GPCR extracellular domain can be linked to a T1R
transmembrane domain. Other heterologous proteins of choice can
include, e.g., green fluorescent protein, .beta.-gal, glutamtate
receptor, and the rhodopsin presequence.
Also within the scope of the invention are host cells for
expressing the T1Rs, fragments, or variants of the invention. To
obtain high levels of expression of a cloned gene or nucleic acid,
such as cDNAs encoding the T1Rs, fragments, or variants of the
invention, one of skill typically subclones the nucleic acid
sequence of interest into an expression vector that contains a
strong promoter to direct transcription, a
transcription/translation terminator, and if for a nucleic acid
encoding a protein, a ribosome binding site for translational
initiation. Suitable bacterial promoters are well known in the art
and described, e.g., in Sambrook et al. However, bacterial or
eukaryotic expression systems can be used.
Any of the well known procedures for introducing foreign nucleotide
sequences into host cells may be used These include the use of
calcium phosphate transfection, polybrene, protoplast fusion,
electroporation, liposomes, microinjection, plasma vectors, viral
vectors and any of the other well known methods for introducing
cloned genomic DNA, cDNA, synthetic DNA or other foreign genetic
material into a host cell (see, e.g., Sambrook et al.) It is only
necessary that the particular genetic engineering procedure used be
capable of successfully introducing at lest one nucleic acid
molecule into the host cell capable of expressing the T1R,
fragment, or variant of interest.
After the expression vector is introduced into the cells, the
transfected cells are cultured under conditions favoring expression
of the receptor, fragment, or variant of interest, which is then
recovered from the culture using standard techniques. Examples of
such techniques are well known in the art. See, e.g., WO 00/06593,
which is incorporated by reference in a manner consistent with this
disclosure.
C. DETECTION OF T1R POLYPEPTIDES
In addition to the detection of T1R genes and gene expression using
nucleic acid hybridization technology, one can also use
immunoassays to detect T1Rs, e.g., to identify taste receptor
cells, and variants of T1R family members. Immunoassays can be used
to qualitatively or quantitatively analyze the T1Rs. A general
overview of the applicable technology can be found in Harlow &
Lane, Antibodies: A Laboratory Manual (1988).
1. Antibodies to T1R Family Members
Methods of producing polyclonal and monoclonal antibodies that
react specifically with a T1R family member are known to those of
skill in the art (see, e.g., Coligan, Current Protocols in
Immunology (1991); Harlow & Lane, supra; Goding, Monoclonal
Antibodies: Principles and Practice (2d ed. 1986); and Kohler &
Milstein, Nature, 256:495-497 (1975)). Such techniques include
antibody preparation by selection of antibodies from libraries of
recombinant antibodies in phage or similar vectors, as well as
preparation of polyclonal and monoclonal antibodies by immunizing
rabbits or mice (see, e.g., Huse et al., Science, 246:1275-1281
(1989); Ward et al., Nature, 341:544-546 (1989)).
A number of T1R-comprising immunogens may be used to produce
antibodies specifically reactive with a T1R family member. For
example, a recombinant T1R polypeptide, or an antigenic fragment
thereof, can be isolated as described herein. Suitable antigenic
regions include, e.g., the consensus sequences that are used to
identify members of the T1R family. Recombinant proteins can be
expressed in eukaryotic or prokaryotic cells as described above,
and purified as generally described above. Recombinant protein is
the preferred immunogen for the production of monoclonal or
polyclonal antibodies. Alternatively, a synthetic peptide derived
from the sequences disclosed herein and conjugated to a carrier
protein can be used an immunogen. Naturally occurring protein may
also be used either in pure or impure form. The product is then
injected into an animal capable of producing antibodies. Either
monoclonal or polyclonal antibodies may be generated, for
subsequent use in immunoassays to measure the protein.
Methods of production of polyclonal antibodies are known to those
of skill in the art. For example, an inbred strain of mice (e.g.,
BALB/C mice) or rabbits is immunized with the protein using a
standard adjuvant, such as Freund's adjuvant, and a standard
immunization protocol. The animal's immune response to the
immunogen preparation is monitored by taking test bleeds and
determining the titer of reactivity to the T1R. When appropriately
high titers of antibody to the immunogen are obtained, blood is
collected from the animal and antisera are prepared. Further
fractionation of the antisera to enrich for antibodies reactive to
the protein can be done if desired (see Harlow & Lane,
supra).
Monoclonal antibodies may be obtained by various techniques
familiar to those skilled in the art. Briefly, spleen cells from an
animal immunized with a desired antigen may be immortalized,
commonly by fusion with a myeloma cell (see Kohler & Milstein,
Eur. J. Immunol., 6:511-519 (1976)). Alternative methods of
immortalization include transformation with Epstein Barr Virus,
oncogenes, or retroviruses, or other methods well known in the art.
Colonies arising from single immortalized cells are screened for
production of antibodies of the desired specificity and affinity
for the antigen, and yield of the monoclonal antibodies produced by
such cells may be enhanced by various techniques, including
injection into the peritoneal cavity of a vertebrate host.
Alternatively, one may isolate DNA sequences which encode a
monoclonal antibody or a binding fragment thereof by screening a
DNA library from human B cells according to the general protocol
outlined by Huse et al., Science, 246:1275-1281 (1989).
Monoclonal antibodies and polyclonal sera are collected and titered
against the immunogen protein in an immunoassay, for example, a
solid phase immunoassay with the immunogen immobilized on a solid
support. Typically, polyclonal antisera with a titer of 104 or
greater are selected and tested for their cross reactivity against
non-T1R polypeptides, or even other T1R family members or other
related proteins from other organisms, using a competitive binding
immunoassay. Specific polyclonal antisera and monoclonal antibodies
will usually bind with a Kd of at least about 0.1 mM, more usually
at least about 1 pM, optionally at least about 0.1 p.M or better,
and optionally 0.01 pM or better.
Once T1R family member specific antibodies are available,
individual T1R proteins and protein fragments can be detected by a
variety of immunoassay methods. For a review of immunological and
immunoassay procedures, see Basic and Clinical Immunology (Stites
& Terr eds., 7th ed. 1991). Moreover, the immunoassays of the
present invention can be performed in any of several
configurations, which are reviewed extensively in Enzyme
Immunoassay (Maggio, ed., 1980); and Harlow & Lane, supra.
2. Immunological Binding Assays
T1R proteins, fragments, and variants can be detected and/or
quantified using any of a number of well recognized immunological
binding assays (see, e.g., U.S. Pat. Nos. 4,366,241; 4,376,110;
4,517,288; and 4,837,168). For a review of the general
immunoassays, see also Methods in Cell Biology: Antibodies in Cell
Biology, volume 37 (Asai, ed. 1993); Basic and Clinical Immunology
(Stites & Terr, eds., 7th ed. 1991). Immunological binding
assays (or immunoassays) typically use an antibody that
specifically binds to a protein or antigen of choice (in this case
a T1R family member or an antigenic subsequence thereof). The
antibody (e.g., anti-T1R) may be produced by any of a number of
means well known to those of skill in the art and as described
above.
Immunoassays also often use a labeling agent to specifically bind
to and label the complex formed by the antibody and antigen. The
labeling agent may itself be one of the moieties comprising the
antibody/antigen complex. Thus, the labeling agent may be a labeled
T1R polypeptide or a labeled anti-T1R antibody. Alternatively, the
labeling agent may be a third moiety, such a secondary antibody,
that specifically binds to the antibody/T1R complex (a secondary
antibody is typically specific to antibodies of the species from
which the first antibody is derived). Other proteins capable of
specifically binding immunoglobulin constant regions, such as
protein A or protein G may also be used as the label agent. These
proteins exhibit a strong non-immunogenic reactivity with
immunoglobulin constant regions from a variety of species (see,
e.g., Kronval et al., J. Immunol., 111:1401-1406 (1973); Akerstrom
et al., J. Immunol., 135:2589-2542 (1985)). The labeling agent can
be modified with a detectable moiety, such as biotin, to which
another molecule can specifically bind, such as streptavidin. A
variety of detectable moieties are well known to those skilled in
the art.
Throughout the assays, incubation and/or washing steps may be
required after each combination of reagents. Incubation steps can
vary from about 5 seconds to several hours, optionally from about 5
minutes to about 24 hours. However, the incubation time will depend
upon the assay format, antigen, volume of solution, concentrations,
and the like. Usually, the assays will be carried out at ambient
temperature, although they can be conducted over a range of
temperatures, such as 10.degree. C. to 40.degree. C.
a. Non-Competitive Assay Formats
Immunoassays for detecting a T1R polypeptide in a sample may be
either competitive or noncompetitive. Noncompetitive immunoassays
are assays in which the amount of antigen is directly measured. In
one preferred "sandwich" assay, for example, the anti-T1R
antibodies can be bound directly to a solid substrate on which they
are immobilized. These immobilized antibodies then capture the T1R
polypeptide present in the test sample. The T1R polypeptide is thus
immobilized is then bound by a labeling agent, such as a second T1R
antibody bearing a label. Alternatively, the second antibody may
lack a label, but it may, in turn, be bound by a labeled third
antibody specific to antibodies of the species from which the
second antibody is derived. The second or third antibody is
typically modified with a detectable moiety, such as biotin, to
which another molecule specifically binds, e.g., streptavidin, to
provide a detectable moiety.
b. Competitive Assay Formats
In competitive assays, the amount of T1R polypeptide present in the
sample is measured indirectly by measuring the amount of a known,
added (exogenous) T1R polypeptide displaced (competed away) from an
anti-T1R antibody by the unknown T1R polypeptide present in a
sample. In one competitive assay, a known amount of T1R polypeptide
is added to a sample and the sample is then contacted with an
antibody that specifically binds to the T1R. The amount of
exogenous T1R polypeptide bound to the antibody is inversely
proportional to the concentration of T1R polypeptide present in the
sample. In a particularly preferred embodiment, the antibody is
immobilized on a solid substrate. The amount of T1R polypeptide
bound to the antibody may be determined either by measuring the
amount of T1R polypeptide present in a T1R/antibody complex, or
alternatively by measuring the amount of remaining uncomplexed
protein. The amount of T1R polypeptide may be detected by providing
a labeled T1R molecule.
A hapten inhibition assay is another preferred competitive assay.
In this assay the known T1R polypeptide is immobilized on a solid
substrate. A known amount of anti-T1R antibody is added to the
sample, and the sample is then contacted with the immobilized T1R.
The amount of anti-T1R antibody bound to the known immobilized T1R
polypeptide is inversely proportional to the amount of T1R
polypeptide present in the sample. Again, the amount of immobilized
antibody may be detected by detecting either the immobilized
fraction of antibody or the fraction of the antibody that remains
in solution. Detection may be direct where the antibody is labeled
or indirect by the subsequent addition of a labeled moiety that
specifically binds to the antibody as described above.
c. Cross-Reactivity Determinations
Immunoassays in the competitive binding format can also be used for
cross-reactivity determinations. For example, a protein at least
partially encoded by the nucleic, acid sequences disclosed herein
can be immobilized to a solid support. Proteins (e.g., T1R
polypeptides and homologs) are added to the assay that compete for
binding of the antisera to the immobilized antigen. The ability of
the added proteins to compete for binding of the antisera to the
immobilized protein is compared to the ability of the T1R
polypeptide encoded by the nucleic acid sequences disclosed herein
to compete with itself. The percent cross-reactivity for the above
proteins is calculated, using standard calculations. Those antisera
with less than 10% cross-reactivity with each of the added proteins
listed above are selected and pooled. The cross-reacting antibodies
are optionally removed from the pooled antisera by immunoabsorption
with the added considered proteins, e.g., distantly related
homologs. In addition, peptides comprising amino acid sequences
representing conserved motifs that are used to identify members of
the T1R family can be used in cross-reactivity determinations.
The immunoabsorbed and pooled antisera are then used in a
competitive binding immunoassay as described above to compare a
second protein, thought to be perhaps an allele or polymorphic
variant of a T1R family member, to the immunogen protein (i.e., T1R
polypeptide encoded by the nucleic acid sequences disclosed
herein). In order to make this comparison, the two proteins are
each assayed at a wide range of concentrations and the amount of
each protein required to inhibit 50% of the binding of the antisera
to the immobilized protein is determined. If the amount of the
second protein required to inhibit 50% of binding is less than 10
times the amount of the protein encoded by nucleic acid sequences
disclosed herein required to inhibit 50% of binding, then the
second protein is said to specifically bind to the polyclonal
antibodies generated to a T1R immunogen.
Antibodies raised against T1R conserved motifs can also be used to
prepare antibodies that specifically bind only to GPCRs of the T1R
family, but not to GPCRs from other families.
Polyclonal antibodies that specifically bind to a particular member
of the T1R family can be made by subtracting out cross-reactive
antibodies using other T1R family members. Species-specific
polyclonal antibodies can be made in a similar way. For example,
antibodies specific to human T1R1 can be made by, subtracting out
antibodies that are cross-reactive with orthologous sequences,
e.g., rat T1R1 or mouse T1R1.
d. Other Assay Formats
Western blot (immunoblot) analysis is used to detect and quantify
the presence of T1R polypeptide in the sample. The technique
generally comprises separating sample proteins by gel
electrophoresis on the basis of molecular weight, transferring the
separated proteins to a suitable solid support, (such as a
nitrocellulose filter, a nylon filter, or derivatized nylon
filter), and incubating the sample with the antibodies that
specifically bind the T1R polypeptide. The anti-T1R polypeptide
antibodies specifically bind to the T1R polypeptide on the solid
support. These antibodies may be directly labeled or alternatively
may be subsequently detected using labeled antibodies (e.g.,
labeled sheep anti-mouse antibodies) that specifically bind to the
anti-T1R antibodies.
Other, assay formats include liposome immunoassays (LIA), which use
liposomes designed to bind specific molecules (e.g., antibodies)
and release encapsulated reagents or markers. The released
chemicals are then detected according to standard techniques (see
Monroe et al., Amer. Clin. Prod. Rev., 5:34-41 (1986)).
e. Reduction of Non-Specific Binding
One of skill in the art will appreciate that it is often desirable
to minimize non-specific binding in immunoassays. Particularly,
where the assay involves an antigen or antibody immobilized on a
solid substrate it is desirable to minimize the amount of
non-specific binding to the substrate. Means of reducing such
non-specific binding are well known to those of skill in the art.
Typically, this technique involves coating the substrate with a
proteinaceous composition. In particular, protein compositions such
as bovine serum albumin (BSA), nonfat powdered milk, and gelatin
are widely used with powdered milk being most preferred.
f. Labels
The particular label or detectable group used in the assay is not a
critical aspect of the invention, as long as it does not
significantly interfere with the specific binding of the antibody
used in the assay. The detectable group can be any material having
a detectable physical or chemical property. Such detectable labels
have been well developed in the field of immunoassays and, in
general, most any label useful in such methods can be applied to
the present invention. Thus, a label is any composition detectable
by spectroscopic, photochemical, biochemical, immunochemical,
electrical, optical, or chemical means. Useful labels in the
present invention include magnetic beads (e.g., DYNABEADS.TM.),
fluorescent dyes (e.g., fluorescein isothiocyanate, Texas red,
rhodamine, and the like), radiolabels (e.g., 3H, 1251, 3sS, 14C, or
.sup.32P), enzymes (e.g., horseradish peroxidase, alkaline
phosphatase and others commonly used in an ELISA), and colorimetric
labels such as colloidal gold or colored glass or plastic beads
(e.g., polystyrene, polypropylene, latex, etc.).
The label may be coupled directly or indirectly to the desired
component of the assay according to methods well known in the art.
As indicated above, a wide variety of labels may be used, with the
choice of label depending on sensitivity required, ease of
conjugation with the compound, stability requirements, available
instrumentation, and disposal provisions.
Non-radioactive labels are often attached by indirect means.
Generally, a ligand molecule (e.g., biotin) is covalently bound to
the molecule. The ligand then binds to another molecules (e.g.,
streptavidin) molecule, which is either inherently detectable or
covalently bound to a signal system, such as a detectable enzyme, a
fluorescent compound, or a chemiluminescent compound. The ligands
and their targets can be used in any suitable combination with
antibodies that recognize a T1R polypeptide, or secondary
antibodies that recognize anti-T1R.
The molecules can also be conjugated directly to signal generating
compounds, e.g., by conjugation with an enzyme or fluorophore.
Enzymes of interest as labels will primarily be hydrolases,
particularly phosphatases, esterases and glycosidases, or
oxidotases, particularly peroxidases. Fluorescent compounds include
fluorescein and its derivatives, rhodamine and its derivatives,
dansyl, umbelliferone, etc. Chemiluminescent compounds include
luciferin, and 2,3-dihydrophthalazinediones, e.g., luminol. For a
review of various labeling or signal producing systems that may be
used, see U.S. Pat. No. 4,391,904.
Means of detecting labels are well known to those of skill in the
art. Thus, for example, where the label is a radioactive label,
means for detection include a scintillation counter or photographic
film as in autoradiography. Where the label is a fluorescent label,
it may be detected by exciting the fluorochrome with the
appropriate wavelength of light and detecting the resulting
fluorescence. The fluorescence may be detected visually, by means
of photographic film, by the use of electronic detectors such as
charge-coupled devices (CCDs) or photomultipliers and the like.
Similarly, enzymatic labels may be detected by providing the
appropriate substrates for the enzyme and detecting the resulting
reaction product. Finally simple colorimetric labels may be
detected simply by observing the color associated with the label.
Thus, in various dipstick assays, conjugated gold often appears
pink, while various conjugated beads appear the color of the
bead.
Some assay formats do not require the use of labeled components.
For instance, agglutination assays can be used to detect the
presence of the target antibodies. In this case, antigen-coated
particles are agglutinated by samples comprising the target
antibodies. In this format, none of the components need be labeled
and the presence of the target antibody is detected by simple
visual inspection.
D. DETECTION OF MODULATORS
Compositions and methods for determining whether a test compound
specifically binds to a hetero-oligomeric chemosensory receptor
complex of the invention, both in vitro and in vivo, are described
below. Many aspects of cell physiology can be monitored to assess
the effect of ligand binding to a T1R polypeptide of the invention.
These assays may be performed on intact cells expressing a
chemosensory receptor, on permeabilized cells, or on membrane
fractions produced by standard methods.
Taste receptors bind tastants and initiate the transduction of
chemical stimuli into electrical signals. An activated or inhibited
G protein will in turn alter the properties of target enzymes,
channels, and other effector proteins. Some examples are the
activation of cGMP phosphodiesterase by transducin in the visual
system, adenylate cyclase by the stimulatory G protein,
phospholipase C by Gq and other cognate G proteins, and modulation
of diverse channels by Gi and other G proteins. Downstream
consequences can also be examined such as generation of diacyl
glycerol and IP3 by phospholipase C, and in turn, for calcium
mobilization by IP3.
The T1R proteins or polypeptides of the assay will typically be
selected from a polypeptide having a sequence of SEQ ID NOS: 2, 4,
6, or fragments or conservatively modified variants thereof.
Optionally, the fragments and variants can be antigenic fragments
and variants which bind to an anti-T1R antibody.
Alternatively, the T1R proteins or polypeptides of the assay can be
derived from a eukaryote host cell and can include an amino acid
subsequence having amino acid sequence identity to SEQ ID NOS: 2,
4, 6, or fragments or conservatively modified variants thereof.
Generally, the amino acid sequence identity will be at least 35 to
50%, or optionally 75%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.
Optionally, the T1R proteins or polypeptides of the assays can
comprise a domain of a T1R protein, such as an extracellular
domain, transmembrane region, transmembrane domain, cytoplasmic
domain, ligand-binding domain, and the like. Further, as described
above, the T1R protein or a domain thereof can be covalently linked
to a heterologous protein to create a chimeric protein used in the
assays described herein.
Modulators of T1R receptor activity are tested using T1R proteins
or polypeptides as described above, either recombinant or naturally
occurring. The T1R proteins or polypeptides can be isolated,
co-expressed in a cell, co-expressed in a membrane derived from a
cell, co-expressed in tissue or in an animal, either recombinant or
naturally occurring. For example, tongue slices, dissociated cells
from a tongue, transformed cells, or membranes can be used.
Modulation can be tested using one of the in vitro or in vivo
assays described herein.
1. In vitro Binding Assays
Taste transduction can also be examined in vitro with soluble or
solid state reactions, using hetero-oligomeric complexes of the T1R
polypeptides of the invention. In a particular embodiment,
hetero-oligomeric complexes of T1R ligand-binding domains can be
used in vitro in soluble or solid state reactions to assay for
ligand binding.
For instance, the T1R N-terminal domain is predicted to be involved
in ligand binding. More particularly, the T1Rs belong to a GPCR
sub-family that is characterized by large, approximately 600 amino
acid, extracellular N-terminal segments. These N-terminal segments
are thought to form, at least in part, the ligand-binding domains,
and are therefore useful in biochemical assays to identify T1R
agonists and antagonists. The ligand-binding domain may also
contain additional portions of the extracellular domain, such as
the extracellular loops of the transmembrane domain. Similar assays
have been used with other GPCRs that are related to the T1Rs, such
as the metabotropic glutamate receptors (see, e.g., Han and
Hampson, J. Biol. Chem. 274:10008-10013 (1999)). These assays might
involve displacing a radioactively or fluorescently labeled ligand,
measuring changes in intrinsic fluorescence or changes in
proteolytic susceptibility, etc.
Ligand binding to a hetero-oligomeric complex of T1R polypeptides
of the invention can be tested in solution, in a bilayer membrane,
optionally attached to a solid phase, in a lipid monolayer, or in
vesicles. Binding of a modulator can be tested using, e.g., changes
in spectroscopic characteristics (e.g., fluorescence, absorbance,
refractive index) hydrodynamic (e.g., shape), chromatographic, or
solubility properties. Preferred binding assays of the invention
are biochemical binding assays that use recombinant soluble
N-terminal T1R domains.
Receptor-G protein interactions can also be examined. For example,
binding of the G protein to the receptor complex, or its release
from the receptor complex can be examined. More particularly, in
the absence of GTP, an activator will lead to the formation of a
tight complex of a G protein (all three subunits) with the
receptor. This complex can be detected in a variety of ways, as
noted above. Such an assay can be modified to search for
inhibitors, e.g., by adding an activator to the receptor and G
protein in the absence of GTP, which form a tight complex, and then
screen for inhibitors by looking at dissociation of the receptor-G
protein complex. In the presence of GTP, release of the alpha
subunit of the G protein from the other two G protein subunits
serves as a criterion of activation. An activated or inhibited G
protein will in turn alter the properties of target enzymes,
channels, and other effector proteins.
In another embodiment of the invention, a GTP.gamma..sup.35S assay
may be used. As described above, upon activation of a GPCR, the
G.alpha. subunit of the G protein complex is stimulated to exchange
bound GDP for GTP. Ligand-mediated stimulation of G protein
exchange activity can be measured in a biochemical assay measuring
the binding of added radioactively labeled GTP.gamma..sup.35S to
the G protein in the presence of a putative ligand. Typically,
membranes containing the chemosensory receptor of interest are
mixed with a complex of G proteins. Potential inhibitors and/or
activators and GTP.gamma..sup.35S are added to the assay, and
binding of GTP.gamma..sup.35S to the G protein is measured. Binding
can be measured by liquid scintillation counting or by any other
means known in the art, including scintillation proximity assays
(SPA). In other assays formats, fluorescently labeled
GTP.gamma..sup.35S can be utilized.
2. Fluorescence Polarization Assays
In another embodiment, Fluorescence Polarization ("FP") based
assays may be used to detect and monitor ligand binding.
Fluorescence polarization is a versatile laboratory technique for
measuring equilibrium binding, nucleic acid hybridization, and
enzymatic activity. Fluorescence polarization assays are
homogeneous in that they do not require a separation step such as
centrifugation, filtration, chromatography, precipitation, or
electrophoresis. These assays are done in real time, directly in
solution and do not require an immobilized phase. Polarization
values can be measured repeatedly and after the addition of
reagents since measuring the polarization is rapid and does not
destroy the sample. Generally, this technique can be used to
measure polarization values of fluorophores from low picomolar to
micromolar levels. This section describes how fluorescence
polarization can be used in a simple and quantitative way to
measure the binding of ligands to the T1R polypeptides of the
invention.
When a fluorescently labeled molecule is excited with plane
polarized light, it emits light that has a degree of polarization
that is inversely proportional to its molecular rotation. Large
fluorescently labeled molecules remain relatively stationary during
the excited state (4 nanoseconds in the case of fluorescein) and
the polarization of the light remains relatively constant between
excitation and emission. Small fluorescently labeled molecules
rotate rapidly during the excited state and the polarization
changes significantly between excitation and emission. Therefore,
small molecules have low polarization values and large molecules
have high polarization values. For example, a single-stranded
fluorescein-labeled oligonucleotide has a relatively low
polarization value but when it is hybridized to a complementary
strand, it has a higher polarization value. When using FP to detect
and monitor tastant-binding which may activate or inhibit the
chemosensory receptors of the invention, fluorescence-labeled
tastants or auto-fluorescent tastants may be used.
Fluorescence polarization (P) is defined as:
.perp. .perp. ##EQU00001##
Where .PI. is the intensity of the emission light parallel to the
excitation light plane and hit .perp. is the intensity of the
emission light perpendicular to the excitation light plane. P,
being a ratio of light intensities, is a dimensionless number. For
example, the Beacon.RTM. and Beacon 2000.TM. System may be used in
connection with these assays. Such systems typically express
polarization in millipolarization units (1 Polarization Unit=1000
mP Units).
The relationship between molecular rotation and size is described
by the Perrin equation and the reader is referred to Jolley, M. E.
(1991) in Journal of Analytical Toxicology, pp. 236-240, which
gives a thorough explanation of this equation. Summarily, the
Perrin equation states that polarization is directly proportional
to the rotational relaxation time, the time that it takes a
molecule to rotate through an angle of approximately 68.5.degree.
Rotational relaxation time is related to viscosity (.eta.),
absolute temperature (T), molecular volume (V), and the gas
constant (R) by the following equation:
.times..eta..times..times. ##EQU00002##
The rotational relaxation time is small (.apprxeq.1 nanosecond) for
small molecules (e.g. fluorescein) and large (.apprxeq.100
nanoseconds) for large molecules (e.g. immunoglobulins). If
viscosity and temperature are held constant, rotational relaxation
time, and therefore polarization, is directly related to the
molecular volume. Changes in molecular volume may be due to
interactions with other molecules, dissociation, polymerization,
degradation, hybridization, or conformational changes of the
fluorescently labeled molecule. For example, fluorescence
polarization has been used to measure enzymatic cleavage of large
fluorescein labeled polymers by proteases, DNases, and RNases. It
also has been used to measure equilibrium binding for
protein/protein interactions, antibody/antigen binding, and
protein/DNA binding.
3. Solid State and Soluble High Throughout Assays
In yet another embodiment, the invention provides soluble assays
using a hetero-oligomeric T1R polypeptide complex; or a cell or
tissue co-expressing T1R polypeptides. In another embodiment, the
invention provides solid phase based in vitro assays in a high
throughput format, where the T1R polypeptides, or cell or tissue
expressing the T1R polypeptides is attached to a solid phase
substrate.
In the high throughput assays of the invention, it is possible to
screen up to several thousand different modulators or ligands in a
single day. In particular, each well of a microtiter plate can be
used to run a separate assay against a selected potential
modulator, or, if concentration or incubation time effects are to
be observed, every 5-10 wells can test a single modulator. Thus, a
single standard microtiter plate can assay about 100 (e.g., 96)
modulators. If 1536 well plates are used, then a single plate can
easily assay from about 1000 to about 1500 different compounds. It
is also possible to assay multiple compounds in each plate well. It
is possible to assay several different plates per day; assay
screens for up to about 6,000-20,000 different compounds is
possible using the integrated systems of the invention. More
recently, microfluidic approaches to reagent manipulation have been
developed.
The molecule of interest can be bound to the solid state component,
directly or indirectly, via covalent or non-covalent linkage, e.g.,
via a tag. The tag can be any of a variety of components. In
general, a molecule which binds the tag (a tag binder) is fixed to
a solid support, and the tagged molecule of interest (e.g., the
taste transduction molecule of interest) is attached to the solid
support by interaction of the tag and the tag binder.
A number of tags and tag binders can be used, based upon known
molecular interactions well described in the literature. For
example, where a tag has a natural binder, for example, biotin,
protein A, or protein G, it can be used in conjunction with
appropriate tag binders (avidin, streptavidin, neutravidin, the Fc
region of an immunoglobulin, etc.). Antibodies to molecules with
natural binders such as biotin are also widely available and
appropriate tag binders (see, SIGMA Immunochemicals 1998 catalogue
SIGMA, St. Louis Mo.).
Similarly, any haptenic or antigenic compound can be used in
combination with an appropriate antibody to form a tag/tag binder
pair. Thousands of specific antibodies are commercially available
and many additional antibodies are described in the literature. For
example, in one common configuration, the tag is a first antibody
and the tag binder is a second antibody which recognizes the first
antibody. In addition to antibody-antigen interactions,
receptor-ligand interactions are also appropriate as tag and
tag-binder pairs. For example, agonists and antagonists of cell
membrane receptors (e.g., cell receptor-ligand interactions such as
transferrin, c-kit, viral receptor ligands, cytokine receptors,
chemokine receptors, interleukin receptors, inununoglobulin
receptors and antibodies, the cadherein family, the integrin
family, the selectin family, and the like; see, e.g., Pigott &
Power, The Adhesion Molecule Facts Book I (1993)). Similarly,
toxins and venoms, viral epitopes, hormones (e.g., opiates,
steroids, etc.), intracellular receptors (e.g., which mediate the
effects of various small ligands, including steroids, thyroid
hormone, retinoids and vitamin D; peptides), drugs, lectins,
sugars, nucleic acids (both linear and cyclic polymer
configurations), oligosaccharides, proteins, phospholipids and
antibodies can all interact with various cell receptors.
Synthetic polymers, such as polyurethanes, polyesters,
polycarbonates, polyureas, polyamides, polyethyleneimines,
polyarylene sulfides, polysiloxanes, polyimides, and polyacetates
can also form an appropriate tag or tag binder. Many other tag/tag
binder pairs are also useful in assay systems described herein, as
would be apparent to one of skill upon review of this
disclosure.
Common linkers such as peptides, polyethers, and the like can also
serve as tags, and include polypeptide sequences, such as poly gly
sequences of between about 5 and 200 amino acids. Such flexible
linkers are known to persons of skill in the art. For example,
poly(ethelyne glycol) linkers are available from Shearwater
Polymers, Inc. Huntsville, Ala. These linkers optionally have amide
linkages, sulfhydryl linkages, or heterofunctional linkages.
Tag binders are fixed to solid substrates using any of a variety of
methods currently available. Solid substrates are commonly
derivatized or functionalized by exposing all or a portion of the
substrate to a chemical reagent which fixes a chemical group to the
surface which is reactive with a portion of the tag binder. For
example, groups which are suitable for attachment to a longer chain
portion would include amines, hydroxyl, thiol, and carboxyl groups.
Aminoalkylsilanes and hydroxyalkylsilanes can be used to
functionalize a variety of surfaces, such as glass surfaces. The
construction of such solid phase biopolymer arrays is well
described in the literature. See, e.g., Merrifield, J. Am. Chem.
Soc., 85:2149-2154 (1963) (describing solid phase synthesis of,
e.g., peptides); Geysen et al., J. Immun. Meth., 102:259-274 (1987)
(describing synthesis of solid phase components on pins); Frank
& Doring, Tetrahedron, 44:60316040 (1988) (describing synthesis
of various peptide sequences on cellulose disks); Fodor et al.,
Science, 251:767-777 (1991); Sheldon et al., Clinical Chemistry,
39(4):718-719 (1993); and Kozal et al., Nature Medicine,
2(7):753759 (1996) (all describing arrays of biopolymers fixed to
solid substrates). Non-chemical approaches for fixing tag binders
to substrates include other common methods, such as heat,
cross-linking by UV radiation, and the like.
4. Cell-Based Binding Assays
In one embodiment, a T1R proteins or polypeptides are co-expressed
in a eukaryotic cell as chimeric receptors with a heterologous,
chaperone sequence that facilitates its maturation and targeting
through the secretory pathway. Such chimeric T1R polypeptides can
be expressed in any eukaryotic cell, such as HEK-293 cells.
Preferably, the cells comprise a functional G protein, e.g.,
G.alpha.15, that is capable of coupling the chimeric receptor to an
intracellular signaling pathway or to a signaling protein such as
phospholipase C. Activation of such chimeric receptors in such
cells can be detected using any standard method, such as by
detecting changes in intracellular calcium by detecting FURA-2
dependent fluorescence in the cell.
Activated GPCR receptors become substrates for kinases that
phosphorylate the C-terminal tail of the receptor (and possibly
other sites as well). Thus, activators will promote the transfer of
32P from gamma-labeled GTP to the receptor, which can be assayed
with a scintillation counter. The phosphorylation of the C-terminal
tail will promote the binding of arrestin-like proteins and will
interfere with the binding of G proteins. The kinase/arrestin
pathway plays a key role in the desensitization of many GPCR
receptors. For example, compounds that modulate the duration a
taste receptor stays active would be useful as a means of
prolonging a desired taste or cutting off an unpleasant one. For a
general review of GPCR signal transduction and methods of assaying
signal transduction, see, e.g., Methods in Enzymology, vols. 237
and 238 (1994) and volume 96 (1983); Bourne et al., Nature,
10:349:117-27 (1991); Bourne et al., Nature, 348:125-32 (1990);
Pitcher et al., Annu. Rev. Biochem., 67:653-92 (1998).
T1R modulation may be assayed by comparing the response of T1R
polypeptides treated with a putative T1R modulator to the response
of an untreated control sample. Such putative T1R modulators can
include tastants that either inhibit or activate T1R polypeptide
activity. In one embodiment, control samples (untreated with
activators or inhibitors) are assigned a relative T1R activity
value of 100. Inhibition of a T1R polypeptide is achieved when the
T1R activity value relative to the control is about 90%, optionally
50%, optionally 25-0%. Activation of a T1R polypeptide is achieved
when the T1R activity value relative to the control is 110%,
optionally 150%, 200-500%, or 1000-2000%.
Changes in ion flux may be assessed by determining changes in ionic
polarization (i.e., electrical potential) of the cell or membrane
expressing a T1R polypeptide. One means to determine changes in
cellular polarization is by measuring changes in current (thereby
measuring changes in polarization) with voltage-clamp and
patch-clamp techniques (see, e.g., the "cell-attached" mode, the
"inside-out" mode, and the "whole cell" mode, e.g., Ackerman et
al., New Engl. J Med., 336:1575-1595 (1997)). Whole cell currents
are conveniently determined using the standard. Other known assays
include: radiolabeled ion flux assays and fluorescence assays using
voltage-sensitive dyes (see, e.g., Vestergarrd-Bogind et al., J.
Membrane Biol., 88:67-75 (1988); Gonzales & Tsien, Chem. Biol.,
4:269277 (1997); Daniel et al., J. Pharmacol. Meth., 25:185-193
(1991); Holevinsky et al., J. Membrane Biology, 137:59-70 (1994)).
Generally, the compounds to be tested are present in the range from
1 pM to 100 mM.
The effects of the test compounds upon the function of the
polypeptides can be measured by examining any of the parameters
described above. Any suitable physiological change that affects
GPCR activity can be used to assess the influence of a test
compound on the polypeptides of this invention. When the functional
consequences are determined using intact cells or animals, one can
also measure a variety of effects such as transmitter release,
hormone release, transcriptional changes to both known and
uncharacterized genetic markers (e.g., northern blots), changes in
cell metabolism such as cell growth or pH changes, and changes in
intracellular second messengers such as Ca.sup.2+, IP3, cGMP, or
cAMP.
Preferred assays for GPCRs include cells that are loaded with ion
or voltage sensitive dyes to report receptor activity. Assays for
determining activity of such receptors can also use known agonists
and antagonists for other G protein-coupled receptors as negative
or positive controls to assess activity of tested compounds. In
assays for identifying modulatory compounds (e.g., agonists,
antagonists), changes in the level of ions in the cytoplasm or
membrane voltage will be monitored using an ion sensitive or
membrane voltage fluorescent indicator, respectively. Among the
ion-sensitive indicators and voltage probes that may be employed
are those disclosed in the Molecular Probes 1997 Catalog. For G
protein-coupled receptors, promiscuous G proteins such as
G.alpha.15 and G.alpha.16 can be used in the assay of choice
(Wilkie et al., Proc. Nat'l Acad. Sci., 88:10049-10053 (1991)).
Such promiscuous G proteins allow coupling of a wide range of
receptors.
Receptor activation typically initiates subsequent intracellular
events, e.g., increases in second messengers such as IP3, which
releases intracellular stores of calcium ions. Activation of some G
protein-coupled receptors stimulates the formation of inositol
triphosphate (IP3) through phospholipase C-mediated hydrolysis of
phosphatidylinositol (Berridge & Irvine, Nature, 312:315-21
(1984)). IP3 in turn stimulates the release of intracellular
calcium ion stores. Thus, a change in cytoplasmic calcium ion
levels, or a change in second messenger levels such as IP3 can be
used to assess G protein-coupled receptor function. Cells
expressing such G protein-coupled receptors may exhibit increased
cytoplasmic calcium levels as a result of contribution from both
intracellular stores and via activation of ion channels, in which
case it may be desirable although not necessary to conduct such
assays in calcium-free buffer, optionally supplemented with a
chelating agent such as EGTA, to distinguish fluorescence response
resulting from calcium release from internal stores.
Other assays can involve determining the activity of receptors
which, when activated, result in a change in the level of
intracellular cyclic nucleotides, e.g., cAMP or cGMP, by activating
or inhibiting enzymes such as adenylate cyclase. There are cyclic
nucleotide-gated ion channels, e.g., rod photoreceptor cell
channels and olfactory neuron channels that are permeable to
cations upon activation by binding of cAMP or cGMP (see, e.g.,
Altenhofen et al., Proc. Nat'l Acad. Sci., 88:9868-9872 (1991) and
Dhallan et al., Nature, 347:184-187 (1990)). In cases where
activation of the receptor results in a decrease in cyclic
nucleotide levels, it may be preferable to expose the cells to
agents that increase intracellular cyclic nucleotide levels, e.g.,
forskolin, prior to adding a receptor-activating compound to the
cells in the assay. Cells for this type of assay can be made by
co-transfection of a host cell with DNA encoding a cyclic
nucleotide-crated ion channel, GPCR phosphatase and DNA encoding a
receptor (e.g., certain glutamate receptors, muscarinic
acetylcholine receptors, dopamine receptors, serotonin receptors,
and the like), which, when activated, causes a change in cyclic
nucleotide levels in the cytoplasm.
In a preferred embodiment, T1R polypeptide activity is measured by
co-expressing T1R genes in a heterologous cell with a promiscuous G
protein that links the receptor to a phospholipase C signal
transduction pathway (see Offermanns & Simon, J. Biol. Chem.,
270:15175-15180 (1995)). Optionally the cell line is HEK-293 (which
does not naturally express T1R genes) and the promiscuous G protein
is G.alpha.15 (Offermanns & Simon, supra). Modulation of taste
transduction is assayed by measuring changes in intracellular
Ca.sup.2+ levels, which change in response to modulation of the T1R
signal transduction pathway via administration of a molecule that
associates with T1R polypeptides. Changes in Ca.sup.2+ levels are
optionally measured using fluorescent Ca.sup.2+ indicator dyes and
fluorometric imaging.
In one embodiment, the changes in intracellular cAMP or cGMP can be
measured using immunoassays. The method described in Offermanns
& Simon, J. Bio. Chem., 270:15175-15180 (1995), may be used to
determine the level of cAMP. Also, the method described in
Felley-Bosco et al., Am. J. Resp. Cell and Mol. Biol., 11:159-164
(1994), may be used to determine the level of cGMP. Further, an
assay kit for measuring cAMP and/or cGMP is described in U.S. Pat.
No. 4,115,538, herein incorporated by reference.
In another embodiment, phosphatidyl inositol (PI) hydrolysis can be
analyzed according to U.S. Pat. No. 5,436,128, herein incorporated
by reference. Briefly, the assay involves labeling of cells with
3H-myoinositol for 48 or more hrs. The labeled cells are treated
with a test compound for one hour. The treated cells are lysed and
extracted in chloroform-methanol-water after which the inositol
phosphates were separated by ion exchange chromatography and
quantified by scintillation counting. Fold stimulation is
determined by calculating the ratio of cpm in the presence of
agonist, to cpm in the presence of buffer control. Likewise, fold
inhibition is determined by calculating the ratio of cpm in the
presence of antagonist, to cpm in the presence of buffer control
(which may or may not contain an agonist).
In another embodiment, transcription levels can be measured to
assess the effects of a test compound on signal transduction. A
host cell containing T1R polypeptides of interest is contacted with
a test compound for a sufficient time to effect any interactions,
and then the level of gene expression is measured. The amount of
time to effect such interactions may be empirically determined,
such as by running a time course and measuring the level of
transcription as a function of time. The amount of transcription
may be measured by using any method known to those of skill in the
art to be suitable. For example, mRNA expression of the protein of
interest may be detected using northern blots or their polypeptide
products may be identified using immunoassays. Alternatively,
transcription based assays using reporter gene may be used as
described in U.S. Pat. No. 5,436,128, herein incorporated by
reference. The reporter genes can be, e.g., chloramphenicol
acetyltransferase, luciferase, '3-galactosidase and alkaline
phosphatase. Furthermore, the protein of interest can be used as an
indirect reporter via attachment to a second reporter such as green
fluorescent protein (see, e.g., Mistili & Spector, Nature
Biotechnology, 15:961-964 (1997)).
The amount of transcription is then compared to the amount of
transcription in either the same cell in the absence of the test
compound, or it may be compared with the amount of transcription in
a substantially identical cell that lacks the T1R polypeptide of
interest. A substantially identical cell may be derived from the
same cells from which the recombinant cell was prepared but which
had not been modified by introduction of heterologous DNA. Any
difference in the amount of transcription indicates that the test
compound has in some manner altered the activity of the T1R
polypeptides of interest.
5. Transgenic Non-Human Animals Expressing Chemosensory
Receptors
Non-human animals expressing one or more chemosensory receptor
sequences of the invention, can also be used for receptor assays.
Such expression can be used to determine whether a test compound
specifically binds to a mammalian taste transmembrane receptor
complex in vivo by contacting a non-human animal stably or
transiently transfected with nucleic acids encoding chemosensory
receptors or ligand-binding regions thereof with a test compound
and determining whether the animal reacts to the test compound by
specifically binding to the receptor polypeptide complex.
Animals transfected or infected with the vectors of the invention
are particularly useful for assays to identify and characterize
tastants/ligands that can bind to a specific or sets of receptors.
Such vector-infected animals expressing human chemosensory receptor
sequences can be used for in vivo screening of tastants and their
effect on, e.g., cell physiology (e.g., on taste neurons), on the
CNS, or behavior.
Means to infect/express the nucleic acids and vectors, either
individually or as libraries, are well known in the art. A variety
of individual cell, organ, or whole animal parameters can be
measured by a variety of means. The T1R sequences of the invention
can be for example co-expressed in animal taste tissues by delivery
with an infecting agent, e.g., adenovirus expression vector.
The endogenous chemosensory receptor genes can remain functional
and wild-type (native) activity can still be present. In other
situations, where it is desirable that all chemosensory receptor
activity is by the introduced exogenous hybrid receptor, use of a
knockout line is preferred. Methods for the construction of
non-human transgenic animals, particularly transgenic mice, and the
selection and preparation of recombinant constructs for generating
transformed cells are well known in the art.
Construction of a "knockout" cell and animal is based on the
premise that the level of expression of a particular gene in a
mammalian cell can be decreased or completely abrogated by
introducing into the genome a new DNA sequence that serves to
interrupt some portion of the DNA sequence of the gene to be
suppressed. Also, "gene trap insertion" can be used to disrupt a
host gene, and mouse embryonic stem (ES) cells can be used to
produce knockout transgenic animals (see, e.g., Holzschu,
Transgenic Res 6:97-106 (1997)). The insertion of the exogenous is
typically by homologous recombination between complementary nucleic
acid sequences. The exogenous sequence is some portion of the
target gene to be modified, such as exonic, intronic or
transcriptional regulatory sequences, or any genomic sequence which
is able to affect the level of the target gene's expression; or a
combination thereof. Gene targeting via homologous recombination in
pluripotential embryonic stem cells allows one to modify precisely
the genomic sequence of interest. Any technique can be used to
create, screen for, propagate, a knockout animal, e.g., see
Bijvoet, Hum. Mol. Genet. 7:53-62 (1998); Moreadith, J. Mol. Med.
75:208-216 (1997); Tojo, Cytotechnology 19:161-165 (1995); Mudgett,
Methods Mol. Biol. 48:167-184 (1995); Longo, Transgenic Res.
6:321-328 (1997); U.S. Pat. Nos. 5,616,491; 5,464,764; 5,631,153;
5,487,992; 5,627,059; 5,272,071; WO 91/09955; WO93/09222; WO
96/29411; WO 95/31560; WO 91/12650.
The nucleic acids of the invention can also be used as reagents to
produce "knockout" human cells and their progeny. Likewise, the
nucleic acids of the invention can also be used as reagents to
produce "knock-ins" in mice. The human or rat T1R gene sequences
can replace the orthologous T1R in the mouse genome. In this way, a
mouse expressing a human or rat T1R is produced. This mouse can
then be used to analyze the function of human or rat T1Rs, and to
identify ligands for such T1Rs.
E. MODULATORS
The compounds tested as modulators of a T1R family member can be
any small chemical compound, or a biological entity, such as a
protein, sugar, nucleic acid or lipid. Alternatively, modulators
can be genetically altered versions of a T1R gene. Typically, test
compounds will be small chemical molecules and peptides.
Essentially any chemical compound can be used as a potential
modulator or ligand in the assays of the invention, although most
often compounds can be dissolved in aqueous or organic (especially
DMSO-based) solutions are used. The assays are designed to screen
large chemical libraries by automating the assay steps and
providing compounds from any convenient source to assays, which are
typically run in parallel (e.g., in microtiter formats on
microtiter plates in robotic assays). It will be appreciated that
there are many suppliers of chemical compounds, including Sigma
(St. Louis, Mo.), Aldrich (St. Louis, Mo.), Sigma-Aldrich (St.
Louis, Mo.), Fluka Chemika-Biochemica Analytika (Buchs,
Switzerland) and the like.
In one preferred embodiment, high throughput screening methods
involve providing a combinatorial chemical or peptide library
containing a large number of potential therapeutic compounds
(potential modulator or ligand compounds). Such "combinatorial
chemical libraries" or "ligand libraries" are then screened in one
or more assays, as described herein, to identify those library
members (particular chemical species or subclasses) that display a
desired characteristic activity. The compounds thus identified can
serve as conventional "lead compounds" or can themselves be used as
potential or actual therapeutics.
A combinatorial chemical library is a collection of diverse
chemical compounds generated by either chemical synthesis or
biological synthesis, by combining a number of chemical "building
blocks" such as reagents. For example, a linear combinatorial
chemical library such as a polypeptide library is formed by
combining a set of chemical building blocks (amino acids) in every
possible way for a given compound length (i.e., the number of amino
acids in a polypeptide compound). Millions of chemical compounds
can be synthesized through such combinatorial mixing of chemical
building blocks.
Preparation and screening of combinatorial chemical libraries is
well known to those of skill in the art. Such combinatorial
chemical libraries include, but are not limited to, peptide
libraries (see, e.g., U.S. Pat. No. 5,010,175, Furka, Int. J. Pept.
Prot. Res., 37:487-493 (1991) and Houghton et al., Nature,
354:84-88 (1991)). Other chemistries for generating chemical
diversity libraries can also be used. Such chemistries include, but
are not limited to: peptoids (e.g., PCT Publication No. WO
91/19735), encoded peptides (e.g., PCT Publication WO 93/20242),
random bio-oligomers (e.g., PCT Publication No: WO 92/00091),
benzodiazepines (e.g., U.S. Pat. No. 5,288,514), diversomers such
as hydantoins, benzodiazepines and dipeptides (Hobbs et al., Proc.
Nat. Acad. Sci., 90:6909-6913 (1993)), vinylogous polypeptides
(Hagihara et al., J. Amer. Chem. Soc., 114:6568 (1992)),
nonpeptidal peptidomimetics with glucose scaffolding (Hirschmann et
al., J. Amer. Chem. Soc., 114:9217-9218 (1992)), analogous organic
syntheses of small compound libraries (Chen et al., J. Amer. Chem.
Soc., 116:2661 (1994)), oligocarbamates (Cho et al., Science,
261:1303 (1993)), peptidyl phosphonates (Campbell et al., J. Org.
Chem., 59:658 (1994)), nucleic acid libraries (Ausubel, Berger and
Sambrook, all supra), peptide nucleic acid libraries (U.S. Pat. No.
5,539,083), antibody libraries (Vaughn et al., Nature
Biotechnology, 14(3):309-314 (1996) and PCT/US96/10287),
carbohydrate libraries (Liang et al., Science, 274:1520-1522 (1996)
and U.S. Pat. No. 5,593,853), small organic molecule libraries
(benzodiazepines, Baum, C&EN, Jan. 18, page 33 (1993);
thiazolidinones and metathiazanones, U.S. Pat. No. 5,549,974;
pyrrolidines, U.S. Pat. Nos. 5,525,735 and 5,519,134; morpholino
compounds, U.S. Pat. No. 5,506,337; benzodiazepines, U.S. Pat. No.
5,288,514, and the like).
Devices for the preparation of combinatorial libraries are
commercially available (see, e.g., 357 MPS, 390 MPS (Advanced Chem
Tech, Louisville Ky.), Symphony (Rainin, Woburn, Mass.), 433A
(Applied Biosystems, Foster City, Calif.), 9050 Plus (Millipore,
Bedford, Mass.)). In addition, numerous combinatorial libraries are
themselves commercially available (see, e.g., ComGenex, Princeton,
N.J.; Tripos, Inc., St. Louis, Mo.; 3D Pharmaceuticals, Exton, Pa.;
Martek Biosciences; Columbia, Md.; etc.).
In one aspect of the invention, the T1R modulators can be used in
any food product, confectionery, pharmaceutical composition, or
ingredient thereof to thereby modulate the taste of the product,
composition, or ingredient in a desired manner. For instance, T1R
modulators which enhance sweet taste sensation can be added to
sweeten a product or composition, while T1R modulators which block
undesirable taste sensations can be added to improve the taste of a
product or composition.
F. METHODS FOR REPRESENTING AND PREDICTING THE PERCEPTION OF
TASTE
The invention also preferably provides methods for representing the
perception of taste and/or for predicting the perception of taste
in a mammal, including in a human. Preferably, such methods may be
performed by using the receptors and genes encoding said T1R
polypeptides disclosed herein.
In one embodiment, novel molecules or combinations of molecules are
generated which elicit a predetermined taste perception in a mammal
by determining a value of taste perception in a mammal for a known
molecule or combinations of molecules as described above;
determining a value of taste perception in a mammal for one or more
unknown molecules or combinations of molecules as described above;
comparing the value of taste perception in a mammal for one or more
unknown compositions to the value of taste perception in a mammal
for one or more known compositions; selecting a molecule or
combination of molecules that elicits a predetermined taste
perception in a mammal; and combining two or more unknown molecules
or combinations of molecules to form a molecule or combination of
molecules that elicits a predetermined taste perception in a
mammal. The combining step yields a single molecule or a
combination of molecules that elicits a predetermined taste
perception in a mammal.
In another embodiment of the invention, there is provided a method
for simulating a taste, comprising the steps of for each of a
plurality of cloned chemosensory receptors, preferably human
receptors, ascertaining the extent to which the receptors interact
with the tastant; and combining a plurality of compounds, each
having a previously-ascertained interaction with the receptors in
amounts that together provide a receptor-stimulation profile that
mimics the profile for the tastant. Interaction of a tastant with a
chemosensory receptor can be determined using any of the binding or
reporter assays described herein. The plurality of compounds may
then be combined to form a mixture. If desired, one or more of the
plurality of the compounds can be combined covalently. The combined
compounds substantially stimulate at least 75%, 80%, or 90% of the
receptors that are substantially stimulated by the tastant.
In another preferred embodiment of the invention, a plurality of
standard compounds are tested against a plurality of chemosensory
receptors to ascertain the extent to which the receptors interact
with each standard compound, thereby generating a receptor
stimulation profile for each standard compound. These receptor
stimulation profiles may then be stored in a relational database on
a data storage medium. The method may further comprise providing a
desired receptor-stimulation profile for a taste; comparing the
desired receptor stimulation profile to the relational database;
and ascertaining one or more combinations of standard compounds
that most closely match the desired receptor-stimulation profile.
The method may further comprise combining standard compounds in one
or more of the ascertained combinations to simulate the taste.
G. KITS
T1R genes and their homologs are useful tools for identifying
chemosensory receptor cells, for forensics and paternity
determinations, and for examining taste transduction. T1R family
member-specific reagents that specifically hybridize to T1R nucleic
acids, such as T1R probes and primers, and T1R specific reagents
that specifically bind to a T1R polypeptide, e.g., T1R antibodies
are used to examine taste cell expression and taste transduction
regulation.
Nucleic acid assays for the presence of DNA and RNA for a T1R
family member in a sample include numerous techniques are known to
those skilled in the art, such as southern analysis, northern
analysis, dot blots, RNase protection, S1 analysis, amplification
techniques such as PCR, and in situ hybridization. In in situ
hybridization, for example, the target nucleic acid is liberated
from its cellular surroundings in such as to be available for
hybridization within the cell while preserving the cellular
morphology for subsequent interpretation and analysis. The
following articles provide an overview of the art of in situ
hybridization: Singer et al., Biotechniques, 4:230250 (1986); Haase
et al., Methods in Virology, vol. VII, pp. 189-226 (1984); and
Nucleic Acid Hybridization: A Practical Approach (Names et al.,
eds. 1987). In addition, a T1R polypeptide can be detected with the
various immunoassay techniques described above. The test sample is
typically compared to both a positive control (e.g., a sample
expressing a recombinant T1R polypeptide) and a negative
control.
The present invention also provides for kits for screening for
modulators of T1R family members. Such kits can be prepared from
readily available materials and reagents. For example, such kits
can comprise any one or more of the following materials: T1R
nucleic acids or proteins, reaction tubes, and instructions for
testing T1R activity. Optionally, the kit contains a biologically
active T1R receptor. A wide variety of kits and components can be
prepared according to the present invention, depending upon the
intended user of the kit and the particular needs of the user.
EXAMPLES
In the protein sequences presented herein, the one-letter code X or
Xaa refers to any of the twenty common amino acid residues. In the
DNA sequences presented herein, the one letter codes N or n refers
to any of the of the four common nucleotide bases, A, T, C, or
G.
Example 1
hT1R1
The human ortholog (Database accession no. AL159177) of a rat taste
receptor, designated rT1R1, is provided below as SEQ ID NO 1. The
nucleotide and conceptually translated hT1R1 sequence is also
described herein as SEQ ID NO 2.
TABLE-US-00002 (SEQ ID NO 1) hT1R1 predicted cds (SEQ ID NO 1)
ATGCTGCTCTGCACGGCTCGCCTGGTCGGCCTGCAGCTTCTCATTTCCTG
CTGCTGGGCCTTTGCCTGCCATAGCACGGAGTCTTCTCCTGACTTCACCC
TCCCCGGAGATTACCTCCTGGCAGGCCTGTTCCCTCTCCATTCTGGCTGT
CTGCAGGTGAGGCACAGACCCGAGGTGACCCTGTGTGACAGGTCTTGTAG
CTTCAATGAGCATGGCTACCACCTCTTCCAGGCTATGCGGCTTGGGGTTG
AGGAGATAAACAACTCCACGGCCCTGCTGCCCAACATCACCCTGGGGTAC
CAGCTGTATGATGTGTGTTCTGACTCTGCCAATGTGTATGCCACGCTGAG
AGTGCTCTCCCTGCCAGGGCAACACCACATAGAGCTCCAAGGAGACCTTC
TCCACTATTCCCCTACGGTGCTGGCAGTGATTGGGCCTGACAGCACCAAC
CGTGCTGCCACCACAGCCGCCCTGCTGAGCCCTTTCCTGGTGCCCATGAT
TAGCTATGCGGCCAGCAGCGAGACGCTCAGCGTGAAGCGGCAGTATCCCT
CTTTCCTGCGCACCATCCCCAATGACAAGTACCAGGTGGAGACCATGGTG
CTGCTGCTGCAGAAGTTCGGGTGGACCTGGATCTCTCTGGTTGGCAGCAG
TGACGACTATGGGCAGCTAGGGGTGCAGGCACTGGAGAACCAGGCCACTG
GTCAGGGGATCTGCATTGCTTTCAAGGACATCATGCCCTTCTCTGCCCAG
GTGGGCGATGAGAGGATGCAGTGCCTCATGCGCCACCTGGCCCAGGCCGG
GGCCACCGTCGTGGTTGTTTTTTCCAGCCGGCAGTTGGCCAGGGTGTTTT
TCGAGTCCGTGGTGCTGACCAACCTGACTGGCAAGGTGTGGGTCGCCTCA
GAAGCCTGGGCCCTCTCCAGGCACATCACTGGGGTGCCCGGGATCCAGCG
CATTGGGATGGTGCTGGGCGTGGCCATCCAGAAGAGGGCTGTCCCTGGCC
TGAAGGCGTTTGAAGAAGCCTATGCCCGGGCAGACAAGAAGGCCCCTAGG
CCTTGCCACAAGGGCTCCTGGTGCAGCAGCAATCAGCTCTGCAGAGAATG
CCAAGCTTTCATGGCACACACGATGCCCAAGCTCAAAGCCTTCTCCATGA
GTTCTGCCTACAACGCATACCGGGCTGTGTATGCGGTGGCCCATGGCCTC
CACCAGCTCCTGGGCTGTGCCTCTGGAGCTTGTTCCAGGGGCCGAGTCTA
CCCCTGGCAGCTTTTGGAGCAGATCCACAAGGTGCATTTCCTTCTACACA
AGGACACTGTGGCGTTTAATGACAACAGAGATCCCCTCAGTAGCTATAAC
ATAATTGCCTGGGACTGGAATGGACCCAAGTGGACCTTCACGGTCCTCGG
TTCCTCCACATGGTCTCCAGTTCAGCTAAACATAAATGAGACCAAAATCC
AGTGGCACGGAAAGGACAACCAGGTGCCTAAGTCTGTGTGTTCCAGCGAC
TGTCTTGAAGGGCACCAGCGAGTGGTTACGGGTTTCCATCACTGCTGCTT
TGAGTGTGTGCCCTGTGGGGCTGGGACCTTCCTCAACAAGAGTGACCTCT
ACAGATGCCAGCCTTGTGGGAAAGAAGAGTGGGCACCTGAGGGAAGCCAG
ACCTGCTTCCCGCGCACTGTGGTGTTTTTGGCTTTGCGTGAGCACACCTC
TTGGGTGCTGCTGGCAGCTAACACGCTGCTGCTGCTGCTGCTGCTTGGGA
CTGCTGGCCTGTTTGCCTGGCACCTAGACACCCCTGTGGTGAGGTCAGCA
GGGGGCCGCCTGTGCTTTCTTATGCTGGGCTCCCTGGCAGCAGGTAGTGG
CAGCCTCTATGGCTTCTTTGGGGAACCCACAAGGCCTGCGTGCTTGCTAC
GCCAGGCCCTCTTTGCCCTTGGTTTCACCATCTTCCTGTCCTGCCTGACA
GTTCGCTCATTCCAACTAATCATCATCTTCAAGTTTTCCACCAAGGTACC
TACATTCTACCACGCCTGGGTCCAAAACCACGGTGCTGGCCTGTTTGTGA
TGATCAGCTCAGCGGCCCAGCTGCTTATCTGTCTAACTTGGCTGGTGGTG
TGGACCCCACTGCCTGCTAGGGAATACCAGCGCTTCCCCCATCTGGTGAT
GCTTGAGTGCACAGAGACCAACTCCCTGGGCTTCATACTGGCCTTCCTCT
ACAATGGCCTCCTCTCCATCAGTGCCTTTGCCTGCAGCTACCTGGGTAAG
GACTTGCCAGAGAACTACAACGAGGCCAAATGTGTCACCTTCAGCCTGCT
CTTCAACTTCGTGTCCTGGATCGCCTTCTTCACCACGGCCAGCGTCTACG
ACGGCAAGTACCTGCCTGCGGCCAACATGATGGCTGGGCTGAGCAGCCTG
AGCAGCGGCTTCGGTGGGTATTTTCTGCCTAAGTGCTACGTGATCCTCTG
CCGCCCAGACCTCAACAGCACAGAGCACTTCCAGGCCTCCATTCAGGACT
ACACGAGGCGCTGCGGCTCCACCTGA (SEQ ID NO 2) hT1R1 conceptual
translation (SEQ ID NO 2)
MLLCTARLVGLVGLQLLISCCWAFACHSTESSFDFTLPGDYLLAGLFPLH
SGCLQVRHRPEVTLCDRSCSFNEHGYHLFQAMRLGVEEINNSTALLPNIT
LGYQLYDVCSDSANVYATLRVLSLPGQHHIELQGDLLHYSPTVLAVIGPD
STNRAATTAALLSPFLVPMISYAASSETLSVKRQYPSFLRTIPNDKYQVE
TMVLLLQKFGWTWISLVGSSDDYGQLGVQALENQATGQGICIAFKDIMPF
SAQVGDERMQCLMRHLAQAGATVVVYFSSRQLARVFFESVVLTNLTGKVW
VASEAWALSRHITGVFGIQRIGMVLGVAIQKRAVPGLKAFEEAYARADKK
APRPCHKGSWCSSNQLCRECQAFMAHTMPKLKAFSMSSAYNAYRAVYAVA
HGLHQLLGCASGACSRGRVYPWQLLEQIHKVHFLLHKDTVAFNDNRDPLS
SYNILAWDWNGPKWTFTVLGSSTWSPVQLNINETKIQWHGKDNQVPKSVC
SSDCLEGHQRVVTGFHHCCFECVPCGAGTFLNKSDLYRCQPCGKEEWAPE
GSQTCFPRTVVFLALREHTSWVLLAANTLLLLLLLGTAGLFAWHLDTPVV
RSAGGRLCFLMLGSLAAGSGSLYGFFGEPTRPACLLRQALFALGFTTFLS
CLTVRSFQLIIIFKSTKVPTFYHAWVQNHGAGLFVMISSAAQLLICLTWL
VVWTPLPAREYQRFPHLVMLECTETNSLGFILAFLYNGLLSISAFACSYL
GKDLPENYNEAKCVTFSLLFNFVSWIAFFTTASVYDGKYLPAANMMAGLS
SLSSGFGGYFLPKCYVILCRPDLNSTEHFQASIQDYTRRCGST
Example 2
hT1R2
The predicted cds of the human ortholog of a rat taste receptor,
designated rT1R2, is provided below as SEQ ID NO 3. The
conceptually translated hT1R2 sequences is also described herein as
SEQ ID NO 4. According to the present invention, the first two
coding exons of hT1R2 were identified within a PAC by Southern
blot. Exon 1 was isolated within a BamHI/BglII fragment that was
identified in the Southern experiment, and exon 2 was isolated
within a PCR product that spans exon 1 to exon 3. Comparison of the
first two coding exons to the rT1R2 sequence established that the
two exons encode the N-terminus of the human counterpart to rT1R2.
For example, the pairwise amino acid identity between the hT1R2
N-terminal sequence coded by the two exons and corresponding
regions of rT1R2 is approximately 72%, whereas the most related
annotated sequence in public DNA sequence data banks is only
approximately 48% identical to hT1R2.
TABLE-US-00003 (SEQ ID NO 3) hT1R2 predicted cds (SEQ ID NO. 3)
ATGGGGCCCAGGGCAAAGACCATCTGCTCCCTGTTCTTCCTCCTATGGGT
CCTGGCTGAGCCGGCTGAGAACTCGGACTTCTACCTGCCTGGGGATTACC
TCCTGGGTGGCCTCTTCTCCCTCCATGCCAACATGAAGGGCATTGTTCAC
CTTAACTTCCTGCAGGTGCCCATGTGCAAGGAGTATGAAGTGAAGGTGAT
AGGCTACAACCTCATGCAGGCCATGCGCTTCGCGGTGGAGGAGATCAACA
ATGACAGCAGCCTGCTGCCTGGTGTGCTGCTGGGCTATGAGATCGTGGAT
GTGTGCTACATCTCCAACAATGTCCAGCCGGTGCTCTACTTCCTGGCACA
CGAGGACAACCTCCTTCCCATCCAAGAGGACTACAGTAACTACATTTCCC
GTGTGGTGGCTGTCATTGGCCCTGACAACTCCGAGTCTGTCATGACTGTG
GCCAACTTCCTCTCCCTATTTCTCCTTCCACAGATCACCTACAGCGCCAT
CAGCGATGAGCTGCGAGACAAGGTGCGCTTCCCGGCTTTGCTGCGTACCA
CACCCAGCGCCGACCACCACGTCGAGGCCATGGTGCAGCTGATGCTGCAC
TTCCGCTGGAACTGGATCATTGTGCTGGTGAGCAGCGACACCTATGGCCG
CGACAATGGCCAGCTGCTTGGCGAGCGCGTGGCCCGGCGCGACATCTGCA
TCGCCTTCCAGGAGACGCTGCCCACACTGCAGCCCAACCAGAACATGACG
TCAGAGGAGCGCCAGCGCCTGGTGACCATTGTGGACAAGCTGCAGCAGAG
CACAGCGCGCGTCGTGGTCGTGTTCTCGCCCGACCTGACCCTGTACCACT
TCTTCAATGAGGTGCTGCGCCAGAACTTCACGGGCGCCGTGTGGATCGCC
TCCGAGTCCTGGGCCATCGACCCGGTCCTGCACAACCTCACGGAGCTGGG
CCACTTGGGCACCTTCCTGGGCATCACCATCCAGAGCGTGCCCATCCCGG
GCTTCAGTGAGTTCCGCGAGTGGGGCCCACAGGCTGGGCCGCCACCCCTC
AGCAGGACCAGCCAGAGCTATACCTGCAACCAGGAGTGCGACAACTGCCT
GAACGCCACCTTGTCCTTCAACACCATTCTCAGGCTCTCTGGGGAGCGTG
TCGTCTACAGCGTGTACTCTGCGGTCTATGCTGTGGCCCATGCCCTGCAC
AGCCTCCTCGGCTGTGACAAAAGCACCTGCACCAAGAGGGTGGTCTACCC
CTGGCAGCTGCTTGAGGAGATCTGGAAGGTCAACTTCACTCTCCTGGACC
ACCAAATCTTCTTCGACCCGCAAGGGGACGTGGCTCTGCACTTGGAGATT
GTCCAGTGGCAATGGGACCGGAGCCAGAATCCCTTCCAGAGCGTCGCCTC
CTACTACCCCCTGCAGCGACAGCTGAAGAACATCCAAGACATCTCCTGGC
ACACCGTCAACAACACGATCCCTATGTCCATGTGTTCCAAGAGGTGCCAG
TCAGGGCAAAAGAAGAAGCCTGTGGGCATCCACGTCTGCTGCTTCGAGTG
CATCGACTGCCTTCCCGGCACCTTCCTCAACCACACTGAAGATGAATATG
AATGCCAGGCCTGCCCGAATAACGAGTGGTCCTACCAGAGTGAGACCTCC
TGCTTCAAGCGGCAGCTGGTCTTCCTGGAATGGCATGAGGCACCCACCAT
CGCTGTGGCCCTGCTGGCCGCCCTGGGCTTCCTCAGCACCCTGGCCATCC
TGGTGATATTCTGGAGGCACTTCCAGACACCCATAGTTCGCTCGGCTGGG
GGCCCCATGTGCTTCCTGATGCTGACACTGCTGCTGGTGGCATACATGGT
GGTCCCGGTGTACGTGGGGCCGCCCAAGGTCTCCACCTGCCTCTGCCGCC
AGGCCCTCTTTCCCCTCTGCTTCACAATTTGCATCTCCTGTATCGCCGTG
CGTTCTTTCCAGATCGTCTGCGCCTTCAAGATGGCCAGCCGCTTCCCACG
CGCCTACAGCTACTGGGTCCGCTACCAGGGGCCCTACGTCTCTATGGCAT
TTATCACGGTACTCAAAATGGTCATTGTGGTAATTGGCATGCTGGCCACG
GGCCTCAGTCCCACCACCCGTACTGACCCCGATGACCCCAAGATCACAAT
TGTCTCCTGTAACCCCAACTACCGCAACAGCCTGCTGTTCAACACCAGCC
TGGACCTGCTGCTCTCAGTGGTGGGTTTCAGCTTCGCCTACATGGGCAAA
GAGCTGCCCACCAACTACAACGAGGCCAAGTTCATCACCCTCAGCATGAC
CTTCTATTTCACCTCATCCGTCTCCCTCTGCACCTTCATGTCTGCCTACA
GCGGGGTGCTGGTCACCATCGTGGACCTCTTGGTCACTGTGCTCAACCTC
CTGGCCATCAGCCTGGGCTACTTCGGCCCCAAGTGCTACATGATCCTCTT
CTACCCGGAGCGCAACACGCCCGCCTACTTCAACAGCATGATCCAGGGCT
ACACCATGAGGAGGGACTAG (SEQ ID NO 4) hT1R2 conceptual translation
(SEQ ID NO. 4) MGPRAKTICSLFFLLWVLAEPAENSDFYLPGDYLLGGLFSLHANMKGIVH
LNFLQVPMCKEYEVKVIGYNLMQAMRFAVEEINNDSSLLPGVLLGYEIVD
VCYISNNVQPVLYFLAHEDNLLPIQEDYSNYISRVVAVIGPDNSESVMTV
ANFLSLFLLPQITYSAISDELRDKVRFPALLRTTPSADHHVEAMVQLMLH
FRWNWIIVLVSSDTYGRDNGQLLGERVARRDICIAFQETLPTLQPNQNMT
SEERQRLVTIVDKLQQSTARVVVVFSPDLTLYHFFNEVLRQNFTGAVWIA
SESWAIDPVLHNLTELGHLGTFLGITIQSVPIPGFSEFREWGPQAGPPPL
SRTSQSYTCNQECDNCLNATLSFNTILRLSGERVYYSVYSAVYAVAHALH
SLLGCDKSTCTKRVVYPWQLLEEIWKVNFTLLDHQIFFDPQGDVALHLEI
VQWQWDRSQNPFQSVASYYPLQRQLKNIQDISWHTVNNTIPMSMCSKRCQ
SGQKKKPVGIHVCCFECIDCLPGTFLNHTEDEYECQACPNNEWSYQSETS
CFKRQLVFLEWHEAPTIAVALLAALGFLSTLAILVIFWRHFQTPIVRSAG
GPMCFLMLTLLLVAYMVVPVYVGPPKVSTCLCRQALFPLCFTICISCIAV
RSFQIVCAFKMASRFPRAYSYWVRYQGPYVSMAFITVLKMVIVVIGMLAT
GLSPTTRTDPDDPKITIVSCNPNYRNSLLFNTSLDLLLSVVGFSFAYMGK
ELPTNYNEAKFITLSMTFYFTSSVSLCTFMSAYSGVLVTIVDLLVTVLNL
LAISLGYFGPKCYMILFYPERNTPAYFNSMIQGYTMRRD
Example 3
hT1R3
The predicted hT1R3 coding sequence is provided as SEQ ID NO 5 and
the conceptual translation is provided as SEQ ID NO 6. An
alternative form of hT1R3 with a single nucleic acid variation
indicated in bold (designated hT1R3a) is also provided as SEQ ID
NO. 7.
TABLE-US-00004 (SEQ ID NO 5) hT1R3 predicted cds (SEQ ID NO 5)
ATGCTGGGCCCTGCTGTCCTGGGCCTCAGCCTCTGGGCTCTCCTGCACCC
TGGGACGGGGGCCCCATTGTGCCTGTCACAGCAACTTAGGATGAAGGGGG
ACTACGTGCTGGGGGGGCTGTTCCCCCTGGGCGAGGCCGAGGAGGCTGGC
CTCCGCAGCCGGACACGGCCCAGCAGCCCTGTGTGCACCAGGTTCTCCTC
AAACGGCCTGCTCTGGGCACTGGCCATGAAAATGGCCGTGGAGGAGATCA
ACAACAAGTCGGATCTGCTGCCCGGGCTGCGCCTGGGCTACGACCTCTTT
GATACGTGCTCGGAGCCTGTGGTGGCCATGAAGCCCAGCCTCATGTTCCT
GGCCAAGGCAGGCAGCCGCGACATCGCCGCCTACTGCAACTACACGCAGT
ACCAGCCCCGTGTGCTGGCTGTCATCGGGCCCCACTCGTCAGAGCTCGCC
ATGGTCACCGGCAAGTTCTTCAGCTTCTTCCTCATGCCCCAGGTCAGCTA
CGGTGCTAGCATGGAGCTGCTGAGCGCCCGGGAGACCTTCCCCTCCTTCT
TCCGCACCGTGCCCAGCGACCGTGTGCAGCTGACGGCCGCCGCGGAGCTG
CTGCAGGAGTTCGGCTGGAACTGGGTGGCCGCCCTGGGCAGCGACGACGA
GTACGGCCGGCAGGGCCTGAGCATCTTCTCGGCCCTGGCCGCGGCACGCG
GCATCTGCATCGCGCACGAGGGCCTGGTGCCGCTGCCCCGTGCCGATGAC
TCGCGGCTGGGGAAGGTGCAGGACGTCCTGCACCAGGTGAACCAGAGCAG
CGTGCAGGTGGTGCTGCTGTTCGCCTCCGTGCACGCCGCCCACGCCCTCT
TCAACTACAGCATCAGCAGCAGGCTCTCGCCCAAGGTGTGGGTGGCCAGC
GAGGCCTGGCTGACCTCTGACCTGGTCATGGGGCTGCCCGGCATGGCCCA
GATGGGCACGGTGCTTGGCTTCCTCCAGAGGGGTGCCCAGCTGCACGAGT
TCCCCCAGTACGTGAAGACGCACCTGGCCCTGGCCACCGACCCGGCCTTC
TGCTCTGCCCTGGGCGAGAGGGAGCAGGGTCTGGAGGAGGACGTGGTGGG
CCAGCGCTGCCCGCAGTGTGACTGCATCACGCTGCAGAACGTGAGCGCAG
GGCTAAATCACCACCAGACGTTCTCTGTCTACGCAGCTGTGTATAGCGTG
GCCCAGGCCCTGCACAACACTCTTCAGTGCAACGCCTCAGGCTGCCCCGC
GCAGGACCCCGTGAAGCCCTGGCAGCTCCTGGAGAACATGTACAACCTGA
CCTTCCACGTGGGCGGGCTGCCGCTGCGGTTCGACAGCAGCGGAAACGTG
GACATGGAGTACGACCTGAAGCTGTGGGTGTGGCAGGGCTCAGTGCCCAG
GCTCCACGACGTGGGCAGGTTCAACGGCAGCCTCAGGACAGAGCGCCTGA
AGATCCGCTGGCACACGTCTGACAACCAGAAGCCCGTGTCCCGGTGCTCG
CGGCAGTGCCAGGAGGGCCAGGTGCGCCGGGTCAAGGGGTTCCACTCCTG
CTGCTACGACTGTGTGGACTGCGAGGCGGGCAGCTACCGGCAAAACCCAG
ACGACATCGCCTGCACCTTTTGTGGCCAGGATGAGTGGTCCCCGGAGCGA
AGCACACGCTGCTTCCGCCGCAGGTCTCGGTTCCTGGCATGGGGCGAGCC
GGCTGTGCTGCTGCTGCTCCTGCTGCTGAGCCTGGCGCTGGGCCTTGTGC
TGGCTGCTTTGGGGCTGTTCGTTCACCATCGGGACAGCCCACTGGTTCAG
GCCTCGGGGGGGCCCCTGGCCTGCTTTGGCCTGGTGTGCCTGGGCCTGGT
CTGCCTCAGCGTCCTCCTGTTCCCTGGCCAGCCCAGCCCTGCCCGATGCC
TGGCCCAGCAGCCCTTGTCCCACCTCCCGCTCACGGGCTGCCTGAGCACA
CTCTTCCTGCAGGCGGCCGAGATCTTCGTGGAGTCAGAACTGCCTCTGAG
CTGGGCAGACCGGCTGAGTGGCTGCCTGCGGGGGCCCTGGGCCTGGCTGG
TGGTGCTGCTGGCCATGCTGGTGGAGGTCGCACTGTGCACCTGGTACCTG
GTGGCCTTCCCGCCGGAGGTGGTGACGGACTGGCACATGCTGCCCACGGA
GGCGCTGGTGCACTGCCGCACACGCTCCTGGGTCAGCTTCGGCCTAGCGC
ACGCCACCAATGCCACGCTGGCCTTTCTCTGCTTCCTGGGCACTTTCCTG
GTGCGGAGCCAGCCGGGCcGCTACAACCGTGCCCGTGGCCTCACCTTTGC
CATGCTGGCCTACTTCATCACCTGGGTCTCCTTTGTGCCCCTCCTGGCCA
ATGTGCAGGTGGTCCTCAGGCCCGCCGTGCAGATGGGCGCCCTCCTGCTC
TGTGTCCTGGGCATCCTGGCTGCCTTCCACCTGCCCAGGTGTTACCTGCT
CATGCGGCAGCCAGGGCTCAACACCCCCGAGTTCTTCCTGGGAGGGGGCC
CTGGGGATGCCCAAGGCCAGAATGACGGGAACACAGGAAATCAGGGGAAA CATGAGTGA (SEQ
ID NO 6) hT1R3 conceptual translation (SEQ ID NO 6)
MLGPAVLGLSLWALLHPGTGAPLCLSQQLRMKGDYVLGGLFPLGEAEEAG
LRSRTRPSSPVCTRFSSNGLLWALAMKMAVEEINNKSDLLPGLRLGYDLF
DTCSEPVVAMKPSLMFLAKAGSRDIAAYCNYTQYQPRVLAVIGPHSSELA
MVTGKFFSFFLMPQVSYGASMELLSARETFPSFFRTVPSDRVQLTAAAEL
LQEFGWNWVAALGSDDEYGRQGLSIFSALAAARGICIAHEGLVPLPRADD
SRLGKVQDVLHQVNQSSVQVVLLFASVHAAHALFNYSISSRLSPKVWVAS
EAWLTSDLVMGLPGMAQMGTVLGFLQRGAQLHEFPQYVKTHLALATDPAF
CSALGEREQGLEEDVVGQRCPQCDCITLQNVSAGLNHHQTFSVYAAVYSV
AQALHNTLQCNASGCPAQDPVKPWQLLENMYNLTFHVGGLPLRFDSSGNV
DMEYDLKLWVWQGSVPRLHDVGRFNGSLRTERLKIRWHTSDNQKPVSRCS
RQCQEGQVRRVKGFHSCCYDCVDCEAGSYRQNPDDIACTFCGQDEWSPER
STRCFRRRSRFLAWGEPAVLLLLLLLSLALGLVLAALGLFVHHRDSPLVQ
ASGGPLACFGLVCLGLVCLSVLLFPGQPSPARCLAQQPLSHLPLTGCLST
LFLQAAEIFVESELPLSWADRLSGCLRGPWAWLVVLLAMLVEVALCTWYL
VAFPPEVVTDWHMLPTEALVHCRTRSWVSFGLAHATNATLAFLCFLGTFL
VRSQPGCYNRARGLTFAMLAYFITWVSFVPLLANVQVVLRPAVQMGALLL
CVLGILAAFHLPRCYLLMRQPGLNTPEFFLGGGPGDAQGQNDGNTGNQGK HE (SEQ ID NO 7)
HT1R3a predicted cds (SEQ ID NO 7)
ATGCTGGGCCCTGCTGTCCTGGGCCTCAGCCTCTGGGCTCTCCTGCACCC
TGGGACGGGGGCCCCATTGTGCCTGTCACAGCAACTTAGGATGAAGGGGG
ACTACGTGCTGGGGGGGCTGTTCCCCCTGGGCGAGGCCGAGGAGGCTGGC
CTCCGCAGCCGGACACGGCCCAGCAGCCCTGTGTGCACCAGGTTCTCCTC
AAACGGCCTGCTCTGGGCACTGGCCATGAAAATGGCCGTGGAGGAGATCA
ACAACAAGTCGGATCTGCTGCCCGGGCTGCGCCTGGGCTACGACCTCTTT
GATACGTGCTCGGAGCCTGTGGTGGCCATGAAGCCCAGCCTCATGTTCCT
GGCCAAGGCAGGCAGCCGCGACATCGCCGCCTACTGCAACTACACGCAGT
ACCAGCCCCGTGTGCTGGCTGTCATCGGGCCCCACTCGTCAGAGCTCGCC
ATGGTCACCGGCAAGTTCTTCAGCTTCTTCCTCATGCCCCAGGTCAGCTA
CGGTGCTAGCATGGAGCTGCTGAGCGCCCGGGAGACCTTCCCCTCCTTCT
TCCGCACCGTGCCCAGCGACCGTGTGCAGCTGACGGCCGCCGCGGAGCTG
CTGCAGGAGTTCGGCTGGAACTGGGTGGCCGCCCTGGGCAGCGACGACGA
GTACGGCCGGCAGGGCCTGAGCATCTTCTCGGCCCTGGCCGCGGCACGCG
GCATCTGCATCGCGCACGAGGGCCTGGTGCCGCTGCCCCGTGCCGATGAC
TCGCGGCTGGGGAAGGTGCAGGACGTCCTGCACCAGGTGAACCAGAGCAG
CGTGCAGGTGGTGCTGCTGTTCGCCTCCGTGCACGCCGCCCACGCCCTCT
TCAACTACAGCATCAGCAGCAGGCTCTCGCCCAAGGTGTGGGTGGCCAGC
GAGGCCTGGCTGACCTCTGACCTGGTCATGGGGCTGCCCGGCATGGCCCA
GATGGGCACGGTGCTTGGCTTCCTCCAGAGGGGTGCCCAGCTGCACGAGT
TCCCCCAGTACGTGAAGACGCACCTGGCCCTGGCCACCGACCCGGCCTTC
TGCTCTGCCCTGGGCGAGAGGGAGCAGGGTCTGGAGGAGGACGTGGTGGG
CCAGCGCTGCCCGCAGTGTGACTGCATCACGCTGCAGAACGTGAGCGCAG
GGCTAAATCACCACCAGACGTTCTCTGTCTACGCAGCTGTGTATAGCGTG
GCCCAGGCCCTGCACAACACTCTTCAGTGCAACGCCTCAGGCTGCCCCGC
GCAGGACCCCGTGAAGCCCTGGCAGCTCCTGGAGAACATGTACAACCTGA
CCTTCCACGTGGGCGGGCTGCCGCTGCGGTTCGACAGCAGCGGAAACGTG
GACATGGAGTACGACCTGAAGCTGTGGGTGTGGCAGGGCTCAGTGCCCAG
GCTCCACGACGTGGGCAGGTTCAACGGCAGCCTCAGGACAGAGCGCCTGA
AGATCCGCTGGCACACGTCTGACAACCAGAAGCCCGTGTCCCGGTGCTCG
CGGCAGTGCCAGGAGGGCCAGGTGCGCCGGGTCAAGGGGTTCCACTCCTG
CTGCTACGACTGTGTGGACTGCGAGGCGGGCAGCTACCGGCAAAACCCAG
ACGACATCGCCTGCACCTTTTGTGGCCAGGATGAGTGGTCCCCGGAGCGA
AGCACACGCTGCTTCCGCCGCAGGTCTCGGTTCCTGGCATGGGGCGAGCC
GGCTGTGCTGCTGCTGCTCCTGCTGCTGAGCCTGGCGCTGGGCCTTGTGC
TGGCTGCTTTGGGGCTGTTCGTTCACCATCGGGACAGCCCACTGGTTCAG
GCCTCGGGGGGGCCCCTGGCCTGCTTTGGCCTGGTGTGCCTGGGCCTGGT
CTGCCTCAGCGTCCTCCTGTTCCCTGGCCAGCCCAGCCCTGCCCGATGCC
TGGCCCAGCAGCCCTTGTCCCACCTCCCGCTCACGGGCTGCCTGAGCACA
CTCTTCCTGCAGGCGGCCGAGATCTTCGTGGAGTCAGAACTGCCTCTGAG
CTGGGCAGACCGGCTGAGTGGCTGCCTGCGGGGGCCCTGGGCCTGGCTGG
TGGTGCTGCTGGCCATGCTGGTGGAGGTCGCACTGTGCACCTGGTACCTG
GTGGCCTTCCCGCCGGAGGTGGTGACGGACTGGCACATGCTGCCCACGGA
GGCGCTGGTGCACTGCCGCACACGCTCCTGGGTCAGCTTCGGCCTAGCGC
ACGCCACCAATGCCACGCTGGCCTTTCTCTGCTTCCTGGGCACTTTCCTG
GTGCGGAGCCAGCCGGGCCGCTACAACCGTGCCCGTGGCCTCACCTTTGC
CATGCTGGCCTACTTCATCACCTGGGTCTCCTTTGTGCCCCTCCTGGCCA
ATGTGCAGGTGGTCCTCAGGCCCGCCGTGCAGATGGGCGCCCTCCTGCTC
TGTGTCCTGGGCATCCTGGCTGCCTTCCACCTGCCCAGGTGTTACCTGCT
CATGCGGCAGCCAGGGCTCAACACCCCCGAGTTCTTCCTGGGAGGGGGCC
CTGGGGATGCCCAAGGCCAGAATGACGGGAACACAGGAAATCAGGGGAAA
CATGAGTGA
Example 4
PDZIP as an Export Sequence
The six residue PDZIP sequence (SEQ ID NO 10) was fused to the
C-terminus of the orphan GPCR hT1R2 and transfected into an HEK-293
host cell. The surface expression of hT1R2 was then monitored using
immunofluorescence and FACS scanning data. As demonstrated in FIG.
1, the inclusion of the PDZIP sequence acted as a translocation
domain and increased the surface expression of hT1R2-PDZIP relative
to hT1R2.
TABLE-US-00005 PKZIP Sequence (SEQ ID NO 10) SVSTVV (SEQ ID NO
10)
More specifically, FIG. 1A shows an immunofluorescence staining of
Myc-tagged hT1R2 and demonstrated that PDZIP significantly
increases the amount of hT1R2 protein on the plasma membrane.
Further, FIG. 1B shows FACS analysis data demonstrating the same
result--Myc-tagged hT1R2 in indicated in the dotted line and
Myc-tagged hT1R2-PDZIP is indicated in the solid line.
Example 5
Co-Expression of hT1R2 and hT1R3 in Taste Tissue
cDNA-specific amplification products were amplified from cDNA
prepared from resected human circumvallate papillae and run on a
gel with genomic DNA obtained from human tongue epithelium. As
shown in FIG. 3, hT1R2 and hT1R3 are co-expressed in taste
tissue
Example 6
hT1R2/hT1R3 Heterodimeric Complex
HEK-293 cells stably transfected with G.alpha.15 were transfected
with hT1R2, hT1R3, or a combination thereof, both with and without
PDZIP. The response of the various transfected cells to a number of
sweet stimuli were then monitored by calcium-imaging. FIG. 2 shows
the calcium-imaging data demonstrating that hT1R2 and hT1R3 are
both required to trigger a response to the sweet stimuli. Thus, it
was unexpectedly discovered that the response to sweet stimuli is
dependent on the presence of both hT1R2 and hT1R3. Neither receptor
alone resulted in any significant response to the stimuli.
More particularly, FIG. 2A shows untransfected G.alpha.15 stable
host cells in HBS buffer, FIG. 2B shows hT1R2-PDZIP transfected
G.alpha.15 stable host cells in sweetener pool no. 5 (saccharin,
sodium cyclamate, Acesulfame K, and Aspartame--20 mM each in HBS
buffer), FIG. 2C shows hT1R3-PDZIP transfected G.alpha.15 stable
host cells in sweetener pool no. 5, and FIG. 2D shows
hT1R2-PDZIP/hT1R3-PDZIP co-transfected G.alpha.15 stable host cells
in sweetener pool no. 5. Further, FIGS. 2E-2H show dose-dependent
response of hT1R2/hT1R3 co-transfected G.alpha.15 stable host cells
to sucrose--E: 0 mM in HBS buffer; F: 30 mM; G: 60 mM; and H: 250
mM. FIGS. 2I-2L shown the responses of hT1R2/hT1R3 co-transfected
G.alpha.15 stable host cells to individual sweeteners--I: Aspartame
(1.5 mM); Acesulfame K (1 mM); K: Neotame (20 mM); L: Sodium
cyclamate (20 mM). As demonstrated by the calcium-images of FIG. 2,
hT1R2 and hT1R3 are both required for the activities triggered by
the sweet stimuli.
Example 7
hT1R2 and hT1R3 Function in Combination and Couple to
G.alpha.15
To demonstrate that hT1R2 and hT1R3 function in combination, we
transfected the receptors individually and in combination into
HEK-G15 cells. We have determined that T1R2/T1R3 activity is not
enhanced by incorporation of PDZIP into the receptors;
consequently, unmodified receptors are used in the assays described
herein. Transfected cells were loaded with Fluo-4, and their
responses to a mixture of sweet taste stimuli (Saccharin,
Cyclamate, Acesulfame K, Aspartame, 10 mM each) were determined by
fluorescence microscopy. Responses of imaged fields of transfected
cells are shown in FIG. 4. Responses to the sweetener pool were
only detected in cells cotransfected with hT1R2 and hT1R3 (panel
C), but not with hT1R2 (panel A) or hT1R3 (panel B) alone. The
G-protein dependence of T1R2/T1R3 activity was similarly determined
by cotransfection of the T1Rs and different G proteins into
HEK-293T cells, which unlike HEK-G15 cells do not express
G.alpha.15. In the panels below, sucrose (120 mM) responses were
detected in cells that transiently express Ga15 (panel E), but not
Gq (panel D). Thus, T1R2 and T1R3 together are activated by sweet
taste stimuli, and they couple to Ga15, thereby allowing their
activity to be determined by fluorescence-based whole-cell
assay.
Example 8
Quantitative Assay of the Human T1R2/T1R3 Sweet Receptor
We have developed a method to quantitate hT1R2/hT1R3 activity that
can be used, for example, to predict the potency of new candidate
sweeteners. In this quantitative assay, HEK-G15 cells that are
transiently transfected with hT1R2 and hT1R3 are loaded with the
calcium dye Fluo-4, and their responses to sweeteners are observed
with a fluorescent microscope. Dose responses are obtained by
quantitation of the number of responding cells. FIG. 5 presents
dose responses for sucrose, tryptophan, and five commercially
important artificial sweeteners. The dose responses obtained argue
compellingly that T1R2/T1R3 is the human sweet taste receptor
because the rank order and threshold values obtained in this assay
mirrors values for human sweet taste.
Example 9
As an example of how such an assay can be adapted to a
high-throughput screening format, HEK-G15 cells that are
transiently transfected with hT1R2 and hT1R3 were loaded with the
calcium dye Fluo-4, and their responses to sweeteners were
determined using an automated fluorescence plate reader. FIG. 6
presents cyclamate (12.5 mM) responses measured for cells
expressing hT1R2/hT1R3 (K19-22) and for cells expressing only hT1R3
(J19-22). As noted above, responses to this stimulus only occur in
cells expressing T1R2 and T1R3 in combination.
Example 10
Possible Function of T1R1
If the human sweet receptor is composed of hT1R2 and hT1R3 then
what does hT1R1 do? Some of the recent T1R3 papers suggest that,
although T1R1 and T1R2 are predominantly expressed in
nonoverlapping regions of the oral cavity, both T1Rs are
coexpressed with T1R3. Thus, we hypothesize that T1R1, like T1R2,
may function in combination with T1R3 as a taste receptor. The
specificity of the T1R1 or T1R1/T1R3 receptor can only be guessed
at present. It is widely believed, however, that taste buds
throughout the oral cavity--even those that do not express
T1R2--are responsive to sweet taste stimuli. Thus, T1R1 or
T1R1/T1R3 may function, like T1R2/T1R3, as a sweet taste receptor
that is functionally similar to T1R2/T1R3. Alternatively, T1R1 or
T1R1/T1R3 may function as a sweet receptor that is complementary to
T1R2/T1R3, recognizing ligands such as glucose, alanine, and
glycine that do not appear to activate T1R2/T1R3. One further
compelling hypothesis is that T1R1 or T1R1/T1R3 recognizes
glutamate and functions as the umami receptor. Such a possibility
is hinted at by the observation that rodents may not discriminate
between sweet taste stimuli and glutamate, and by the curious
sequence relationship of T1R1 to the metabotropic glutamate
receptors. FIG. 7 depicts the glutamate binding site in the X-ray
crystal structure of mGluR1 (Kunishima et al., Nature 407, 971-977
(200)) with glutamate-binding residues that are conserved between
mGluR1 and T1R1 in space-filling detail. It appears that the
alpha-amino acid-binding determinants of mGluR1 may also be present
in T1R1; thus, T1R1 may recognize the umami taste stimulus
glutamate, or sweet-tasting amino acids such as alanine and
glycine.
While the foregoing detailed description has described several
embodiments of the present invention, it is to be understood that
the above description is illustrative only and not limiting of the
disclosed invention. The invention is to be limited only by the
claims which follow.
SEQUENCE LISTINGS
1
1012526DNAHomo sapiens 1atgctgctct gcacggctcg cctggtcggc ctgcagcttc
tcatttcctg ctgctgggcc 60tttgcctgcc atagcacgga gtcttctcct gacttcaccc
tccccggaga ttacctcctg 120gcaggcctgt tccctctcca ttctggctgt
ctgcaggtga ggcacagacc cgaggtgacc 180ctgtgtgaca ggtcttgtag
cttcaatgag catggctacc acctcttcca ggctatgcgg 240cttggggttg
aggagataaa caactccacg gccctgctgc ccaacatcac cctggggtac
300cagctgtatg atgtgtgttc tgactctgcc aatgtgtatg ccacgctgag
agtgctctcc 360ctgccagggc aacaccacat agagctccaa ggagaccttc
tccactattc ccctacggtg 420ctggcagtga ttgggcctga cagcaccaac
cgtgctgcca ccacagccgc cctgctgagc 480cctttcctgg tgcccatgat
tagctatgcg gccagcagcg agacgctcag cgtgaagcgg 540cagtatccct
ctttcctgcg caccatcccc aatgacaagt accaggtgga gaccatggtg
600ctgctgctgc agaagttcgg gtggacctgg atctctctgg ttggcagcag
tgacgactat 660gggcagctag gggtgcaggc actggagaac caggccactg
gtcaggggat ctgcattgct 720ttcaaggaca tcatgccctt ctctgcccag
gtgggcgatg agaggatgca gtgcctcatg 780cgccacctgg cccaggccgg
ggccaccgtc gtggttgttt tttccagccg gcagttggcc 840agggtgtttt
tcgagtccgt ggtgctgacc aacctgactg gcaaggtgtg ggtcgcctca
900gaagcctggg ccctctccag gcacatcact ggggtgcccg ggatccagcg
cattgggatg 960gtgctgggcg tggccatcca gaagagggct gtccctggcc
tgaaggcgtt tgaagaagcc 1020tatgcccggg cagacaagaa ggcccctagg
ccttgccaca agggctcctg gtgcagcagc 1080aatcagctct gcagagaatg
ccaagctttc atggcacaca cgatgcccaa gctcaaagcc 1140ttctccatga
gttctgccta caacgcatac cgggctgtgt atgcggtggc ccatggcctc
1200caccagctcc tgggctgtgc ctctggagct tgttccaggg gccgagtcta
cccctggcag 1260cttttggagc agatccacaa ggtgcatttc cttctacaca
aggacactgt ggcgtttaat 1320gacaacagag atcccctcag tagctataac
ataattgcct gggactggaa tggacccaag 1380tggaccttca cggtcctcgg
ttcctccaca tggtctccag ttcagctaaa cataaatgag 1440accaaaatcc
agtggcacgg aaaggacaac caggtgccta agtctgtgtg ttccagcgac
1500tgtcttgaag ggcaccagcg agtggttacg ggtttccatc actgctgctt
tgagtgtgtg 1560ccctgtgggg ctgggacctt cctcaacaag agtgacctct
acagatgcca gccttgtggg 1620aaagaagagt gggcacctga gggaagccag
acctgcttcc cgcgcactgt ggtgtttttg 1680gctttgcgtg agcacacctc
ttgggtgctg ctggcagcta acacgctgct gctgctgctg 1740ctgcttggga
ctgctggcct gtttgcctgg cacctagaca cccctgtggt gaggtcagca
1800gggggccgcc tgtgctttct tatgctgggc tccctggcag caggtagtgg
cagcctctat 1860ggcttctttg gggaacccac aaggcctgcg tgcttgctac
gccaggccct ctttgccctt 1920ggtttcacca tcttcctgtc ctgcctgaca
gttcgctcat tccaactaat catcatcttc 1980aagttttcca ccaaggtacc
tacattctac cacgcctggg tccaaaacca cggtgctggc 2040ctgtttgtga
tgatcagctc agcggcccag ctgcttatct gtctaacttg gctggtggtg
2100tggaccccac tgcctgctag ggaataccag cgcttccccc atctggtgat
gcttgagtgc 2160acagagacca actccctggg cttcatactg gccttcctct
acaatggcct cctctccatc 2220agtgcctttg cctgcagcta cctgggtaag
gacttgccag agaactacaa cgaggccaaa 2280tgtgtcacct tcagcctgct
cttcaacttc gtgtcctgga tcgccttctt caccacggcc 2340agcgtctacg
acggcaagta cctgcctgcg gccaacatga tggctgggct gagcagcctg
2400agcagcggct tcggtgggta ttttctgcct aagtgctacg tgatcctctg
ccgcccagac 2460ctcaacagca cagagcactt ccaggcctcc attcaggact
acacgaggcg ctgcggctcc 2520acctga 25262841PRTHomo sapiens 2Met Leu
Leu Cys Thr Ala Arg Leu Val Gly Leu Gln Leu Leu Ile Ser 1 5 10
15Cys Cys Trp Ala Phe Ala Cys His Ser Thr Glu Ser Ser Pro Asp Phe
20 25 30Thr Leu Pro Gly Asp Tyr Leu Leu Ala Gly Leu Phe Pro Leu His
Ser 35 40 45Gly Cys Leu Gln Val Arg His Arg Pro Glu Val Thr Leu Cys
Asp Arg 50 55 60Ser Cys Ser Phe Asn Glu His Gly Tyr His Leu Phe Gln
Ala Met Arg 65 70 75 80Leu Gly Val Glu Glu Ile Asn Asn Ser Thr Ala
Leu Leu Pro Asn Ile 85 90 95Thr Leu Gly Tyr Gln Leu Tyr Asp Val Cys
Ser Asp Ser Ala Asn Val 100 105 110Tyr Ala Thr Leu Arg Val Leu Ser
Leu Pro Gly Gln His His Ile Glu 115 120 125Leu Gln Gly Asp Leu Leu
His Tyr Ser Pro Thr Val Leu Ala Val Ile 130 135 140Gly Pro Asp Ser
Thr Asn Arg Ala Ala Thr Thr Ala Ala Leu Leu Ser145 150 155 160Pro
Phe Leu Val Pro Met Ile Ser Tyr Ala Ala Ser Ser Glu Thr Leu 165 170
175Ser Val Lys Arg Gln Tyr Pro Ser Phe Leu Arg Thr Ile Pro Asn Asp
180 185 190Lys Tyr Gln Val Glu Thr Met Val Leu Leu Leu Gln Lys Phe
Gly Trp 195 200 205Thr Trp Ile Ser Leu Val Gly Ser Ser Asp Asp Tyr
Gly Gln Leu Gly 210 215 220Val Gln Ala Leu Glu Asn Gln Ala Thr Gly
Gln Gly Ile Cys Ile Ala225 230 235 240Phe Lys Asp Ile Met Pro Phe
Ser Ala Gln Val Gly Asp Glu Arg Met 245 250 255Gln Cys Leu Met Arg
His Leu Ala Gln Ala Gly Ala Thr Val Val Val 260 265 270Val Phe Ser
Ser Arg Gln Leu Ala Arg Val Phe Phe Glu Ser Val Val 275 280 285Leu
Thr Asn Leu Thr Gly Lys Val Trp Val Ala Ser Glu Ala Trp Ala 290 295
300Leu Ser Arg His Ile Thr Gly Val Pro Gly Ile Gln Arg Ile Gly
Met305 310 315 320Val Leu Gly Val Ala Ile Gln Lys Arg Ala Val Pro
Gly Leu Lys Ala 325 330 335Phe Glu Glu Ala Tyr Ala Arg Ala Asp Lys
Lys Ala Pro Arg Pro Cys 340 345 350His Lys Gly Ser Trp Cys Ser Ser
Asn Gln Leu Cys Arg Glu Cys Gln 355 360 365Ala Phe Met Ala His Thr
Met Pro Lys Leu Lys Ala Phe Ser Met Ser 370 375 380Ser Ala Tyr Asn
Ala Tyr Arg Ala Val Tyr Ala Val Ala His Gly Leu385 390 395 400His
Gln Leu Leu Gly Cys Ala Ser Gly Ala Cys Ser Arg Gly Arg Val 405 410
415Tyr Pro Trp Gln Leu Leu Glu Gln Ile His Lys Val His Phe Leu Leu
420 425 430His Lys Asp Thr Val Ala Phe Asn Asp Asn Arg Asp Pro Leu
Ser Ser 435 440 445Tyr Asn Ile Ile Ala Trp Asp Trp Asn Gly Pro Lys
Trp Thr Phe Thr 450 455 460Val Leu Gly Ser Ser Thr Trp Ser Pro Val
Gln Leu Asn Ile Asn Glu465 470 475 480Thr Lys Ile Gln Trp His Gly
Lys Asp Asn Gln Val Pro Lys Ser Val 485 490 495Cys Ser Ser Asp Cys
Leu Glu Gly His Gln Arg Val Val Thr Gly Phe 500 505 510His His Cys
Cys Phe Glu Cys Val Pro Cys Gly Ala Gly Thr Phe Leu 515 520 525Asn
Lys Ser Asp Leu Tyr Arg Cys Gln Pro Cys Gly Lys Glu Glu Trp 530 535
540Ala Pro Glu Gly Ser Gln Thr Cys Phe Pro Arg Thr Val Val Phe
Leu545 550 555 560Ala Leu Arg Glu His Thr Ser Trp Val Leu Leu Ala
Ala Asn Thr Leu 565 570 575Leu Leu Leu Leu Leu Leu Gly Thr Ala Gly
Leu Phe Ala Trp His Leu 580 585 590Asp Thr Pro Val Val Arg Ser Ala
Gly Gly Arg Leu Cys Phe Leu Met 595 600 605Leu Gly Ser Leu Ala Ala
Gly Ser Gly Ser Leu Tyr Gly Phe Phe Gly 610 615 620Glu Pro Thr Arg
Pro Ala Cys Leu Leu Arg Gln Ala Leu Phe Ala Leu625 630 635 640Gly
Phe Thr Ile Phe Leu Ser Cys Leu Thr Val Arg Ser Phe Gln Leu 645 650
655Ile Ile Ile Phe Lys Phe Ser Thr Lys Val Pro Thr Phe Tyr His Ala
660 665 670Trp Val Gln Asn His Gly Ala Gly Leu Phe Val Met Ile Ser
Ser Ala 675 680 685Ala Gln Leu Leu Ile Cys Leu Thr Trp Leu Val Val
Trp Thr Pro Leu 690 695 700Pro Ala Arg Glu Tyr Gln Arg Phe Pro His
Leu Val Met Leu Glu Cys705 710 715 720Thr Glu Thr Asn Ser Leu Gly
Phe Ile Leu Ala Phe Leu Tyr Asn Gly 725 730 735Leu Leu Ser Ile Ser
Ala Phe Ala Cys Ser Tyr Leu Gly Lys Asp Leu 740 745 750Pro Glu Asn
Tyr Asn Glu Ala Lys Cys Val Thr Phe Ser Leu Leu Phe 755 760 765Asn
Phe Val Ser Trp Ile Ala Phe Phe Thr Thr Ala Ser Val Tyr Asp 770 775
780Gly Lys Tyr Leu Pro Ala Ala Asn Met Met Ala Gly Leu Ser Ser
Leu785 790 795 800Ser Ser Gly Phe Gly Gly Tyr Phe Leu Pro Lys Cys
Tyr Val Ile Leu 805 810 815Cys Arg Pro Asp Leu Asn Ser Thr Glu His
Phe Gln Ala Ser Ile Gln 820 825 830Asp Tyr Thr Arg Arg Cys Gly Ser
Thr 835 84032520DNAHomo sapiens 3atggggccca gggcaaagac catctgctcc
ctgttcttcc tcctatgggt cctggctgag 60ccggctgaga actcggactt ctacctgcct
ggggattacc tcctgggtgg cctcttctcc 120ctccatgcca acatgaaggg
cattgttcac cttaacttcc tgcaggtgcc catgtgcaag 180gagtatgaag
tgaaggtgat aggctacaac ctcatgcagg ccatgcgctt cgcggtggag
240gagatcaaca atgacagcag cctgctgcct ggtgtgctgc tgggctatga
gatcgtggat 300gtgtgctaca tctccaacaa tgtccagccg gtgctctact
tcctggcaca cgaggacaac 360ctccttccca tccaagagga ctacagtaac
tacatttccc gtgtggtggc tgtcattggc 420cctgacaact ccgagtctgt
catgactgtg gccaacttcc tctccctatt tctccttcca 480cagatcacct
acagcgccat cagcgatgag ctgcgagaca aggtgcgctt cccggctttg
540ctgcgtacca cacccagcgc cgaccaccac gtcgaggcca tggtgcagct
gatgctgcac 600ttccgctgga actggatcat tgtgctggtg agcagcgaca
cctatggccg cgacaatggc 660cagctgcttg gcgagcgcgt ggcccggcgc
gacatctgca tcgccttcca ggagacgctg 720cccacactgc agcccaacca
gaacatgacg tcagaggagc gccagcgcct ggtgaccatt 780gtggacaagc
tgcagcagag cacagcgcgc gtcgtggtcg tgttctcgcc cgacctgacc
840ctgtaccact tcttcaatga ggtgctgcgc cagaacttca cgggcgccgt
gtggatcgcc 900tccgagtcct gggccatcga cccggtcctg cacaacctca
cggagctggg ccacttgggc 960accttcctgg gcatcaccat ccagagcgtg
cccatcccgg gcttcagtga gttccgcgag 1020tggggcccac aggctgggcc
gccacccctc agcaggacca gccagagcta tacctgcaac 1080caggagtgcg
acaactgcct gaacgccacc ttgtccttca acaccattct caggctctct
1140ggggagcgtg tcgtctacag cgtgtactct gcggtctatg ctgtggccca
tgccctgcac 1200agcctcctcg gctgtgacaa aagcacctgc accaagaggg
tggtctaccc ctggcagctg 1260cttgaggaga tctggaaggt caacttcact
ctcctggacc accaaatctt cttcgacccg 1320caaggggacg tggctctgca
cttggagatt gtccagtggc aatgggaccg gagccagaat 1380cccttccaga
gcgtcgcctc ctactacccc ctgcagcgac agctgaagaa catccaagac
1440atctcctggc acaccgtcaa caacacgatc cctatgtcca tgtgttccaa
gaggtgccag 1500tcagggcaaa agaagaagcc tgtgggcatc cacgtctgct
gcttcgagtg catcgactgc 1560cttcccggca ccttcctcaa ccacactgaa
gatgaatatg aatgccaggc ctgcccgaat 1620aacgagtggt cctaccagag
tgagacctcc tgcttcaagc ggcagctggt cttcctggaa 1680tggcatgagg
cacccaccat cgctgtggcc ctgctggccg ccctgggctt cctcagcacc
1740ctggccatcc tggtgatatt ctggaggcac ttccagacac ccatagttcg
ctcggctggg 1800ggccccatgt gcttcctgat gctgacactg ctgctggtgg
catacatggt ggtcccggtg 1860tacgtggggc cgcccaaggt ctccacctgc
ctctgccgcc aggccctctt tcccctctgc 1920ttcacaattt gcatctcctg
tatcgccgtg cgttctttcc agatcgtctg cgccttcaag 1980atggccagcc
gcttcccacg cgcctacagc tactgggtcc gctaccaggg gccctacgtc
2040tctatggcat ttatcacggt actcaaaatg gtcattgtgg taattggcat
gctggccacg 2100ggcctcagtc ccaccacccg tactgacccc gatgacccca
agatcacaat tgtctcctgt 2160aaccccaact accgcaacag cctgctgttc
aacaccagcc tggacctgct gctctcagtg 2220gtgggtttca gcttcgccta
catgggcaaa gagctgccca ccaactacaa cgaggccaag 2280ttcatcaccc
tcagcatgac cttctatttc acctcatccg tctccctctg caccttcatg
2340tctgcctaca gcggggtgct ggtcaccatc gtggacctct tggtcactgt
gctcaacctc 2400ctggccatca gcctgggcta cttcggcccc aagtgctaca
tgatcctctt ctacccggag 2460cgcaacacgc ccgcctactt caacagcatg
atccagggct acaccatgag gagggactag 25204839PRTHomo sapiens 4Met Gly
Pro Arg Ala Lys Thr Ile Cys Ser Leu Phe Phe Leu Leu Trp 1 5 10
15Val Leu Ala Glu Pro Ala Glu Asn Ser Asp Phe Tyr Leu Pro Gly Asp
20 25 30Tyr Leu Leu Gly Gly Leu Phe Ser Leu His Ala Asn Met Lys Gly
Ile 35 40 45Val His Leu Asn Phe Leu Gln Val Pro Met Cys Lys Glu Tyr
Glu Val 50 55 60Lys Val Ile Gly Tyr Asn Leu Met Gln Ala Met Arg Phe
Ala Val Glu 65 70 75 80Glu Ile Asn Asn Asp Ser Ser Leu Leu Pro Gly
Val Leu Leu Gly Tyr 85 90 95Glu Ile Val Asp Val Cys Tyr Ile Ser Asn
Asn Val Gln Pro Val Leu 100 105 110Tyr Phe Leu Ala His Glu Asp Asn
Leu Leu Pro Ile Gln Glu Asp Tyr 115 120 125Ser Asn Tyr Ile Ser Arg
Val Val Ala Val Ile Gly Pro Asp Asn Ser 130 135 140Glu Ser Val Met
Thr Val Ala Asn Phe Leu Ser Leu Phe Leu Leu Pro145 150 155 160Gln
Ile Thr Tyr Ser Ala Ile Ser Asp Glu Leu Arg Asp Lys Val Arg 165 170
175Phe Pro Ala Leu Leu Arg Thr Thr Pro Ser Ala Asp His His Val Glu
180 185 190Ala Met Val Gln Leu Met Leu His Phe Arg Trp Asn Trp Ile
Ile Val 195 200 205Leu Val Ser Ser Asp Thr Tyr Gly Arg Asp Asn Gly
Gln Leu Leu Gly 210 215 220Glu Arg Val Ala Arg Arg Asp Ile Cys Ile
Ala Phe Gln Glu Thr Leu225 230 235 240Pro Thr Leu Gln Pro Asn Gln
Asn Met Thr Ser Glu Glu Arg Gln Arg 245 250 255Leu Val Thr Ile Val
Asp Lys Leu Gln Gln Ser Thr Ala Arg Val Val 260 265 270Val Val Phe
Ser Pro Asp Leu Thr Leu Tyr His Phe Phe Asn Glu Val 275 280 285Leu
Arg Gln Asn Phe Thr Gly Ala Val Trp Ile Ala Ser Glu Ser Trp 290 295
300Ala Ile Asp Pro Val Leu His Asn Leu Thr Glu Leu Gly His Leu
Gly305 310 315 320Thr Phe Leu Gly Ile Thr Ile Gln Ser Val Pro Ile
Pro Gly Phe Ser 325 330 335Glu Phe Arg Glu Trp Gly Pro Gln Ala Gly
Pro Pro Pro Leu Ser Arg 340 345 350Thr Ser Gln Ser Tyr Thr Cys Asn
Gln Glu Cys Asp Asn Cys Leu Asn 355 360 365Ala Thr Leu Ser Phe Asn
Thr Ile Leu Arg Leu Ser Gly Glu Arg Val 370 375 380Val Tyr Ser Val
Tyr Ser Ala Val Tyr Ala Val Ala His Ala Leu His385 390 395 400Ser
Leu Leu Gly Cys Asp Lys Ser Thr Cys Thr Lys Arg Val Val Tyr 405 410
415Pro Trp Gln Leu Leu Glu Glu Ile Trp Lys Val Asn Phe Thr Leu Leu
420 425 430Asp His Gln Ile Phe Phe Asp Pro Gln Gly Asp Val Ala Leu
His Leu 435 440 445Glu Ile Val Gln Trp Gln Trp Asp Arg Ser Gln Asn
Pro Phe Gln Ser 450 455 460Val Ala Ser Tyr Tyr Pro Leu Gln Arg Gln
Leu Lys Asn Ile Gln Asp465 470 475 480Ile Ser Trp His Thr Val Asn
Asn Thr Ile Pro Met Ser Met Cys Ser 485 490 495Lys Arg Cys Gln Ser
Gly Gln Lys Lys Lys Pro Val Gly Ile His Val 500 505 510Cys Cys Phe
Glu Cys Ile Asp Cys Leu Pro Gly Thr Phe Leu Asn His 515 520 525Thr
Glu Asp Glu Tyr Glu Cys Gln Ala Cys Pro Asn Asn Glu Trp Ser 530 535
540Tyr Gln Ser Glu Thr Ser Cys Phe Lys Arg Gln Leu Val Phe Leu
Glu545 550 555 560Trp His Glu Ala Pro Thr Ile Ala Val Ala Leu Leu
Ala Ala Leu Gly 565 570 575Phe Leu Ser Thr Leu Ala Ile Leu Val Ile
Phe Trp Arg His Phe Gln 580 585 590Thr Pro Ile Val Arg Ser Ala Gly
Gly Pro Met Cys Phe Leu Met Leu 595 600 605Thr Leu Leu Leu Val Ala
Tyr Met Val Val Pro Val Tyr Val Gly Pro 610 615 620Pro Lys Val Ser
Thr Cys Leu Cys Arg Gln Ala Leu Phe Pro Leu Cys625 630 635 640Phe
Thr Ile Cys Ile Ser Cys Ile Ala Val Arg Ser Phe Gln Ile Val 645 650
655Cys Ala Phe Lys Met Ala Ser Arg Phe Pro Arg Ala Tyr Ser Tyr Trp
660 665 670Val Arg Tyr Gln Gly Pro Tyr Val Ser Met Ala Phe Ile Thr
Val Leu 675 680 685Lys Met Val Ile Val Val Ile Gly Met Leu Ala Thr
Gly Leu Ser Pro 690 695 700Thr Thr Arg Thr Asp Pro Asp Asp Pro Lys
Ile Thr Ile Val Ser Cys705 710 715 720Asn Pro Asn Tyr Arg Asn Ser
Leu Leu Phe Asn Thr Ser Leu Asp Leu 725 730 735Leu Leu Ser Val Val
Gly Phe Ser Phe Ala Tyr Met Gly Lys Glu Leu 740 745 750Pro Thr Asn
Tyr Asn Glu Ala Lys Phe Ile Thr Leu Ser Met Thr Phe 755 760 765Tyr
Phe Thr Ser Ser Val Ser Leu Cys Thr Phe Met Ser Ala Tyr Ser 770
775
780Gly Val Leu Val Thr Ile Val Asp Leu Leu Val Thr Val Leu Asn
Leu785 790 795 800Leu Ala Ile Ser Leu Gly Tyr Phe Gly Pro Lys Cys
Tyr Met Ile Leu 805 810 815Phe Tyr Pro Glu Arg Asn Thr Pro Ala Tyr
Phe Asn Ser Met Ile Gln 820 825 830Gly Tyr Thr Met Arg Arg Asp
83552559DNAHomo sapiens 5atgctgggcc ctgctgtcct gggcctcagc
ctctgggctc tcctgcaccc tgggacgggg 60gccccattgt gcctgtcaca gcaacttagg
atgaaggggg actacgtgct gggggggctg 120ttccccctgg gcgaggccga
ggaggctggc ctccgcagcc ggacacggcc cagcagccct 180gtgtgcacca
ggttctcctc aaacggcctg ctctgggcac tggccatgaa aatggccgtg
240gaggagatca acaacaagtc ggatctgctg cccgggctgc gcctgggcta
cgacctcttt 300gatacgtgct cggagcctgt ggtggccatg aagcccagcc
tcatgttcct ggccaaggca 360ggcagccgcg acatcgccgc ctactgcaac
tacacgcagt accagccccg tgtgctggct 420gtcatcgggc cccactcgtc
agagctcgcc atggtcaccg gcaagttctt cagcttcttc 480ctcatgcccc
aggtcagcta cggtgctagc atggagctgc tgagcgcccg ggagaccttc
540ccctccttct tccgcaccgt gcccagcgac cgtgtgcagc tgacggccgc
cgcggagctg 600ctgcaggagt tcggctggaa ctgggtggcc gccctgggca
gcgacgacga gtacggccgg 660cagggcctga gcatcttctc ggccctggcc
gcggcacgcg gcatctgcat cgcgcacgag 720ggcctggtgc cgctgccccg
tgccgatgac tcgcggctgg ggaaggtgca ggacgtcctg 780caccaggtga
accagagcag cgtgcaggtg gtgctgctgt tcgcctccgt gcacgccgcc
840cacgccctct tcaactacag catcagcagc aggctctcgc ccaaggtgtg
ggtggccagc 900gaggcctggc tgacctctga cctggtcatg gggctgcccg
gcatggccca gatgggcacg 960gtgcttggct tcctccagag gggtgcccag
ctgcacgagt tcccccagta cgtgaagacg 1020cacctggccc tggccaccga
cccggccttc tgctctgccc tgggcgagag ggagcagggt 1080ctggaggagg
acgtggtggg ccagcgctgc ccgcagtgtg actgcatcac gctgcagaac
1140gtgagcgcag ggctaaatca ccaccagacg ttctctgtct acgcagctgt
gtatagcgtg 1200gcccaggccc tgcacaacac tcttcagtgc aacgcctcag
gctgccccgc gcaggacccc 1260gtgaagccct ggcagctcct ggagaacatg
tacaacctga ccttccacgt gggcgggctg 1320ccgctgcggt tcgacagcag
cggaaacgtg gacatggagt acgacctgaa gctgtgggtg 1380tggcagggct
cagtgcccag gctccacgac gtgggcaggt tcaacggcag cctcaggaca
1440gagcgcctga agatccgctg gcacacgtct gacaaccaga agcccgtgtc
ccggtgctcg 1500cggcagtgcc aggagggcca ggtgcgccgg gtcaaggggt
tccactcctg ctgctacgac 1560tgtgtggact gcgaggcggg cagctaccgg
caaaacccag acgacatcgc ctgcaccttt 1620tgtggccagg atgagtggtc
cccggagcga agcacacgct gcttccgccg caggtctcgg 1680ttcctggcat
ggggcgagcc ggctgtgctg ctgctgctcc tgctgctgag cctggcgctg
1740ggccttgtgc tggctgcttt ggggctgttc gttcaccatc gggacagccc
actggttcag 1800gcctcggggg ggcccctggc ctgctttggc ctggtgtgcc
tgggcctggt ctgcctcagc 1860gtcctcctgt tccctggcca gcccagccct
gcccgatgcc tggcccagca gcccttgtcc 1920cacctcccgc tcacgggctg
cctgagcaca ctcttcctgc aggcggccga gatcttcgtg 1980gagtcagaac
tgcctctgag ctgggcagac cggctgagtg gctgcctgcg ggggccctgg
2040gcctggctgg tggtgctgct ggccatgctg gtggaggtcg cactgtgcac
ctggtacctg 2100gtggccttcc cgccggaggt ggtgacggac tggcacatgc
tgcccacgga ggcgctggtg 2160cactgccgca cacgctcctg ggtcagcttc
ggcctagcgc acgccaccaa tgccacgctg 2220gcctttctct gcttcctggg
cactttcctg gtgcggagcc agccgggccg ctacaaccgt 2280gcccgtggcc
tcacctttgc catgctggcc tacttcatca cctgggtctc ctttgtgccc
2340ctcctggcca atgtgcaggt ggtcctcagg cccgccgtgc agatgggcgc
cctcctgctc 2400tgtgtcctgg gcatcctggc tgccttccac ctgcccaggt
gttacctgct catgcggcag 2460ccagggctca acacccccga gttcttcctg
ggagggggcc ctggggatgc ccaaggccag 2520aatgacggga acacaggaaa
tcaggggaaa catgagtga 25596852PRTHomo sapiens 6Met Leu Gly Pro Ala
Val Leu Gly Leu Ser Leu Trp Ala Leu Leu His 1 5 10 15Pro Gly Thr
Gly Ala Pro Leu Cys Leu Ser Gln Gln Leu Arg Met Lys 20 25 30Gly Asp
Tyr Val Leu Gly Gly Leu Phe Pro Leu Gly Glu Ala Glu Glu 35 40 45Ala
Gly Leu Arg Ser Arg Thr Arg Pro Ser Ser Pro Val Cys Thr Arg 50 55
60Phe Ser Ser Asn Gly Leu Leu Trp Ala Leu Ala Met Lys Met Ala Val
65 70 75 80Glu Glu Ile Asn Asn Lys Ser Asp Leu Leu Pro Gly Leu Arg
Leu Gly 85 90 95Tyr Asp Leu Phe Asp Thr Cys Ser Glu Pro Val Val Ala
Met Lys Pro 100 105 110Ser Leu Met Phe Leu Ala Lys Ala Gly Ser Arg
Asp Ile Ala Ala Tyr 115 120 125Cys Asn Tyr Thr Gln Tyr Gln Pro Arg
Val Leu Ala Val Ile Gly Pro 130 135 140His Ser Ser Glu Leu Ala Met
Val Thr Gly Lys Phe Phe Ser Phe Phe145 150 155 160Leu Met Pro Gln
Val Ser Tyr Gly Ala Ser Met Glu Leu Leu Ser Ala 165 170 175Arg Glu
Thr Phe Pro Ser Phe Phe Arg Thr Val Pro Ser Asp Arg Val 180 185
190Gln Leu Thr Ala Ala Ala Glu Leu Leu Gln Glu Phe Gly Trp Asn Trp
195 200 205Val Ala Ala Leu Gly Ser Asp Asp Glu Tyr Gly Arg Gln Gly
Leu Ser 210 215 220Ile Phe Ser Ala Leu Ala Ala Ala Arg Gly Ile Cys
Ile Ala His Glu225 230 235 240Gly Leu Val Pro Leu Pro Arg Ala Asp
Asp Ser Arg Leu Gly Lys Val 245 250 255Gln Asp Val Leu His Gln Val
Asn Gln Ser Ser Val Gln Val Val Leu 260 265 270Leu Phe Ala Ser Val
His Ala Ala His Ala Leu Phe Asn Tyr Ser Ile 275 280 285Ser Ser Arg
Leu Ser Pro Lys Val Trp Val Ala Ser Glu Ala Trp Leu 290 295 300Thr
Ser Asp Leu Val Met Gly Leu Pro Gly Met Ala Gln Met Gly Thr305 310
315 320Val Leu Gly Phe Leu Gln Arg Gly Ala Gln Leu His Glu Phe Pro
Gln 325 330 335Tyr Val Lys Thr His Leu Ala Leu Ala Thr Asp Pro Ala
Phe Cys Ser 340 345 350Ala Leu Gly Glu Arg Glu Gln Gly Leu Glu Glu
Asp Val Val Gly Gln 355 360 365Arg Cys Pro Gln Cys Asp Cys Ile Thr
Leu Gln Asn Val Ser Ala Gly 370 375 380Leu Asn His His Gln Thr Phe
Ser Val Tyr Ala Ala Val Tyr Ser Val385 390 395 400Ala Gln Ala Leu
His Asn Thr Leu Gln Cys Asn Ala Ser Gly Cys Pro 405 410 415Ala Gln
Asp Pro Val Lys Pro Trp Gln Leu Leu Glu Asn Met Tyr Asn 420 425
430Leu Thr Phe His Val Gly Gly Leu Pro Leu Arg Phe Asp Ser Ser Gly
435 440 445Asn Val Asp Met Glu Tyr Asp Leu Lys Leu Trp Val Trp Gln
Gly Ser 450 455 460Val Pro Arg Leu His Asp Val Gly Arg Phe Asn Gly
Ser Leu Arg Thr465 470 475 480Glu Arg Leu Lys Ile Arg Trp His Thr
Ser Asp Asn Gln Lys Pro Val 485 490 495Ser Arg Cys Ser Arg Gln Cys
Gln Glu Gly Gln Val Arg Arg Val Lys 500 505 510Gly Phe His Ser Cys
Cys Tyr Asp Cys Val Asp Cys Glu Ala Gly Ser 515 520 525Tyr Arg Gln
Asn Pro Asp Asp Ile Ala Cys Thr Phe Cys Gly Gln Asp 530 535 540Glu
Trp Ser Pro Glu Arg Ser Thr Arg Cys Phe Arg Arg Arg Ser Arg545 550
555 560Phe Leu Ala Trp Gly Glu Pro Ala Val Leu Leu Leu Leu Leu Leu
Leu 565 570 575Ser Leu Ala Leu Gly Leu Val Leu Ala Ala Leu Gly Leu
Phe Val His 580 585 590His Arg Asp Ser Pro Leu Val Gln Ala Ser Gly
Gly Pro Leu Ala Cys 595 600 605Phe Gly Leu Val Cys Leu Gly Leu Val
Cys Leu Ser Val Leu Leu Phe 610 615 620Pro Gly Gln Pro Ser Pro Ala
Arg Cys Leu Ala Gln Gln Pro Leu Ser625 630 635 640His Leu Pro Leu
Thr Gly Cys Leu Ser Thr Leu Phe Leu Gln Ala Ala 645 650 655Glu Ile
Phe Val Glu Ser Glu Leu Pro Leu Ser Trp Ala Asp Arg Leu 660 665
670Ser Gly Cys Leu Arg Gly Pro Trp Ala Trp Leu Val Val Leu Leu Ala
675 680 685Met Leu Val Glu Val Ala Leu Cys Thr Trp Tyr Leu Val Ala
Phe Pro 690 695 700Pro Glu Val Val Thr Asp Trp His Met Leu Pro Thr
Glu Ala Leu Val705 710 715 720His Cys Arg Thr Arg Ser Trp Val Ser
Phe Gly Leu Ala His Ala Thr 725 730 735Asn Ala Thr Leu Ala Phe Leu
Cys Phe Leu Gly Thr Phe Leu Val Arg 740 745 750Ser Gln Pro Gly Cys
Tyr Asn Arg Ala Arg Gly Leu Thr Phe Ala Met 755 760 765Leu Ala Tyr
Phe Ile Thr Trp Val Ser Phe Val Pro Leu Leu Ala Asn 770 775 780Val
Gln Val Val Leu Arg Pro Ala Val Gln Met Gly Ala Leu Leu Leu785 790
795 800Cys Val Leu Gly Ile Leu Ala Ala Phe His Leu Pro Arg Cys Tyr
Leu 805 810 815Leu Met Arg Gln Pro Gly Leu Asn Thr Pro Glu Phe Phe
Leu Gly Gly 820 825 830Gly Pro Gly Asp Ala Gln Gly Gln Asn Asp Gly
Asn Thr Gly Asn Gln 835 840 845Gly Lys His Glu 85072559DNAHomo
sapiens 7atgctgggcc ctgctgtcct gggcctcagc ctctgggctc tcctgcaccc
tgggacgggg 60gccccattgt gcctgtcaca gcaacttagg atgaaggggg actacgtgct
gggggggctg 120ttccccctgg gcgaggccga ggaggctggc ctccgcagcc
ggacacggcc cagcagccct 180gtgtgcacca ggttctcctc aaacggcctg
ctctgggcac tggccatgaa aatggccgtg 240gaggagatca acaacaagtc
ggatctgctg cccgggctgc gcctgggcta cgacctcttt 300gatacgtgct
cggagcctgt ggtggccatg aagcccagcc tcatgttcct ggccaaggca
360ggcagccgcg acatcgccgc ctactgcaac tacacgcagt accagccccg
tgtgctggct 420gtcatcgggc cccactcgtc agagctcgcc atggtcaccg
gcaagttctt cagcttcttc 480ctcatgcccc aggtcagcta cggtgctagc
atggagctgc tgagcgcccg ggagaccttc 540ccctccttct tccgcaccgt
gcccagcgac cgtgtgcagc tgacggccgc cgcggagctg 600ctgcaggagt
tcggctggaa ctgggtggcc gccctgggca gcgacgacga gtacggccgg
660cagggcctga gcatcttctc ggccctggcc gcggcacgcg gcatctgcat
cgcgcacgag 720ggcctggtgc cgctgccccg tgccgatgac tcgcggctgg
ggaaggtgca ggacgtcctg 780caccaggtga accagagcag cgtgcaggtg
gtgctgctgt tcgcctccgt gcacgccgcc 840cacgccctct tcaactacag
catcagcagc aggctctcgc ccaaggtgtg ggtggccagc 900gaggcctggc
tgacctctga cctggtcatg gggctgcccg gcatggccca gatgggcacg
960gtgcttggct tcctccagag gggtgcccag ctgcacgagt tcccccagta
cgtgaagacg 1020cacctggccc tggccaccga cccggccttc tgctctgccc
tgggcgagag ggagcagggt 1080ctggaggagg acgtggtggg ccagcgctgc
ccgcagtgtg actgcatcac gctgcagaac 1140gtgagcgcag ggctaaatca
ccaccagacg ttctctgtct acgcagctgt gtatagcgtg 1200gcccaggccc
tgcacaacac tcttcagtgc aacgcctcag gctgccccgc gcaggacccc
1260gtgaagccct ggcagctcct ggagaacatg tacaacctga ccttccacgt
gggcgggctg 1320ccgctgcggt tcgacagcag cggaaacgtg gacatggagt
acgacctgaa gctgtgggtg 1380tggcagggct cagtgcccag gctccacgac
gtgggcaggt tcaacggcag cctcaggaca 1440gagcgcctga agatccgctg
gcacacgtct gacaaccaga agcccgtgtc ccggtgctcg 1500cggcagtgcc
aggagggcca ggtgcgccgg gtcaaggggt tccactcctg ctgctacgac
1560tgtgtggact gcgaggcggg cagctaccgg caaaacccag acgacatcgc
ctgcaccttt 1620tgtggccagg atgagtggtc cccggagcga agcacacgct
gcttccgccg caggtctcgg 1680ttcctggcat ggggcgagcc ggctgtgctg
ctgctgctcc tgctgctgag cctggcgctg 1740ggccttgtgc tggctgcttt
ggggctgttc gttcaccatc gggacagccc actggttcag 1800gcctcggggg
ggcccctggc ctgctttggc ctggtgtgcc tgggcctggt ctgcctcagc
1860gtcctcctgt tccctggcca gcccagccct gcccgatgcc tggcccagca
gcccttgtcc 1920cacctcccgc tcacgggctg cctgagcaca ctcttcctgc
aggcggccga gatcttcgtg 1980gagtcagaac tgcctctgag ctgggcagac
cggctgagtg gctgcctgcg ggggccctgg 2040gcctggctgg tggtgctgct
ggccatgctg gtggaggtcg cactgtgcac ctggtacctg 2100gtggccttcc
cgccggaggt ggtgacggac tggcacatgc tgcccacgga ggcgctggtg
2160cactgccgca cacgctcctg ggtcagcttc ggcctagcgc acgccaccaa
tgccacgctg 2220gcctttctct gcttcctggg cactttcctg gtgcggagcc
agccgggccg ctacaaccgt 2280gcccgtggcc tcacctttgc catgctggcc
tacttcatca cctgggtctc ctttgtgccc 2340ctcctggcca atgtgcaggt
ggtcctcagg cccgccgtgc agatgggcgc cctcctgctc 2400tgtgtcctgg
gcatcctggc tgccttccac ctgcccaggt gttacctgct catgcggcag
2460ccagggctca acacccccga gttcttcctg ggagggggcc ctggggatgc
ccaaggccag 2520aatgacggga acacaggaaa tcaggggaaa catgagtga
2559814PRTArtificial SequenceDescription of Artificial Sequence
Consensus sequence 8Xaa Cys Xaa Xaa Arg Xaa Xaa Xaa Phe Leu Xaa Xaa
Xaa Glu 1 5 10915PRTArtificial SequenceDescription of Artificial
Sequence Consensus sequence 9Xaa Pro Xaa Xaa Tyr Asn Xaa Ala Xaa
Xaa Xaa Thr Xaa Xaa Xaa 1 5 10 15106PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 10Ser
Val Ser Thr Val Val 1 5
* * * * *